,Data
0,"{'kol': 'Aaron Park', 'Interaction_Date': ['9-Sep-19', '4-Oct-19', '1-Nov-19', '30-Nov-19', '21-Dec-19', '18-Jan-20', '15-Feb-20', '10-Mar-20', '5-Apr-20', '1-Jun-20', '29-Jun-20', '25-Jul-20', '20-Aug-20', '11-Sep-20', '7-Oct-20', '3-Nov-20', '25-Nov-20', '20-Dec-20', '16-Jan-21', '14-Feb-21', '10-Mar-21', '5-Apr-21', '1-May-21', '31-May-21', '25-Jun-21', '21-Jul-21', '18-Aug-21', '16-Sep-21', '15-Oct-21', '12-Nov-21', '10-Dec-21', '9-Jan-22', '7-Feb-22', '4-Mar-22', '31-Mar-22', '26-Apr-22', '23-May-22', '18-Jun-22', '15-Jul-22', '12-Aug-22'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer'], 'KOL_years_of_Experience': [33, 33, 33, 33, 33, 34, 34, 34, 34, 34, 34, 34, 34, 34, 34, 34, 34, 34, 35, 35, 35, 35, 35, 35, 35, 35, 35, 35, 35, 35, 35, 36, 36, 36, 36, 36, 36, 36, 36, 36], 'KOL_Location': ['New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['53K', '53.4K', '55.1K', '55.7K', '56.2K', '58.1K', '59.3K', '61K', '61.7K', '62.5K', '63.4K', '64.1K', '64.7K', '65.6K', '66.2K', '66.7K', '67.2K', '68.1K', '69.2K', '70.1K', '70.6K', '71K', '71.5K', '72.2K', '73K', '73.6K', '74.1K', '74.5K', '75.1K', '75.6K', '76.1K', '76.5K', '76.9K', '77.8K', '78.5K', '79.3K', '80.1K', '81.3K', '82.2K', '82.9K'], 'SocialMedia_Linkedin': ['22K', '22.5K', '23.4K', '23.7K', '24.1K', '24.6K', '25.2K', '25.7K', '26.5K', '27.1K', '27.5K', '27.9K', '28.6K', '29.1K', '29.6K', '30.1K', '30.4K', '31K', '31.7K', '32.3K', '32.8K', '33.2K', '33.4K', '33.9K', '34.3K', '34.8K', '35.2K', '35.6K', '35.8K', '36.2K', '36.7K', '37.1K', '37.5K', '38.1K', '38.6K', '38.9K', '39.4K', '40.2K', '41K', '41.4K'], 'SocialMedia_YouTube': ['13.4K', '13.7K', '14.2K', '14.8K', '15.3K', '16K', '16.7K', '17.2K', '17.9K', '18.5K', '19.1K', '19.3K', '19.7K', '20.2K', '21.1K', '21.7K', '22.3K', '22.7K', '23.5K', '23.7K', '24.1K', '24.5K', '24.7K', '24.9K', '25.2K', '25.7K', '28.1K', '28.1', '28.4K', '28.7K', '29.1K', '29.5K', '29.9K', '30.5K', '30.9K', '31.4K', '31.6K', '31.7K', '32.1K', '32.4K'], 'Overall_Kol_Rating': [4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6], 'Connection_to_Advisory_Boards': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6], 'Research_Participated': [19, 19, 19, 19, 19, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22], 'Research_Experience': [31, 31, 31, 31, 31, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 34, 34, 34, 34, 34, 34, 34, 34, 34], 'Fundinghistory_researchgrants': ['800000', '800000', '800000', '800000', '800000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1300000', '1300000', '1300000', '1300000', '1300000', '1300000', '1300000'], 'Fundinghistory_ConsultingFees': [750, 750, 750, 750, 750, 750, 750, 750, 750, 750, 750, 750, 750, 750, 750, 750, 750, 750, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900], 'Fundinghistory_EducationalGrants': ['800000', '800000', '800000', '800000', '800000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '950000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1050000', '1300000', '1300000', '1300000', '1300000', '1300000', '1300000', '1300000'], 'No_Of_Publications': [22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23, 23, 23, 23, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 25, 25, 25, 25], 'Trainings_Delivered': [24, 24, 24, 24, 25, 25, 25, 25, 25, 25, 25, 25, 26, 26, 26, 26, 26, 26, 26, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 29], 'Professional_Certification': [14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 15, 15, 15, 15, 15, 15, 15, 15, 16, 16, 16, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [72, 72, 72, 73, 73, 74, 74, 74, 75, 75, 75, 76, 76, 76, 76, 77, 77, 77, 77, 78, 78, 78, 78, 79, 79, 79, 80, 80, 80, 80, 81, 81, 81, 81, 81, 82, 82, 82, 83, 83], 'National_presentations_Presented': [186, 186, 187, 187, 188, 188, 189, 190, 190, 190, 191, 191, 192, 193, 194, 195, 196, 197, 198, 198, 200, 201, 202, 202, 202, 203, 203, 205, 206, 207, 208, 209, 210, 211, 212, 213, 213, 214, 215, 217], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Introduction to new drug Research', 'Reseach direction', 'Feasibility of Study', 'Discussion about effectivness of study.', 'Competition of study', 'Guidlines for trial', 'Selecting sites as per patient demographic', 'Principal Investigator support role', 'Safety procedure for trial', 'Selcting sites for clinical trial', 'To get KoL aggrement.', 'Guidlines for the trial sites', 'Finalizing sites for clinical trial', 'Principal Investigator support onboarding.', 'Guidlines for the trial sites', 'Guidlines for safety in trial sites', 'Completed Onboarding', 'Sites setup completion', 'Efficiency of competitive drug', 'Guidlines for trial start', 'Trial Progress', 'Initial cost of drug', 'Safety of volunteer', 'Reseach comparision', 'Insurance coverage draft for drug', 'Copay for claims', 'Trial Progress report', 'Guidlines for trial end', 'Side Effect', 'Efficiency of competitive drug', 'Trial Status', 'Trial closure inititation', 'Post Trial Implementation', 'Post Trial report', 'Trial report', 'Trial Result w.r.t Competitive drug', 'Insurance coverage draft review', 'Copay for claims review', 'Side Effect Noticed post trial', 'Trial Result'], 'Previous_Meeting_SubTopics': ['New Research', 'Feasibility of Study', 'Feasibility of Study', 'Competition analysis', 'Regulatory Guidlines', 'Patient Demographics for clinical trial sites', 'Principal Investigator support', 'Safety', 'Patient Demographics for clinical trial sites', 'Principal Investigator support', 'Regulatory Guidlines', 'Patient Demographics for clinical trial sites', 'Principal Investigator support', 'Regulatory Guidlines', 'Safety', 'Principal Investigator support', 'Patient Demographics for clinical trial sites', 'Competition analysis', 'Regulatory Guidlines', 'Feasibility of Study', 'Claims/Insurance/Copay Programs', 'Safety', 'Competition analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Feasibility of Study', 'Regulatory Guidlines', 'Safety', 'Competition analysis', 'Feasibility of Study', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Feasibility of Study', 'Competition analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Safety', 'Feasibility of Study', 'Competition analysis'], 'Current_Discussion_Topic': ['Reseach direction', 'Feasibility of Study', 'Discussion about effectivness of study.', 'Competition of study', 'Guidlines for trial', 'Sites recommendation for clinical trial', 'Principal Investigator support role', 'Safety procedure for trial', 'Selcting sites for clinical trial', 'To get KoL aggrement.', 'Guidlines for the trial sites', 'Finalizing sites for clinical trial', 'Principal Investigator support onboarding.', 'Guidlines for the trial sites', 'Guidlines for safety in cases of adverse reaction', 'Completed Onboarding', 'Sites setup completion', 'Efficiency of competitive drug', 'Guidlines for trial start', 'Trial Progress report', 'Initial cost of drug', 'Side Effect', 'Reseach comparision', 'Insurance coverage draft for drug', 'Copay for claims', 'Trial Progress report', 'Guidlines for trial end', 'Side Effect', 'Efficiency of competitive drug', 'Trial Status', 'Trial closure inititation', 'Post Trial Implementation', 'Post Trial report', 'Trial Result Progress', 'Trial Result w.r.t Competitive drug', 'Insurance coverage draft review', 'Copay for claims review', 'Side Effect Noticed post trial', 'Trial Result', 'Compare result with other drug'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'In-Person', 'In-Person', 'Video Conference', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Video Conference', 'In-Person', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Video Conference', 'E-mail', 'Video Conference', 'Video Call', 'In-Person', 'Video Conference', 'Video Conference', 'Video Call', 'In-Person', 'Video Conference', 'Video Call', 'Video Conference', 'In-Person', 'Video Call', 'Video Conference', 'In-Person', 'Video Conference', 'Video Conference', 'Video Conference', 'In-Person', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Video Conference', 'Video Conference'], 'Company_Event': ['Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug'], 'Interaction_intent': ['New Research', 'Feasibility of Study', 'Feasibility of Study', 'Competition analysis', 'Regulatory Guidlines', 'Patient Demographics for clinical trial sites', 'Principal Investigator support', 'Safety', 'Patient Demographics for clinical trial sites', 'Principal Investigator support', 'Regulatory Guidlines', 'Patient Demographics for clinical trial sites', 'Principal Investigator support', 'Regulatory Guidlines', 'Safety', 'Principal Investigator support', 'Patient Demographics for clinical trial sites', 'Competition analysis', 'Regulatory Guidlines', 'Feasibility of Study', 'Claims/Insurance/Copay Programs', 'Safety', 'Competition analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Feasibility of Study', 'Regulatory Guidlines', 'Safety', 'Competition analysis', 'Feasibility of Study', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Feasibility of Study', 'Competition analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Safety', 'Feasibility of Study', 'Competition analysis'], 'Items/topics_to_exchange': ['Reseach direction', 'Feasibility of Study', 'Discussion about effectivness of study.', 'Competition of study', 'Guidlines for trial', 'Sites recommendation for clinical trial', 'Principal Investigator support role', 'Safety procedure for trial', 'Selcting sites for clinical trial', 'To get KoL agreement for the role of Principal Investigator support', 'Guidlines for the trial sites', 'Finalizing sites for clinical trial', 'Principal Investigator support onboarding.', 'Guidlines for the trial sites', 'Guidlines for safety in cases of adverse reaction', 'Completed Onboarding', 'Sites setup completion', 'Efficiency of competitive drug', 'Guidlines for trial start', 'Trial Progress report', 'Initial cost of drug', 'Side effects of durg', 'Comparing trial result with competition', 'Insurance coverage for drug', 'Copay for claims', 'Trial Progress report', 'Guidlines for trial end', 'Side effects noted during study', 'Efficiency w.r.t competitor drug', 'Trial Status', 'Trial closure inititation', 'Post Trial Implementation', 'Post Trial report', 'Trial Result Progress', 'Trial Result w.r.t Competitive drug', 'Insurance coverage draft review', 'Copay for claims review', 'Side Effect Noticed post trial', 'Trial Result', 'Compare result with other drug'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Feasibility of Study', 'Feasibility of Study', 'Feasibility of Study', 'Competition analysis', 'Regulatory Guidlines', 'Regulatory Guidlines', 'Principal Investigator support', 'Safety', 'Regulatory Guidlines', 'Principal Investigator support', 'Regulatory Guidlines', 'Regulatory Guidlines', 'Principal Investigator support', 'Safety', 'Regulatory Guidlines', 'Regulatory Guidlines', 'Patient Demographics for clinical trial sites', 'Competition analysis', 'Regulatory Guidlines', 'Competition analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Competition analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Safety', 'Regulatory Guidlines', 'Regulatory Guidlines', 'Competition analysis', 'Feasibility of Study', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Feasibility of Study', 'Competition analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Competition analysis', 'Feasibility of Study', 'Claims/Insurance/Copay Programs'], 'Proposed_Next_Channel_Of_interaction': ['In-Person', 'In-Person', 'Video Conference', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Video Conference', 'In-Person', 'Video Call', 'Video Conference', 'In-Person', 'Video Conference', 'Video Conference', 'E-mail', 'Video Conference', 'Video Call', 'In-Person', 'Video Conference', 'Video Conference', 'Video Call', 'In-Person', 'Video Conference', 'Video Conference', 'Video Conference', 'In-Person', 'Video Call', 'Video Conference', 'In-Person', 'Video Conference', 'Video Conference', 'Video Conference', 'In-Person', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Video Conference', 'Video Conference', 'In-Person']}"
1,"{'kol': 'Anibal Davis', 'Interaction_Date': ['1-Apr-19', '6-May-19', '28-May-19', '1-Jun-19', '7-Jul-19', '19-Sep-19', '22-Dec-19', '6-Feb-20', '19-Apr-20', '22-Jun-20', '6-Aug-20', '19-Oct-20', '22-Dec-20', '6-Mar-21', '19-May-21', '22-Jul-21', '6-Sep-21', '19-Nov-21', '22-Jan-22', '6-Mar-22', '7-May-22', '8-Jul-22', '10-Oct-22', '10-Dec-22', '10-Jan-23', '24-Feb-23', '30-Mar-23'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer'], 'KOL_years_of_Experience': [23, 23, 23, 23, 23, 23, 23, 23, 24, 24, 24, 24, 24, 25, 25, 25, 25, 25, 26, 26, 26, 26, 26, 26, 27, 27, 27], 'KOL_Location': ['California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California'], 'KOL_Territory': ['West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast'], 'SocialMedia_Twitter': ['23K', '23K', '23K', '23K', '23K', '23K', '23K', '23K', '23K', '23K', '23K', '23K', '23K', '23K', '23.5K', '23.5K', '23.5K', '23.5K', '23.5K', '23.5K', '23.5K', '23.5K', '23.5K', '23.5K', '23.9K', '23.9K', '23.9K'], 'SocialMedia_Linkedin': ['17K', '17K', '17K', '17.5K', '17.5K', '17.5K', '17.5K', '17.5K', '17.9K', '17.9K', '17.9K', '17.9K', '17.9K', '17.9K', '18K', '18K', '18K', '18K', '18K', '18K', '18K', '18K', '18.5K', '18.5K', '18.5K', '18.5K', '18.5K'], 'SocialMedia_YouTube': ['15K', '15K', '15.2K', '15.5K', '15.7K', '15.7K', '15.7K', '15.7K', '15.8K', '15.8K', '15.9K', '15.9K', '15.9K', '15.9K', '17K', '17K', '17K', '17K', '17.3K', '17.7K', '17.7K', '18.4K', '18.4K', '18.4K', '18.4K', '18.4K', '18.4K'], 'Overall_Kol_Rating': [3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'Research_Participated': [15, 15, 15, 16, 16, 16, 16, 16, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 19], 'Research_Experience': [17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 20, 20, 20, 20, 20, 20], 'Fundinghistory_researchgrants': ['130000', '130000', '130000', '130000', '130000', '130000', '130000', '130000', '140000', '140000', '140000', '140000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '170000', '170000', '170000', '170000', '170000', '170000'], 'Fundinghistory_ConsultingFees': [450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 450, 500, 500, 500], 'Fundinghistory_EducationalGrants': ['130000', '130000', '130000', '130000', '130000', '130000', '130000', '130000', '140000', '140000', '140000', '140000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '170000', '170000', '170000', '170000', '170000', '170000'], 'No_Of_Publications': [15, 15, 16, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 21, 21, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'Trainings_Delivered': [20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'Professional_Certification': [7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'KOL_affiliations_academicinstitutionss': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [23, 23, 23, 23, 23, 23, 23, 23, 24, 24, 24, 24, 24, 25, 25, 25, 25, 25, 26, 26, 26, 26, 26, 26, 27, 27, 27], 'National_presentations_Presented': [230, 230, 230, 230, 230, 230, 230, 230, 240, 240, 240, 240, 240, 250, 250, 250, 250, 250, 260, 260, 260, 260, 260, 260, 270, 270, 270], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Discussion regarding long-term risks and benefits of using the drug', 'Identifying various competators and gather information about them', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the clinical trial', 'Safety measures of the drug on general patients', 'Efficacy & Accuracy of Drug', 'Patient Safety during Clinical Trial', 'To discuss regarding \n Procedures\n Risks and benefits and the rights of patients , treatment options in case of adverse events', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Product overview and its differentiating way', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Finding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug'], 'Previous_Meeting_SubTopics': ['Analysis of various competators in industry', 'Analysis of various competators in industry', 'Discussion on Principal Investigator Support', 'Safety', 'Efficacy & Accuracy of Drug', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'Discussion regarding claims/insurance and copay programs', 'Technical feasibility', 'Financial feasibility', 'Market feasibility', 'Operational feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Current_Discussion_Topic': ['Identifying various competators and gather information about them', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the clinical trial', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Finding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'Email', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'Video Conference', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person'], 'Company_Event': ['Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug'], 'Interaction_intent': ['identifying competitors in industry', 'To determine competative advantage by analysing strengths and weaknesses of Competators', 'Indentifying Principal Investigator for the Clinical trial who has substantial experience as PI in past and how much support he can provide in Clinical Trial', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'To discuss about the claims,insurance and copay programs', 'Technical feasibility', 'Financial feasibility', 'Market feasibility', 'Operational feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Items/topics_to_exchange': ['Analysis of various competators in industry', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the Clinical trial who has substantial experience as PI in past', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Are there risks to taking part in the trial?\n Who is watching out for any problems?\n Who is making sure that people who take part are safe?\n Is the trial trying to answer an important research question?', 'To discuss regarding \n Procedures\n Risks and benefits and the rights of patients , treatment options in case of adverse events', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Findiding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Analyse competators strengths & weaknesses and determine your competative advange', 'Discussion on Principal Investigator Support', 'Safety : Discussion on Safety Measures', 'Safety : discussion regarding efficay and accuracy of drug', 'Safety : Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discussion regarding submitting application for investigational new drug', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'Discuss compliance and ethical practices', 'Technical feasibility', 'Financial feasibility', 'Market Feasibility', 'Operational Feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.', 'Discussion regarding rare side effects.'], 'Proposed_Next_Channel_Of_interaction': ['Phone Call', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'Phone Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'In-Person']}"
2,"{'kol': 'Chris Bogan', 'Interaction_Date': ['11-Apr-19', '6-Jun-19', '28-Jun-19', '1-Aug-19', '7-Sep-19', '19-Oct-19', '22-Dec-19', '22-Feb-20', '10-Apr-20', '11-Jun-20', '1-Aug-20', '19-Sep-20', '22-Nov-20', '6-Jan-21', '19-Mar-21', '22-May-21', '6-Jul-21', '19-Oct-21', '20-Jan-22', '11-Mar-22', '17-May-22', '9-Jul-22', '18-Oct-22', '15-Dec-22', '30-Jan-23', '28-Feb-23', '30-Mar-23'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer'], 'KOL_years_of_Experience': [20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 23, 23, 23], 'KOL_Location': ['Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['20K', '20K', '20.2K', '20.4K', '20.6K', '20.6K', '20.6K', '20.6K', '20.8K', '20.8K', '20.9K', '20.9K', '20.9K', '20.9K', '21K', '21K', '21K', '21K', '21.2K', '21.6K', '21.6K', '22K', '22K', '22K', '22K', '22K', '22K'], 'SocialMedia_Linkedin': ['17K', '17K', '17K', '17.2K', '17.5K', '17.5K', '17.5K', '17.5K', '17.8K', '17.8K', '17.8K', '17.8K', '17.8K', '17.8K', '19K', '19K', '19K', '19K', '20K', '20.4K', '20.4K', '21K', '21K', '21K', '21K', '21K', '21K'], 'SocialMedia_YouTube': ['15K', '15K', '15.2K', '15.5K', '15.7K', '15.7K', '15.7K', '15.7K', '15.8K', '15.8K', '15.9K', '15.9K', '15.9K', '15.9K', '17K', '17K', '17K', '17K', '17.3K', '17.7K', '17.7K', '18.4K', '18.4K', '18.4K', '18.4K', '18.4K', '18.4K'], 'Overall_Kol_Rating': [3.7, 3.7, 3.7, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'Research_Participated': [15, 15, 15, 16, 16, 16, 16, 16, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 19], 'Research_Experience': [17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 20, 20, 20, 20, 20, 20], 'Fundinghistory_researchgrants': ['120000', '120000', '120000', '130000', '130000', '130000', '130000', '130000', '140000', '140000', '140000', '140000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '170000', '170000', '170000', '170000', '170000', '170000'], 'Fundinghistory_ConsultingFees': [220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220], 'Fundinghistory_EducationalGrants': ['120000', '120000', '120000', '130000', '130000', '130000', '130000', '130000', '140000', '140000', '140000', '140000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '170000', '170000', '170000', '170000', '170000', '170000'], 'No_Of_Publications': [15, 15, 16, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 21, 21, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'Trainings_Delivered': [20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'Professional_Certification': [7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'KOL_affiliations_academicinstitutionss': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [40, 40, 40, 40, 40, 40, 40, 42, 42, 42, 42, 42, 42, 42, 42, 42, 42, 42, 44, 44, 44, 44, 44, 44, 46, 46, 46], 'National_presentations_Presented': [120, 120, 120, 120, 120, 120, 120, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 132, 132, 132, 132, 132, 132, 138, 138, 138], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Discussion regarding long-term risks and benefits of using the drug', 'Identifying various competators and gather information about them', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the clinical trial', 'Safety measures of the drug on general patients', 'Efficacy & Accuracy of Drug', 'Patient Safety during Clinical Trial', 'To discuss regarding \n Procedures\n Risks and benefits and the rights of patients , treatment options in case of adverse events', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Product overview and its differentiating way', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Finding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug'], 'Previous_Meeting_SubTopics': ['Analysis of various competators in industry', 'Analysis of various competators in industry', 'Discussion on Principal Investigator Support', 'Safety', 'Efficacy & Accuracy of Drug', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'Discussion regarding claims/insurance and copay programs', 'Technical feasibility', 'Financial feasibility', 'Market feasibility', 'Operational feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Current_Discussion_Topic': ['Identifying various competators and gather information about them', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the clinical trial', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Finding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'Email', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'Video Conference', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person'], 'Company_Event': ['Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug'], 'Interaction_intent': ['identifying competitors in industry', 'To determine competative advantage by analysing strengths and weaknesses of Competators', 'Indentifying Principal Investigator for the Clinical trial who has substantial experience as PI in past and how much support he can provide in Clinical Trial', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'To discuss about the claims,insurance and copay programs', 'Technical feasibility', 'Financial feasibility', 'Market feasibility', 'Operational feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Items/topics_to_exchange': ['Analysis of various competators in industry', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the Clinical trial who has substantial experience as PI in past', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Are there risks to taking part in the trial?\n Who is watching out for any problems?\n Who is making sure that people who take part are safe?\n Is the trial trying to answer an important research question?', 'To discuss regarding \n Procedures\n Risks and benefits and the rights of patients , treatment options in case of adverse events', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Findiding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Analyse competators strengths & weaknesses and determine your competative advange', 'Discussion on Principal Investigator Support', 'Safety : Discussion on Safety Measures', 'Safety : discussion regarding efficay and accuracy of drug', 'Safety : Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discussion regarding submitting application for investigational new drug', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'Discuss compliance and ethical practices', 'Technical feasibility', 'Financial feasibility', 'Market Feasibility', 'Operational Feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.', 'Discussion regarding rare side effects.'], 'Proposed_Next_Channel_Of_interaction': ['Phone Call', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'Phone Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'In-Person']}"
3,"{'kol': 'D.Singh', 'Interaction_Date': ['3-Apr-19', '1-May-19', '10-Jun-19', '7-Jul-19', '14-Aug-19', '20-Sep-19', '10-Oct-19', '4-Nov-19', '4-Dec-19', '10-Jan-20', '12-Feb-20', '1-Mar-20', '1-Apr-20', '5-May-20', '13-Jun-20', '9-Jul-20', '4-Aug-20', '4-Sep-20', '10-Oct-20', '16-Nov-21', '11-Dec-21', '8-Jan-21', '10-Feb-21', '1-Mar-21', '5-Apr-21', '3-May-21', '15-Jun-21', '11-Jul-21', '2-Aug-21', '6-Sep-21', '1-Oct-21', '20-Nov-21', '17-Dec-21', '22-Jan-22', '10-Feb-22', '1-Mar-22', '5-Apr-22', '7-May-22', '16-Jun-22', '1-Jul-22'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer'], 'KOL_years_of_Experience': [31, 31, 31, 31, 31, 31, 31, 31, 31, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 34, 34, 34, 34, 34, 34, 34], 'KOL_Location': ['New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['38k', '38k', '38k', '38k', '38k', '39k', '39k', '39k', '39k', '39k', '39k', '39k', '39k', '40k', '40k', '40k', '40k', '40k', '40k', '40k', '40k', '40k', '40k', '41k', '41k', '41k', '41k', '41k', '41k', '41k', '41k', '41k', '41k', '41k', '42k', '42k', '42k', '42k', '42k', '42k'], 'SocialMedia_Linkedin': ['30k', '30k', '30k', '30k', '30k', '30k', '31k', '31k', '31k', '31k', '31k', '31k', '31k', '32k', '32k', '32k', '32k', '32k', '32k', '32k', '32k', '32k', '32k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '34k', '34k'], 'SocialMedia_YouTube': ['30k', '30k', '30k', '30k', '30k', '30k', '31k', '31k', '31k', '31k', '31k', '31k', '31k', '32k', '32k', '32k', '32k', '32k', '32k', '32k', '32k', '32k', '32k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k', '33k'], 'Overall_Kol_Rating': [4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5, 4.4, 4.4, 4.4, 4.4, 4.5, 4.5, 4.5, 4.5, 4.5, 4.5], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'Research_Participated': [36, 36, 36, 36, 36, 36, 36, 36, 36, 36, 36, 36, 36, 36, 36, 36, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38, 38], 'Research_Experience': [18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19], 'Fundinghistory_researchgrants': ['20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '21000', '21000', '21000', '21000', '21000', '21000', '21000', '21000', '21000', '21000', '21000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000'], 'Fundinghistory_ConsultingFees': [900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900], 'Fundinghistory_EducationalGrants': ['20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '21000', '21000', '21000', '21000', '21000', '21000', '21000', '21000', '21000', '21000', '21000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000', '23000'], 'No_Of_Publications': [20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23, 23, 23, 23], 'Trainings_Delivered': [19, 19, 19, 19, 19, 19, 19, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22], 'Professional_Certification': [20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23, 23, 23, 23], 'KOL_affiliations_academicinstitutionss': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'National_presentations_Presented': [20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22], 'KOL_FollowUp': ['No', 'No', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['No', 'No', 'Addressing the challenges and opportunities of using Internet of Things (IoT) technology in medical asset management.', 'Discussing the potential of big data analytics in optimizing medical asset utilization and performance.', 'Exploring the use of blockchain technology in securing medical asset supply chains and preventing counterfeit products.', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Exploring the potential of tele-rehabilitation and remote monitoring devices in post-acute care medical asset development.', 'Addressing the challenges and opportunities in the development of assistive technologies and adaptive medical assets.', 'Strategies for integrating data privacy and security measures in connected medical assets.', 'Discussing the potential impact of 3D bioprinting in tissue and organ replacement medical asset development.', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Discussing the potential impact of microfluidics and lab-on-a-chip technologies in medical asset development.', 'No', 'No', 'No', 'No'], 'Previous_Meeting_SubTopics': ['No', 'No', 'How IOT has potential to revolutionize medical asset management', 'how big data analytics can optimize medical asset utilization', 'how blockchain can be utilized', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Discussing major points how tele-rehabilitation and remote monitoring devices can be integrated with assets', 'Discussing challenges and opportunities that exist in their development', 'strategies for effectively addressing data privacy and security', 'impact of 3D bioprinting', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'potential impacts of microfluidics', 'No', 'No', 'No', 'No'], 'Current_Discussion_Topic': ['Exploring the use of virtual reality and augmented reality in medical asset training and simulation.', 'Addressing the challenges and opportunities of using Internet of Things (IoT) technology in medical asset management.', 'Discussing the potential of big data analytics in optimizing medical asset utilization and performance.', 'Exploring the use of blockchain technology in securing medical asset supply chains and preventing counterfeit products.', 'Addressing the ethical considerations in the development and use of autonomous medical assets.', 'Strategies for promoting diversity and inclusivity in the design and development of medical assets.', 'Discussing the role of human-centered design principles in improving the usability and user experience of medical assets.', 'Exploring the potential of precision medicine and genetic testing in personalized medical asset generation.', 'Addressing the challenges of integrating medical assets into telemedicine and remote healthcare delivery models.', 'Strategies for promoting sustainability in the lifecycle of medical assets, from production to disposal.', 'Discussing the potential impact of 5G technology on the development and utilization of medical assets.', 'Exploring the use of robotics and automation in surgical and procedural medical asset development.', 'Addressing the challenges and opportunities in the development of point-of-care diagnostic medical assets.', 'Strategies for enhancing collaboration between healthcare professionals and engineers in medical asset generation.', 'Discussing the role of virtual reality and telepresence technologies in remote training and support for medical asset users.', 'Exploring the use of bioengineering and biomimicry in the design and development of medical assets.', 'Addressing the ethical implications of artificial intelligence algorithms in medical asset decision-making processes.', 'Strategies for incorporating patient-generated data into the design and optimization of medical assets.', 'Discussing the potential of nanomedicine in the development of targeted therapeutic medical assets.', 'Exploring the use of smart sensors and wearable devices in monitoring and managing chronic conditions.', 'Addressing the challenges and opportunities in the development of sustainable packaging for medical assets.', 'Strategies for ensuring the safety and efficacy of medical assets in low-resource settings.', 'Discussing the role of medical asset generation in advancing global health security and pandemic preparedness.', 'Exploring the potential of tele-rehabilitation and remote monitoring devices in post-acute care medical asset development.', 'Addressing the challenges and opportunities in the development of assistive technologies and adaptive medical assets.', 'Strategies for integrating data privacy and security measures in connected medical assets.', 'Discussing the potential impact of 3D bioprinting in tissue and organ replacement medical asset development.', 'Exploring the use of natural language processing and voice recognition technologies in medical asset interfaces.', 'Addressing the challenges and opportunities of using mobile health applications in conjunction with medical assets.', 'Strategies for promoting interdisciplinary collaboration in medical asset generation and innovation.', 'Discussing the role of patient education and training in optimizing the use of medical assets.', 'Exploring the potential of tele-robotic systems in surgical and interventional medical asset development.', 'Addressing the challenges and opportunities in the development of drug delivery medical assets.', 'Strategies for enhancing the resilience and adaptability of medical asset supply chains during crises and emergencies.', 'Discussing the potential impact of microfluidics and lab-on-a-chip technologies in medical asset development.', 'Exploring the use of biocompatible materials and coatings in medical asset design and manufacturing.', 'Addressing the challenges and opportunities in the development of remote patient monitoring medical assets.', 'Strategies for promoting regulatory harmonization and alignment in medical asset generation.', 'Discussing the role of artificial intelligence in medical asset predictive maintenance and fault detection.', 'Discussing major changes being added to the asset generation process'], 'Current_Meeting_Subtopics': ['ways VR and AR can be utilized', 'How IOT has potential to revolutionize medical asset management', 'how big data analytics can optimize medical asset utilization', 'how blockchain can be utilized', 'key ethical considerations', 'strategies to foster diversity and inclusivity', 'Discussing the role of human-centered design principles in improving the usability and user experience of medical assets.', 'How Precision medicine can be utilized to develop personalized medical assets', 'key challenges and strategies to overcome challenges', 'Steps to be taken for promoting sustainability', 'potential impacts of 5G on medical assets', 'aspects and benefits of incorporating robotics and automation', 'Measures being taken to overcome challenges, Discussing opportunities in the development of point of care diagnostic assets', 'strategies to promote effective collaboration', 'How technologies provide immersive and interactive experiences', 'ways bioengineering and biomimicry are utilized', 'key ethical concerns', 'Discussing strategies for using pateint generated data', 'key aspects of the potential of nanomedicine in targeted therapeutics', 'key aspects of use in chronic condition monitoring', 'Measures to betaken for development of sustainable packaging', 'discussing strategies that help address challenges and promote the safe and effective use of medical assets', 'key aspects of its contribution', 'Discussing major points how tele-rehabilitation and remote monitoring devices can be integrated with assets', 'Discussing challenges and opportunities that exist in their development', 'strategies for effectively addressing data privacy and security', 'impact of 3D bioprinting', 'key aspects to consider', 'Measures to be taken to overcome challenges', 'strategies to foster such collaboration', 'Report on skills necessary to utilize medical assets effectively', 'key aspects of tele-robotic systems', 'key considerations for addressing these aspects', 'Key points for enhancing the resilience and adaptability', 'potential impacts of microfluidics', 'key aspects to consider', 'key considerations', 'strategies to consider', 'key aspects of AI', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In Person', 'In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'Video', 'In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person'], 'Company_Event': ['Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation'], 'Interaction_intent': ['areas where VR and AR have been utilized in medical asset training and simulation', 'use of Internet of Things (IoT) technology in medical asset management', 'ways big data analytics can be leveraged', 'solutions for securing medical asset supply chains and preventing counterfeit products', 'key ethical considerations associated with autonomous medical assets', 'strategies to consider for promoting diversity and inclusivity in the design and development of medical assets', 'key aspects of human-centered design and their impact on medical asset usability and user experience', 'Discussing potential of precision medicine and genetic testing in personalized medical asset generation', 'key considerations to Addressing the challenges of integrating medical assets into telemedicine and remote healthcare delivery models', 'strategies to consider promoting sustainability in the lifecycle of medical assets, from production to disposal', 'ways in which 5g technology can have impact on development and utilization of medical assets', 'key aspects and benefits of this technology', 'key considerations Addressing the challenges and opportunities', 'strategies to promote effective collaboration', 'role of virtual reality and telepresence technologies in remote training and support for medical asset users', 'some aspects to consider for use of bioengineering and biomimicry in the design and development of medical assets', 'key aspects to Addressing the ethical implications of artificial intelligence algorithms in medical asset decision-making processes.', 'strategies to consider for incorporating patient-generated data into the design and optimization', 'key aspects to consider regarding the potential of nanomedicine in the development of targeted therapeutic medical assets', 'some ways in which these technologies are being employed', 'key considerations for Addressing the challenges and opportunities in the development of sustainable packaging', 'strategies to consider for ensuring the safety and efficacy of medical assets', 'key contributions', 'key aspects to consider while Exploring the potential of tele-rehabilitation and remote monitoring devices', 'challenges and opportunities in enhancing the quality of life for individuals with disabilities', 'strategies for effectively addressing data privacy and security', 'key aspects to consider', 'Discussing the use of natural language processing and voice recognition technologies in medical asset interfaces.', 'challenges and opportunities of using mobile health applications in conjunction with medical assets', 'some strategies to encourage interdisciplinary collaboration', 'role of patient education and training in optimizing the use of medical assets', 'Discussing potential of tele-robotic systems in surgical and interventional medical asset development', 'challenges and opportunities in the development of drug delivery medical assets', 'discussing strategies to consider for enhancing the resilience and adaptability', 'How Microfluidics and lab-on-a-chip technologies have the potential to revolutionize medical asset development', 'key aspects of their utilization', 'key considerations', 'strategies to promote regulatory harmonization', 'key aspects of AI', 'Discussing major changes being added to the asset generation process'], 'Items/topics_to_exchange': ['Report how VR and AR have been utilized', 'Challenges and opportunities of using IOT in medical asset management', 'potential of big data analytics in optimizing medical asset utilization', 'how blockchain technology can be utilized', 'ethical considerations in the development and use of autonomous medical assets', 'Discussing strategies, Promotion Ideas', 'role of human-centered design principles in improving the usability and user experience of medical assets', 'how these technologies can work together', 'measures to overcome challenges', 'Discussing diffrent strategies for promoting sustainability', 'Enhanced Connectivity using 5G technology, Data Security and Privacy using 5G technology', 'How robotics and automation can increase Workflow Efficiency', 'Quality Control and Standardization, accessibility and Affordability', 'Establish Interdisciplinary Teams, Joint Problem Identification and Solution Development', 'Immersive Training, Remote Training and Education', 'Disucssion use of bioengineering and biomimicry in the design and development of medical assets', 'Transparency and Explainability, Data Privacy and Security', 'Discussing the strategies to consider for incorporating pateint generated data into the design and optimization', 'Regenerative Medicine, Safety and Regulatory Considerations', 'Disease Management and Medication Adherence, Behavior Modification and Lifestyle Management', 'Discussing challenges and oppotunities', 'Training and Capacity Building, Infrastructure Support', 'global health security and pandemic preparedness', 'Access to Specialized Care, Personalized Rehabilitation Plans', 'measures to overcome challenges , Discussing opportunities', 'Secure Network Infrastructure, Secure Data Storage and Transmission', 'Accelerating Drug Discovery and Testing, Regenerative Medicine and Tissue Engineering', 'Time-Saving and Efficiency, report on NLP and voice recognition technologies', 'Plans to overcome challenges', 'Discussing and Defining Clear Goals and Objectives', 'Plans to Enhance Safety and Efficacy, Improving Treatment Adherence', 'key aspects', 'key challenges and opportunities associated with drug delivery medical asset development', 'Implement Risk Management Strategies, enchancing the resilience and adaptability', 'Faster and More Efficient Analysis, Drug Delivery and Therapy Monitoring', 'Discussing safety, effectiveness, and compatibility of these assets with the human body', 'Discussion on development of remote patient monitoring (RPM) medical assets', 'discussing promoting regulatory harmonization and alignment in medical asset generation', 'Fault Detection and Diagnosis, Condition Monitoring using AI', 'Discussion on impact of major things that are being added'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Addressing the challenges and opportunities of using Internet of Things (IoT) technology in medical asset management.', 'Discussing the potential of big data analytics in optimizing medical asset utilization and performance.', 'Exploring the use of blockchain technology in securing medical asset supply chains and preventing counterfeit products.', 'Addressing the ethical considerations in the development and use of autonomous medical assets.', 'Strategies for promoting diversity and inclusivity in the design and development of medical assets.', 'Discussing the role of human-centered design principles in improving the usability and user experience of medical assets.', 'Exploring the potential of precision medicine and genetic testing in personalized medical asset generation.', 'Addressing the challenges of integrating medical assets into telemedicine and remote healthcare delivery models.', 'Strategies for promoting sustainability in the lifecycle of medical assets, from production to disposal.', 'Discussing the potential impact of 5G technology on the development and utilization of medical assets.', 'Exploring the use of robotics and automation in surgical and procedural medical asset development.', 'Addressing the challenges and opportunities in the development of point-of-care diagnostic medical assets.', 'Strategies for enhancing collaboration between healthcare professionals and engineers in medical asset generation.', 'Discussing the role of virtual reality and telepresence technologies in remote training and support for medical asset users.', 'Exploring the use of bioengineering and biomimicry in the design and development of medical assets.', 'Addressing the ethical implications of artificial intelligence algorithms in medical asset decision-making processes.', 'Strategies for incorporating patient-generated data into the design and optimization of medical assets.', 'Discussing the potential of nanomedicine in the development of targeted therapeutic medical assets.', 'Exploring the use of smart sensors and wearable devices in monitoring and managing chronic conditions.', 'Addressing the challenges and opportunities in the development of sustainable packaging for medical assets.', 'Strategies for ensuring the safety and efficacy of medical assets in low-resource settings.', 'Discussing the role of medical asset generation in advancing global health security and pandemic preparedness.', 'Exploring the potential of tele-rehabilitation and remote monitoring devices in post-acute care medical asset development.', 'Addressing the challenges and opportunities in the development of assistive technologies and adaptive medical assets.', 'Strategies for integrating data privacy and security measures in connected medical assets.', 'Discussing the potential impact of 3D bioprinting in tissue and organ replacement medical asset development.', 'Exploring the use of natural language processing and voice recognition technologies in medical asset interfaces.', 'Addressing the challenges and opportunities of using mobile health applications in conjunction with medical assets.', 'Strategies for promoting interdisciplinary collaboration in medical asset generation and innovation.', 'Discussing the role of patient education and training in optimizing the use of medical assets.', 'Exploring the potential of tele-robotic systems in surgical and interventional medical asset development.', 'Addressing the challenges and opportunities in the development of drug delivery medical assets.', 'Strategies for enhancing the resilience and adaptability of medical asset supply chains during crises and emergencies.', 'Discussing the potential impact of microfluidics and lab-on-a-chip technologies in medical asset development.', 'Exploring the use of biocompatible materials and coatings in medical asset design and manufacturing.', 'Addressing the challenges and opportunities in the development of remote patient monitoring medical assets.', 'Strategies for promoting regulatory harmonization and alignment in medical asset generation.', 'Discussing the role of artificial intelligence in medical asset predictive maintenance and fault detection.', 'Discussing major changes being added to the asset generation process', 'Addressing roadblocks in asset generation'], 'Proposed_Next_Channel_Of_interaction': ['In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'Video', 'In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person', 'Video']}"
4,"{'kol': 'David Kim', 'Interaction_Date': ['1-Mar-21', '20-Mar-21', '1-May-21', '22-May-21', '6-Jun-21', '21-Jun-21', '2-Jul-21', '16-Jul-21', '1-Aug-21', '21-Aug-21', '2-Sep-21', '21-Sep-21', '2-Jan-22', '26-Jan-22', '1-Feb-22', '22-Feb-22', '6-Mar-22', '19-Mar-22', '2-Apr-22', '16-Apr-22', '1-May-22', '22-May-22', '6-Jun-22', '19-Jun-22', '2-Jul-22', '26-Jul-22', '1-Aug-22', '22-Aug-22', '6-Sep-22', '19-Sep-22', '2-Oct-22', '26-Oct-22', '1-Nov-22', '22-Nov-22', '2-Dec-22', '19-Dec-22', '2-Jan-23', '26-Jan-23', '1-Feb-23', '22-Feb-23'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer'], 'KOL_years_of_Experience': [9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10], 'KOL_Location': ['New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K', '9K'], 'SocialMedia_Linkedin': ['7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '7.1K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K', '8.3K'], 'SocialMedia_YouTube': ['6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '6.5K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K', '7.4K'], 'Overall_Kol_Rating': [3.7, 3.8, 3.9, 3.9, 3.9, 3.9, 4.1, 4.1, 4.0, 4.2, 4.4, 4.4, 4.3, 4.2, 4.2, 4.6, 4.6, 4.6, 4.6, 4.7, 4.71, 4.72, 4.8, 4.83, 4.7, 4.65, 4.54, 4.57, 4.58, 4.6, 4.3, 4.3, 4.3, 4.3, 4.3, 4.35, 4.3, 4.3, 4.4, 4.6], 'Connection_to_Advisory_Boards': [2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6], 'Research_Participated': [12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 15, 15, 15, 15, 15, 15, 15], 'Research_Experience': [9, 9, 9, 10, 10, 10, 10, 10, 10, 11, 11, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 13, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14], 'Fundinghistory_researchgrants': ['20000', '20000', '20000', '20000', '20000', '20000', '20000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000'], 'Fundinghistory_ConsultingFees': [0, 0, 0, 0, 0, 0, 0, 0, 0, 100, 100, 100, 100, 100, 100, 200, 200, 200, 200, 200, 200, 200, 300, 300, 300, 400, 400, 400, 500, 500, 500, 500, 500, 600, 600, 600, 600, 600, 600, 600], 'Fundinghistory_EducationalGrants': ['20000', '20000', '20000', '20000', '20000', '20000', '20000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000'], 'No_Of_Publications': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6], 'Trainings_Delivered': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6], 'Professional_Certification': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'International_Presentations_Presented': [18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20], 'National_presentations_Presented': [135, 135, 135, 135, 135, 135, 135, 135, 135, 135, 135, 135, 135, 135, 135, 135, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['New drug launch initiation', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Cancer Awareness', 'Cost Analysis', 'Campaigns', 'Safety measures of the drug on general patients', 'Product overview and its differentiating way', 'Awareness Campaigns', 'Target receptor of drug', 'Efficacy and effectivenes of drug', 'Target receptor of drug', 'Product overview and its differentiating way', 'Product overview and its differentiating way', 'Efficacy and effectivenes of drug', 'Safety measures of the drug on general patients', 'New drug launch initiation', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Intro and overview of marketing strategy', 'New Insurance policy', 'Product overview and its differentiating way', 'Awareness Campaigns', 'Target receptor of drug', 'Intro and overview of claims procedure', 'Target receptor of drug', 'Product overview and its differentiating way', 'Discuss conference themes,outline session objectives,explore potential subtopics for Dr David Kim presenatation', 'Competitive Analysis of the drug', 'Study Design and Protocol Development,Regulatory Compliance,Site Selection', 'Awareness Campaigns', 'New drug launch initiation', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Intro and overview of copay programs', 'Intro and onvview of clinical safety'], 'Previous_Meeting_SubTopics': ['Introduction and overview of drug', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Address Problems regarding cost and usage of Verzenio brand', 'Public Outreach awareness', 'Share information on upcoming brand Verzenio launch', 'Sponsored patient programs', 'Discuss the event objectives,agenda and topics to be covered', 'Marketing Startegy', 'Patient Demographics', 'Discussion regarding claims/insurance and copay programs', 'Safety', 'Discussion regarding claims/insurance and copay programs', 'Discussion regarding claims/insurance and copay programs', 'Discuss the event objectives,agenda and topics to be covered', 'Sponsored patient programs', 'Introduction and overview of drug', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Into and overview of market strategy', 'Into and overview of Insurance policy', 'Discuss the event objectives,agenda and topics to be covered', 'Marketing Startegy', 'Patient Demographics', 'Discussion regarding claims/insurance and copay programs', 'Safety', 'Discussion regarding claims/insurance and copay programs', 'Competitive Analysis\u200b', 'Principal Investigator Support', 'Safety', 'Safety', 'Introduction and overview of drug', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Discussion regarding claims/insurance and copay programs', 'share information on upcoming clinical safety'], 'Current_Discussion_Topic': ['Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Cost Analysis', 'Campaigns', 'Verzenio Brand attributes', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Event agenda,subtopics,objectives', 'Advertisments,brand reach', 'Health Status,Origin ,age,race,gender of patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Safety measures of the drug on general patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Event agenda,subtopics,objectives', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Into and overview of Insurance policy', 'Event agenda,subtopics,objectives', 'Advertisments,brand reach', 'Health Status,Origin ,age,race,gender of patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Safety measures of the drug on general patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Competitive Analysis of the drug', 'Study Design and Protocol Development,Regulatory Compliance,Site Selection', 'Safety measures of the drug on general patients', 'Safety measures of the drug on general patients', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Discussion about clinical safety'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In Person', 'In Person', 'email', 'Email', 'Video Conference', 'In-Person', 'In -Person', 'Video Conference', 'Video Call', 'Video Conference', 'Video Conference', 'Video Conference', 'Email', 'In-Person', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In -Person', 'Video Conference', 'In-Person', 'In -Person', 'Video Conference', 'Video Call', 'Video Conference', 'In -Person', 'Video Conference', 'Email', 'Video Call', 'In-Person', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In -Person'], 'Company_Event': ['Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim'], 'Interaction_intent': ['To get acquanitance of the drug', 'To know about drug action and how it works', 'To spread the awareness of the talim drug', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'Engagement', 'Awareness to mass', 'Launch of new Verzenio brand', 'Discussion on supporting patients with access to medicine,education and other programs', 'Discussion on event agenda,topics so that they align with company objectives', 'Discussion about how to market the product to increase its reach', 'To study the patient demographics on which the drug is tested before launch', 'To discuss about the claims,insurance and copay programs', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss about the claims,insurance and copay programs', 'To discuss about the claims,insurance and copay programs', 'Discussion on event agenda,topics so that they align with company objectives', 'Discussion on supporting patients with access to medicine,education and other programs', 'To get acquanitance of the drug', 'To know about drug action and how it works', 'To spread the awareness of the talim drug', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'To get acquanitance of the Insurance policy', 'Discussion on event agenda,topics so that they align with company objectives', 'Discussion about how to market the product to increase its reach', 'To study the patient demographics on which the drug is tested before launch', 'To discuss about the claims,insurance and copay programs', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss about the claims,insurance and copay programs', 'Discussion about competitive analysis to get overview of market', 'Oversseeing the entire study,ensuring compliance with rights and guidelines and protecting rights and welfare of participants', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To get acquanitance of the drug', 'To know about drug action and how it works', 'To spread the awareness of the talim drug', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss about the claims,insurance and copay programs', 'To discuss the safety measures of drug on general patients and discuss complications if any'], 'Items/topics_to_exchange': ['Introduction and overview of drug', 'Target interaction of drug', 'Spreading awareness about talim drug', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Early detection methods and awareness', 'Spreading awareness through mediums', 'Verzenio Brand launch details and impact of brand launch', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Event Agenda,Topics', 'Promotion channels and tactics,Pharmacovigilance and safety monitoring', 'Health Status,Origin ,age,race,gender of patients', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Safety measures and its complications', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Event Agenda,Topics', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Introduction and overview of drug', 'Target interaction of drug', 'Spreading awareness about talim drug', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Intro and overview of Insurance policy', 'Event Agenda,Topics', 'Promotion channels and tactics,Pharmacovigilance and safety monitoring', 'Health Status,Origin ,age,race,gender of patients', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Safety measures and its complications', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Competitor drugs,their advantages and disadvantages', 'Study Design and Protocol Development,Regulatory Compliance,Site Selection,Participant Recruitment,Safety and Adverse Event Monitoring', 'Safety measures and its complications', 'Safety measures and its complications', 'Introduction and overview of drug', 'Target interaction of drug', 'Spreading awareness about talim drug', 'Safety measures and its complications', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Health Status,Origin ,age,race,gender of patients'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral'], 'Next_Action_Items': ['Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Patient Demographics', 'Public Outreach awareness', 'Share information on upcoming brand launch', 'Verzenio Brand Endorsement collaterals for upcoming launch event', 'Review and provide feedback on campaign designs', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss compliance and ethical practices', 'Efficacy', 'Discuss compliance and ethical practices', 'Discuss compliance and ethical practices', 'Scientific communication materials', 'Review and provide feedback on campaign designs', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Patient Demographics', 'Discuss various phases of Insurance policy', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss compliance and ethical practices', 'Efficacy', 'Discuss compliance and ethical practices', 'Principal Investigator Support', 'Safety', 'Efficacy', 'Efficacy', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Discuss compliance and ethical practices', 'Discuss various phases of testing in patients'], 'Proposed_Next_Channel_Of_interaction': ['In-Person', 'Email', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'email', 'Video Call', 'Video Conference', 'Video Conference', 'Email', 'Video Conference', 'Phone Call', 'Video Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Video Conference', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In-Person', 'Video Conference', 'Video Conference', 'Email', 'Video Conference', 'Phone Call', 'Video Call', 'Phone Call', 'Video Conference', 'Email', 'Video Call', 'Video Call', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In-Person', 'Video Conference']}"
5,"{'kol': 'Dr. Chris Smith', 'Interaction_Date': ['2-Apr-19', '9-May-19', '15-Jun-19', '22-Jul-19', '28-Aug-19', '4-Oct-19', '10-Nov-19', '17-Dec-19', '23-Jan-20', '29-Feb-20', '6-Apr-20', '13-May-20', '19-Jun-20', '26-Jul-20', '1-Sep-20', '8-Oct-20', '14-Nov-20', '21-Dec-20', '27-Jan-21', '5-Mar-21', '11-Apr-21', '18-May-21', '24-Jun-21', '31-Jul-21', '6-Sep-21', '13-Oct-21', '19-Nov-21', '26-Dec-21', '1-Feb-22', '10-Mar-22', '16-Apr-22', '23-May-22', '29-Jun-22', '5-Aug-22', '11-Sep-22', '18-Oct-22', '24-Nov-22', '31-Dec-22', '6-Feb-23', '15-Mar-23'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)', 'B. Sc. (Microbiology)\n Ph.D. (Biological Science)'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer'], 'KOL_years_of_Experience': [27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29], 'KOL_Location': ['Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston'], 'KOL_Territory': ['North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US', 'North-eastern US'], 'SocialMedia_Twitter': ['19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176', '19176'], 'SocialMedia_Linkedin': ['5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095', '5095'], 'SocialMedia_YouTube': ['15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098', '15098'], 'Overall_Kol_Rating': [4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7, 4.7], 'Connection_to_Advisory_Boards': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'Research_Participated': [7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7], 'Research_Experience': [16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16], 'Fundinghistory_researchgrants': ['30.7K', '43.3K', '44K', '50K', '52K', '58K', '70K', '80K', '80K', '81K', '82K', '83K', '84K', '90K', '92K', '94K', '98K', '100K', '105K', '110K', '115K', '117K', '127K', '130K', '132K', '134K', '138K', '140K', '142K', '144K', '150K', '155K', '156K', '157K', '159K', '165K', '175K', '180K', '190K', '200K'], 'Fundinghistory_ConsultingFees': [700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 720, 720, 720, 720, 720, 720, 720], 'Fundinghistory_EducationalGrants': ['30.7K', '43.3K', '44K', '50K', '52K', '58K', '70K', '80K', '80K', '81K', '82K', '83K', '84K', '90K', '92K', '94K', '98K', '100K', '105K', '110K', '115K', '117K', '127K', '130K', '132K', '134K', '138K', '140K', '142K', '144K', '150K', '155K', '156K', '157K', '159K', '165K', '175K', '180K', '190K', '200K'], 'No_Of_Publications': [27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27], 'Trainings_Delivered': [14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14], 'Professional_Certification': [8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [0, 0, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 1, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29], 'National_presentations_Presented': [135, 135, 135, 135, 135, 135, 135, 135, 135, 135, 140, 140, 140, 140, 140, 140, 140, 140, 140, 140, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145, 145], 'KOL_FollowUp': ['No', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Overview', 'Study Design and Protocol Development', 'Ethical Considerations and Regulatory Approval', 'Patient Recruitment and Informed Consent', 'Randomization and Blinding', 'Intervention and Treatment Administration', 'Data Collection and Monitoring', 'Data Analysis and Statistical Evaluation', 'Reporting and Publication', 'Cluster Randomized Trials', 'Pharmacodynamics', 'Trial Simulation', 'Drug-Device Combination Trials', 'Pharmacogenetics', 'Drug Repositioning', 'Adaptive Sample Size Modification', 'Efficacy-to-Effectiveness Transition', 'Health-Related Quality of Life Validation', 'Multiple Comparison Issues', 'Surrogate Endpoints Validation', 'Trial Conduct in Low-Resource Settings', 'Predictive Biomarkers', 'Composite Endpoints', 'Adaptive Treatment Strategies', 'Clinical Trial Simulation Software', 'Pharmacoeconomics in Clinical Trials', 'Patient Engagement in Trial Design', 'Data Integration and Data Sharing', 'Precision Oncology Trials', 'Drug Safety Surveillance', 'Pragmatic Trials', 'Mobile Health Technologies', 'Adaptive Endpoint Selection', 'Trial Design for Rare Diseases', 'Drug Interactions with Food', 'Biosimilar Trials', 'Comparative Safety Trials', 'Drug-Induced Liver Injury Trials', 'Data Monitoring Committee', 'Clinical Endpoint Adjudication'], 'Previous_Meeting_SubTopics': ['Discussion on important trends worth focusing upon', 'Selection of the Primary Endpoint(s)', 'Informed Consent Process and Documentation', 'Eligibility Criteria and Screening Procedures', 'Generation of Randomization Sequence', 'Drug Formulation and Manufacturing', 'Adverse Event Reporting and Safety Monitoring', 'Statistical Methods for Endpoint Analysis', 'Clinical Trial Registration and Results Reporting', 'Implementing randomization at the group or cluster level.', ""Investigating the drug's effects on the body and its mechanism of action."", 'Conducting simulation studies to evaluate trial design and sample size calculations.', 'Assessing the safety and efficacy of drug-device combinations.', 'Studying the influence of genetic variations on individual drug responses.', 'Exploring the potential use of an existing drug for a new indication.', 'Modifying sample size during the trial based on interim results.', ""Assessing the drug's effectiveness in real-world settings."", 'Validating quality of life assessment tools specific to the trial population.', 'Addressing statistical challenges associated with multiple comparisons.', 'Evaluating the correlation between a surrogate endpoint and clinical outcomes.', 'Overcoming challenges and adapting trial conduct in resource-limited settings.', 'Identifying biomarkers to predict treatment response or toxicity.', 'Designing trials with composite endpoints to capture multiple outcomes.', 'Evaluating adaptive treatment strategies based on individual responses.', 'Utilizing software tools to simulate and optimize trial design.', 'Incorporating economic evaluation alongside clinical outcomes.', 'Involving patients in trial design and decision-making processes.', 'Integrating data from multiple sources and sharing trial data for transparency.', 'Designing trials to target specific genomic alterations in cancer.', 'Implementing systems for post-marketing surveillance of drug safety.', 'Conducting trials in real-world settings to evaluate treatment effectiveness.', 'Utilizing mobile apps and wearables for data collection and participant monitoring.', 'Modifying or adding endpoints based on evolving clinical knowledge.', 'Overcoming challenges in trial design for small patient populations.', 'Assessing the impact of food on drug absorption and efficacy.', 'Conducting trials to demonstrate the similarity of a biosimilar to the reference product.', 'Comparing the safety profiles of different treatments in a trial.', 'Evaluating the risk of liver injury associated with the drug.', 'Establishing an independent committee to monitor trial data and safety.', 'Implementing a process for independent assessment of clinical endpoints.'], 'Current_Discussion_Topic': ['Study Design and Protocol Development', 'Ethical Considerations and Regulatory Approval', 'Patient Recruitment and Informed Consent', 'Randomization and Blinding', 'Intervention and Treatment Administration', 'Data Collection and Monitoring', 'Data Analysis and Statistical Evaluation', 'Reporting and Publication', 'Preclinical Studies', 'Pharmacokinetics', 'Dose-Response Relationship', 'Drug-Drug Interactions', 'Special Populations', 'Drug Safety Monitoring', 'Quality Control and Manufacturing', 'Long-Term Safety and Follow-Up', 'Compliance and Adherence', 'Quality of Life Assessment', 'Biomarkers and Surrogate Endpoints', 'Genetic Variations', 'Immunogenicity', 'Data Safety Monitoring Board', 'Statistical Analysis Plan', 'Pharmacovigilance', 'Drug Formulation Optimization', 'Comparative Effectiveness', 'Health Economics and Outcomes Research', 'Drug Resistance', 'Mechanism of Action', 'Concomitant Medications', 'Pharmacogenomics', 'Drug Stability', 'Drug Administration Devices', 'Drug Discontinuation and Withdrawal Effects', 'Patient Reported Outcomes', 'Subgroup Analysis', 'Drug Safety in Specific Organs or Systems', 'Health-Related Quality of Life Measures', 'Drug Repurposing', 'Health Technology Assessment'], 'Current_Meeting_Subtopics': ['Selection of the Primary Endpoint(s)', 'Informed Consent Process and Documentation', 'Eligibility Criteria and Screening Procedures', 'Generation of Randomization Sequence', 'Drug Formulation and Manufacturing', 'Adverse Event Reporting and Safety Monitoring', 'Statistical Methods for Endpoint Analysis', 'Clinical Trial Registration and Results Reporting', 'Conducting animal experiments to evaluate drug safety and efficacy.', 'Studying how the body absorbs, distributes, metabolizes, and excretes the drug.', ""Investigating the drug's effectiveness at different doses."", 'Assessing potential interactions with other medications.', ""Studying the drug's effects in specific patient groups (e.g., pediatrics, elderly)."", 'Monitoring and reporting adverse events during the trial.', 'Ensuring drug consistency and quality during production.', ""Examining the drug's safety over extended periods."", 'Monitoring participant adherence to the treatment plan.', ""Evaluating the drug's impact on participants' well-being."", 'Identifying indicators that correlate with drug response.', 'Investigating how genetic factors influence drug responses.', 'Assessing the potential for the drug to trigger immune responses.', 'Establishing an independent committee to monitor trial safety.', 'Developing a plan for data analysis.', 'Monitoring drug safety after approval and widespread use.', 'Improving drug delivery systems for better efficacy.', ""Comparing the drug's efficacy against other treatments."", 'Evaluating the cost-effectiveness of the drug.', 'Monitoring and managing drug resistance during the trial.', ""Studying the drug's underlying biological mechanisms."", 'Evaluating the effects of other medications used during the trial.', 'Analyzing how genetic variations affect drug response.', ""Assessing the drug's stability under different conditions."", 'Evaluating devices used for drug administration.', 'Investigating the effects of stopping the drug.', ""Collecting data on participants' subjective treatment experiences."", 'Analyzing treatment effects in specific participant subgroups.', ""Assessing the drug's impact on specific organs or systems."", 'Analyzing the different dimensions of which health quality are measured', 'Exploring how the correlations can be marked from one drug to another', 'Understanding the various recent developments made in new wearable medical devices'], 'Current_Channel_of_interaction': ['Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call'], 'Company_Event': ['Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials'], 'Interaction_intent': [""Collating all the popular methods and measures for drug's effectiveness"", 'Discussion on an acceptable consent forms', 'Reviewing the procedure to select participants', 'What is the main measure used to determine the effectiveness of the drug in the trial?', 'How are participants fully informed about the trial and their consent documented properly?', 'What are the criteria for selecting participants and the screening procedures in the trial?', 'How is the process of assigning participants to treatment groups fair and unbiased?', ""What is the process of developing the drug's form and ensuring its quality during manufacturing?"", 'How are any adverse events experienced by participants recorded and reported during the trial?', 'What statistical methods are used to analyze the primary outcome(s) of the trial?', 'How is the trial registered, and when are the results shared in a timely and transparent manner?', 'Are there any known interactions between the investigational drug and commonly prescribed medications?', 'What is known about the safety and effectiveness of the drug in pregnant women?', 'How are adverse events monitored and reported during the clinical trial?', 'What measures are in place to ensure the consistency and quality of the drug throughout the trial?', ""What are the findings from long-term follow-up studies on the drug's safety and effectiveness?"", 'How is participant adherence to the treatment regimen assessed and monitored?', ""What is the impact of the drug on participants' overall quality of life and well-being?"", 'Have any biomarkers or surrogate endpoints been validated to assess drug response?', 'How do genetic factors influence individual responses to the drug?', 'What are the potential immune responses or antibody formation associated with the drug?', 'What is the role and function of the independent data safety monitoring board in the trial?', 'What are the statistical methods used to analyze the trial data?', 'How is the long-term safety profile of the drug monitored and evaluated?', ""Are there any ongoing studies to optimize the drug's formulation or delivery system?"", 'How does the investigational drug compare to currently available treatment options?', 'What is the economic impact and cost-effectiveness of the drug compared to standard treatments?', 'Is there a risk of developing drug resistance with prolonged use of the drug?', 'What is the underlying mechanism through which the drug exerts its therapeutic effects?', 'Are there any interactions or effects between the investigational drug and other medications taken by participants?', 'How do genetic factors impact individual responses to the drug?', 'What is the stability of the drug under various storage and handling conditions?', 'What devices are used for administering the drug, and how are they assessed for safety and efficacy?', 'What are the potential risks and effects associated with discontinuing the drug?', ""What data are collected on participants' subjective assessments of treatment effects?"", 'Are there any subgroup-specific treatment effects observed in the trial?', ""What is known about the drug's safety profile in relation to specific organs or physiological systems?"", ""How does the drug impact different aspects of participants' health-related quality of life?"", 'What evidence exists for using the drug for a new indication?', 'What are the various risks and benefits?'], 'Items/topics_to_exchange': [""Defining the main measure to determine the drug's effectiveness."", 'Ensuring participants are fully informed and their consent is documented properly.', 'Establishing the criteria for selecting participants and screening procedures.', 'Creating a fair and unbiased process to assign participants to treatment groups.', ""Developing the drug's form and ensuring its quality during manufacturing."", 'Recording and reporting any adverse events experienced by participants.', 'Applying appropriate statistical methods to analyze the primary outcome(s) of the trial.', 'Registering the trial and sharing the results in a timely and transparent manner.', ""Conducting animal studies to evaluate the drug's safety and efficacy before human trials."", ""Assessing the drug's absorption, distribution, metabolism, and elimination in humans."", 'Investigating the relationship between different drug doses and their corresponding effects.', 'Evaluating potential interactions between the investigational drug and other medications.', ""Studying the drug's safety and effectiveness in specific populations such as children, elderly individuals, or pregnant women."", 'Establishing procedures for monitoring and reporting adverse events during the trial.', 'Ensuring the consistency, quality, and reproducibility of the drug throughout the trial.', ""Assessing the drug's safety and efficacy over an extended period of time after treatment."", ""Monitoring participants' adherence to the prescribed treatment regimen."", ""Evaluating the drug's impact on participants' overall quality of life and well-being."", 'Identifying and validating biomarkers or surrogate endpoints to assess drug response.', 'Investigating how genetic variations influence individual responses to the drug.', 'Assessing the potential for the drug to elicit immune responses or antibody formation.', 'Establishing an independent board to monitor trial progress and participant safety.', 'Developing a detailed plan outlining the statistical methods to be used for data analysis.', 'Implementing systems to monitor and evaluate the long-term safety profile of the drug.', 'Investigating different formulations or delivery systems to enhance drug efficacy or patient compliance.', 'Comparing the investigational drug with existing treatment options to assess its superiority or non-inferiority.', 'Evaluating the cost-effectiveness and economic impact of the drug.', 'Investigating the potential for the development of drug resistance over time.', 'Studying the underlying biological mechanisms through which the drug exerts its therapeutic effects.', 'Assessing the potential interactions or effects of other medications taken by participants during the trial.', 'Exploring the influence of genetic factors on individual responses to the drug.', 'Evaluating the stability of the drug under different storage and handling conditions.', 'Assessing the safety and efficacy of devices used for drug administration (e.g., inhalers, syringes).', 'Investigating the effects and potential risks associated with discontinuing the drug.', ""Collecting and analyzing data on participants' subjective assessments of treatment effects."", 'Conducting exploratory analyses to assess treatment effects in specific subgroups of participants.', ""Evaluating the drug's safety profile in relation to specific organs or physiological systems."", ""Assessing the impact of the drug on various aspects of participants' health-related quality of life."", 'Investigating the potential use of an existing drug for a new indication.', 'Evaluating the value, benefits, and risks of the drug in the context of healthcare systems.'], 'KOLMSL_Relation': ['Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good'], 'Next_Action_Items': ['Determine the specific primary endpoint(s) and clearly define its measurement criteria.', 'Develop an informed consent form that provides comprehensive information to participants and ensures their understanding.', 'Establish a process for identifying eligible participants and implementing a systematic screening procedure.', 'Generate a randomization sequence using appropriate methods and ensure the allocation concealment.', 'Develop the drug formulation and manufacturing process in accordance with regulatory standards.', 'Implement a robust adverse event reporting system and establish regular safety monitoring procedures.', 'Select the appropriate statistical methods to analyze the primary endpoint(s) and determine the statistical significance.', 'Register the clinical trial on a publicly accessible database and prepare a comprehensive report for publication, adhering to reporting guidelines.', ""Conduct animal studies to evaluate the drug's safety and efficacy before proceeding to human trials."", ""Conduct clinical trials to assess the drug's absorption, distribution, metabolism, and elimination in humans."", 'Design and conduct clinical trials with different drug doses to establish the dose-response relationship.', 'Conduct clinical trials to evaluate potential interactions between the investigational drug and other commonly used medications.', ""Conduct clinical trials specifically targeting the identified special populations to assess the drug's safety and efficacy in these groups."", 'Implement a comprehensive adverse event monitoring system to promptly detect and report any adverse events during the trial.', 'Ensure that the drug manufacturing process adheres to established quality control procedures and meets regulatory standards.', ""Plan and conduct long-term follow-up studies to assess the drug's safety and efficacy over an extended period."", ""Implement strategies to monitor and improve participants' adherence to the prescribed treatment regimen."", ""Include validated quality of life assessment tools in the trial to measure the drug's impact on participants' well-being."", 'Identify and validate relevant biomarkers or surrogate endpoints to assess drug response.', 'Include genetic testing in the trial to investigate how genetic variations influence individual responses to the drug.', 'Monitor and assess the potential for the drug to elicit immune responses or antibody formation.', ""Establish an independent board to monitor the trial's progress and participant safety regularly."", 'Develop a detailed statistical analysis plan outlining the methods for analyzing the trial data.', ""Implement a pharmacovigilance system to monitor the drug's long-term safety after approval and widespread use."", ""Conduct formulation studies to optimize the drug's delivery system for enhanced efficacy and patient compliance."", ""Conduct head-to-head trials to compare the investigational drug's effectiveness with existing treatment options."", 'Conduct health economic studies to assess the cost-effectiveness of the drug.', 'Monitor and analyze the potential development of drug resistance during the trial.', 'Conduct mechanistic studies to understand the underlying biological mechanisms of the drug.', 'Monitor and analyze the effects of concomitant medications used by participants during the trial.', 'Incorporate pharmacogenomic testing into the trial to assess its influence on individual drug responses.', ""Conduct stability studies to assess the drug's stability under various storage and handling conditions."", 'Evaluate the safety and efficacy of devices used for drug administration during the trial.', 'Plan and conduct studies to assess the effects and potential risks of discontinuing the drug.', ""Collect and analyze data on participants' subjective assessments of treatment effects."", 'Conduct exploratory analyses to assess treatment effects in specific subgroups of participants.', ""Monitor and evaluate the drug's safety profile in relation to specific organs or physiological systems."", ""Incorporate health-related quality of life measures into the trial to assess the drug's impact on participants."", 'Plan and conduct trials to investigate the potential use of the drug for a new indication.', 'Preparing a detailed report with potential risks, benefits, and values.'], 'Proposed_Next_Channel_Of_interaction': ['Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call']}"
6,"{'kol': 'Dr. Enrique Vasquez', 'Interaction_Date': ['3-Apr-19', '10-May-19', '16-Jun-19', '23-Jul-19', '29-Aug-19', '5-Oct-19', '11-Nov-19', '18-Dec-19', '24-Jan-20', '1-Mar-20', '7-Apr-20', '14-May-20', '20-Jun-20', '27-Jul-20', '2-Sep-20', '9-Oct-20', '15-Nov-20', '22-Dec-20', '28-Jan-21', '6-Mar-21', '12-Apr-21', '19-May-21', '25-Jun-21', '1-Aug-21', '7-Sep-21', '14-Oct-21', '20-Nov-21', '27-Dec-21', '2-Feb-22', '11-Mar-22', '17-Apr-22', '24-May-22', '30-Jun-22', '6-Aug-22', '12-Sep-22', '19-Oct-22', '25-Nov-22', '1-Jan-23', '7-Feb-23', '16-Mar-23'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer'], 'KOL_years_of_Experience': [22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22], 'KOL_Location': ['Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington', 'Springfield, Washington'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['4500', '4500', '4500', '4500', '4500', '4500', '4500', '4500', '4500', '4500', '4500', '4500', '4500', '4500', '4500', '4876', '4876', '4876', '4876', '4876', '4876', '4876', '4876', '4876', '4876', '4876', '4876', '4876', '4876', '5013', '5013', '5013', '5013', '5013', '5013', '5013', '5013', '5013', '5013', '5013'], 'SocialMedia_Linkedin': ['3247', '3247', '3247', '3247', '3247', '3247', '3247', '3247', '3247', '3247', '3247', '3247', '3247', '3329', '3329', '3329', '3329', '3329', '3329', '3329', '3329', '3329', '3329', '3329', '3329', '3329', '3400', '3400', '3400', '3400', '3400', '3400', '3400', '3400', '3400', '3512', '3512', '3512', '3512', '3512'], 'SocialMedia_YouTube': ['5211', '5211', '5211', '5211', '5211', '5211', '5211', '5211', '5211', '5211', '5211', '5432', '5432', '5432', '5432', '5432', '5432', '5432', '5432', '5432', '5432', '5432', '5432', '5432', '5432', '5432', '5432', '5991', '5991', '5991', '5991', '5991', '5991', '5991', '5991', '5991', '5991', '5991', '6020', '6020'], 'Overall_Kol_Rating': [4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2], 'Connection_to_Advisory_Boards': [6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5], 'Research_Participated': [9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9], 'Research_Experience': [17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17], 'Fundinghistory_researchgrants': ['125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '190k', '190k', '190k', '190k', '240k', '240k', '240k', '240k', '240k', '240k', '240k', '240k', '320k', '320k', '320k', '320k', '320k'], 'Fundinghistory_ConsultingFees': [250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 250, 275, 275, 275, 275, 275, 275, 280, 280, 280, 280, 280, 280, 280], 'Fundinghistory_EducationalGrants': ['125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '125k', '190k', '190k', '190k', '190k', '240k', '240k', '240k', '240k', '240k', '240k', '240k', '240k', '320k', '320k', '320k', '320k', '320k'], 'No_Of_Publications': [24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 27, 27, 27], 'Trainings_Delivered': [32, 32, 32, 32, 32, 32, 32, 32, 32, 32, 33, 33, 33, 33, 33, 33, 33, 33, 33, 33, 34, 34, 34, 34, 35, 35, 35, 35, 35, 36, 36, 36, 36, 37, 37, 37, 37, 37, 37, 37], 'Professional_Certification': [19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20], 'KOL_affiliations_academicinstitutionss': [3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'KOL_Affiliations_Hospital_and_medical_Centres': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'KOL_Affiliations_Government_and_Regulatory_bodies': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5], 'International_Presentations_Presented': [12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12], 'National_presentations_Presented': [126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126, 126], 'KOL_FollowUp': ['No', 'No', 'Yes', 'No', 'No', 'No', 'Yes', 'Yes', 'No', 'No', 'No', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Different points of action in place for clinical studies', 'Potential steps to be taken by different units before actual clinical trials can be started', 'Share insights on different test conducted for impacts over different age groups', 'Impact of early infants, teenagers and their side effects. Potential Relapse', 'Molecular activity of the drug', 'Discuss on potential drug interactivity with various conditions', 'Effects of the drug with different medications', 'Drug effects during pregnancy.', 'Interrelativity of drug symtoms during pregnancy from mother to child', 'Change of existing prescribed drug to new drug', 'Risk associated with the drug during administration', 'Discuss on potential drug dosage and drug efficacy over short and long duration', 'Understand the patient demographic of KOL', 'Discussion on patient candidate requirements', 'Methods and technologies used to deliver the drug', 'Discuss on drug resistance in certain patients', 'Ideate on the drug resistance due in elderly patients', 'Discuss with KOL the current stage of human trials with respect to guidelines', 'Talk over the optimal drug dosage in constrained environments', 'Government regulations and processes for drug evaluation and market authorization.', 'Discuss on the safety of the trial patient involved', 'Discuss trends in patient safety', 'Post Drug administration recovery', 'Conditions that prevent administration of drugs', 'Consult the KOL on potential reactions certain patients might face due to drug administration', 'Consult the KOL on potential adverse events certain patients might face due to drug administration', 'Problems related to drug overdose', ""Patient's Genetic Response"", 'Protection of Trial patients Identity', 'Discuss potential Withdrawal symptoms of candidates', 'Take KOLs input on prescriptive information', 'Inform the KOL on drug lifespan', 'Discuss drug pricing post trials', 'On the Drug availability to patients', 'Insurance coverage of the drug over different patient demographics', 'Discuss on the coverage of the drug by co-pay programs', 'Understand directives before sharing report to FDA for phase trials', 'Share information on new trials', 'Invite the KOL to be a potential committee member for the new trials phase', 'Discuss on company plan of action for the new phase'], 'Previous_Meeting_SubTopics': ['Next Steps before initiation of clinical trials', 'Impact of drug over different age groups', 'Address impact of children', 'Drug Mechanism', 'Drug interactivity', 'Interactions with medications for potential stimuli', 'Drug interations during pregnancy', 'Understand KOLs perspective on drug interactions from pregnancy to post birth', 'Drug transferance', 'Drug safety', 'Drug Efficacy', 'Identification of potential Candidates', 'Identification of potential Candidates', 'Delivery of Drug and Drug administration', 'Drug resistance', 'Special case of Elderly patients', 'Current stage of human trials', 'Optimum Drug dosage', 'Drug regulations and approvals', 'Patient Safety', 'Patient Safety', 'Drug Recovery', 'Contraindications for the drug', 'Reactions based on drug administration', 'Adverse Events based on drug administration', 'Drug Overdose issues', 'Genetic Response', 'Identity Protection', 'Patient Withdrawal Symptops', 'Prescriptive information', 'Drug Lifespan', 'Drug Pricing', 'Drug Availability', 'Insurance coverage', 'Insurance Co-pay coverage', 'Trial reports for FDA', 'Beginning of New trials', 'Invitation as trials committee member', 'Plan of action', 'Meet and Greet'], 'Current_Discussion_Topic': ['Potential steps to be taken by different units before actual clinical trials can be started', 'Share insights on different test conducted for impacts over different age groups', 'Impact of early infants, teenagers and their side effects. Potential Relapse', 'Molecular activity of the drug', 'Discuss on potential drug interactivity with various conditions', 'Effects of the drug with different medications', 'Drug effects during pregnancy.', 'Interrelativity of drug symtoms during pregnancy from mother to child', 'Change of existing prescribed drug to new drug', 'Risk associated with the drug during administration', 'Discuss on potential drug dosage and drug efficacy over short and long duration', 'Understand the patient demographic of KOL', 'Discussion on patient candidate requirements', 'Methods and technologies used to deliver the drug', 'Discuss on drug resistance in certain patients', 'Ideate on the drug resistance due in elderly patients', 'Discuss with KOL the current stage of human trials with respect to guidelines', 'Talk over the optimal drug dosage in constrained environments', 'Government regulations and processes for drug evaluation and market authorization.', 'Discuss on the safety of the trial patient involved', 'Discuss trends in patient safety', 'Post Drug administration recovery', 'Conditions that prevent administration of drugs', 'Consult the KOL on potential reactions certain patients might face due to drug administration', 'Consult the KOL on potential adverse events certain patients might face due to drug administration', 'Problems related to drug overdose', ""Patient's Genetic Response"", 'Protection of Trial patients Identity', 'Discuss potential Withdrawal symptoms of candidates', 'Take KOLs input on prescriptive information', 'Inform the KOL on drug lifespan', 'Discuss drug pricing post trials', 'On the Drug availability to patients', 'Insurance coverage of the drug over different patient demographics', 'Discuss on the coverage of the drug by co-pay programs', 'Understand directives before sharing report to FDA for phase trials', 'Share information on new trials', 'Invite the KOL to be a potential committee member for the new trials phase', 'Discuss on company plan of action for the new phase', 'Introduce the KOL to expected patients participating in trials'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['Video call', 'Video call', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'In-Person', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'In-person', 'Video Call', 'Video Call', 'In-person', 'Video Call', 'In-person'], 'Company_Event': ['Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials'], 'Interaction_intent': ['Make the KOL aware about the steps taken before any clinical trials happen', 'Give a brisk overview of how the drug is reacting in test environments over artifically created test samples of different age groups', 'Discuss with the KOL on drug Impact in children', 'How the drug is targetting the required molecules and what is the effective time', 'Discuss how the drug may interact with patients having different conditions', 'Discuss on how the drug might have different effect with respect to different forms of ongoing medication', 'Seek opinions on the different drug effects and side effects during pregnancy', 'Understand and come to a conclusion about the drug interaction', 'Exchange on drug transferance', 'Seek advice on drug risks and potential mitigations', 'Seek Guidance on drug administration over variety of patient demographic', 'Scout potential candidates for clinical trials with guidance from KOL', 'Understand potential candidate choices in consultation to KOL', 'Consult with the KOL on identification of drug delivery', 'Explore ways on which patients and generate drug resistance', 'Identify factors for potential drug ambiguity in elderly patients', 'Elevate the human trial phases with KOL', 'Elaborate on the effective optimal dosge discovered during the initial test phases over different patient groups', 'Understand the regulatory requirements and processes involved in evaluating and authorizing the drug for the market.', 'Understand KOLs perspective on patient safety', 'Based on the previous study report consult the KOL on Safety measures over patient demographics', 'Discuss on the drug recovery phase', 'Extrapolate on existing reports and seek advice on situations where the drug should not be used', 'Proper understanding on side effects and reactions after drug administration', 'Root cause discussion over molecularity of Adverse effects', 'Discuss on the scenarios of drug overdose and its effect', 'Understanding Genetic responses to drug', 'Guidance on protection of identity of patient trials', 'Understand different kinds of patient withdrawal symptoms from the KOL', 'Understand the core prescriptive information to be adhered to', ""Share company outlook of the drug's vision"", 'Share with KOL the current vision on the price of drugs', 'Discuss with the KOL on the current drug availability scenrio to patients', 'Share with KOL current insurance vetted programs that might cover the drug cost', 'Discuss exsiting norms and new items to be informed to the insurance firms for the addition of the drug to the co-pay programs', 'Seek KOLs clarity and his stance post phase trials', 'Discuss with KOL the affirmative plans for new trials', 'Share with KOL the overall plans and his role as a committee member for the new phase trials', 'Seek advice on the plan of action', 'Discuss with KOL the client report and take and expected response'], 'Items/topics_to_exchange': ['List of permissions taken, premtive tests conducted, key objective of this clinical trial', 'Test sample procurement, drug dosage, drug reaction, possible side effects, possible ressuciations', 'Drug Reaction Reports, testing virulity conducted', 'Reports generated during drug discovery', 'List of key identified factors', 'Reports on existing identified drug reactions', 'Drug interaction reports and studies', 'Reports of drug administration, lab sheets, and moleular reports', 'Drug analysis, fall throughs', 'Molecular report, drug dynamics, and drug delivery methods', 'Drug interaction study', 'List of company identified factors', 'Closed case study suiting the patient demographic', 'How to deliver drug to the human body and potential target site', 'Abalation study over previous records of similar compounds', 'Causesheet of existing drug apenditures', 'Patient reports for the trials', 'Patient trial reports and results', 'Regulatory compliancec requirements and operative indices for drug mitosis', 'Regulatory checks, and guidelines on patient safety', 'Safe study documents, extended safety measures, patient bifurcation rules', 'Preliminary study reports and patient transripts', 'List of identified potential causes', 'Drug administration related reactions', 'Labs reports of first cases', 'Potential patient fall through reports, expected behaviour, consolidation reports of patient recovery', 'Drug induced genetic responses', 'Previous trial methodicals', 'List of essential practices used for patient wellness', 'share current drug labels', 'Current Vision Statements', 'Share the development cost sheet and expected return', 'Redaction reports encompassing the drug availability', 'Insurance plantiffs report for drug coverage', 'Insurance co-pay programs report for drug coverage', 'Share all premtive documents and reports', 'Trial site plan, target demographic and time period', 'Target reports and expected outcomes', 'Share extensive checklist and memorandum', 'HER of petients and their current dianostics'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Share updated factsheets on drug impact over different age groups', 'Address impact of children', ""Present a summary on the drug's mechanism of action"", 'Share the potantial drug usage charts', 'Create a repository of existing and future reports of drug interactivity for easy referrals', 'Inquire about drug reactions during pregnancy', 'Create a consolidation of interactiosn ranging from early pregnancy to early infacy post birth', 'Create a reference guide', ""Do a survey with HCO's on understanding existing dynamics"", 'Consultation report with HCPs', 'Identify groups of candidates for clinical studies currently consulting with KOL', 'Create a report based on company factors and patient demographic', 'Referendum', 'Create comparative study', 'Seek clarity and generate report with the help of biochemists', 'Study existing reports and create abalation report', 'Extended study reports', 'Create a chart of dosage versus effectiveness', 'Correlate all the sources of potential regulations and their compliances', 'Create a study on different levels of patient involvement through different stages of the trials', 'Revise study on new inputs', 'Consult and create report with phase trial officers', 'Make a dosier to help future drug administrators on potential challenges', 'Share with KOL a report of existing understanding and prolific study', 'Send extended study reports', 'Create a short report on different patient groups', 'Study on genetic mutation', 'Liability report', 'Seek incidents and reports during past trials of drug', 'Incorporate the feedback into a decadence report for the internal teams', 'Include KOLs feedback', 'Take KOL feedback report for adjustment if needed', 'Updation of factsheets', 'Research on whatnew items checklist might need to be added', 'Seek information from Insurance companies and seek advisory chairs extension', 'Compile all the reports and feedbacks from KOL', 'Create KPI injunction report', 'Share KOLs intention with advisory body', 'Include KOLs feedback', 'Recooperate the KOLs ontake on the patients and share with delegates'], 'Proposed_Next_Channel_Of_interaction': ['Video call', 'In-person', 'Video Call', 'Video Call', 'Video Call', 'In-person', 'In-Person', 'Video Call', 'Phone call', 'Video Call', 'In-Person', 'In-Person', 'Phone call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'In-person', 'Video Call', 'Video Call', 'In-person', 'Video Call', 'In-person', 'Video Call']}"
7,"{'kol': 'Dr. Joseph Matthews', 'Interaction_Date': ['4-Apr-19', '11-May-19', '17-Jun-19', '24-Jul-19', '30-Aug-19', '6-Oct-19', '12-Nov-19', '19-Dec-19', '25-Jan-20', '2-Mar-20', '8-Apr-20', '15-May-20', '21-Jun-20', '28-Jul-20', '3-Sep-20', '10-Oct-20', '16-Nov-20', '23-Dec-20', '29-Jan-21', '7-Mar-21', '13-Apr-21', '20-May-21', '26-Jun-21', '2-Aug-21', '8-Sep-21', '15-Oct-21', '21-Nov-21', '28-Dec-21', '3-Feb-22', '12-Mar-22', '18-Apr-22', '25-May-22', '1-Jul-22', '7-Aug-22', '13-Sep-22', '20-Oct-22', '26-Nov-22', '2-Jan-23', '8-Feb-23', '17-Mar-23'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer'], 'KOL_years_of_Experience': [20, 20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23, 23, 23, 23, 24, 24, 24], 'KOL_Location': ['Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia', 'Philadelphia'], 'KOL_Territory': ['Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA', 'Eastern USA'], 'SocialMedia_Twitter': ['17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654', '17654'], 'SocialMedia_Linkedin': ['3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542', '3542'], 'SocialMedia_YouTube': ['13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788', '13788'], 'Overall_Kol_Rating': [4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6, 4.6], 'Connection_to_Advisory_Boards': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'Research_Participated': [7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7], 'Research_Experience': [16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16], 'Fundinghistory_researchgrants': ['200K', '220K', '250K', '270K', '290K', '300K', '320K', '360K', '380K', '390K', '400K', '410K', '420K', '430K', '450K', '450K', '450K', '450K', '450K', '460K', '480K', '500K', '510K', '520K', '530K', '540K', '540K', '550K', '550K', '550K', '560K', '570K', '590K', '600K', '620K', '620K', '630K', '640K', '660K', '670K'], 'Fundinghistory_ConsultingFees': [600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 650, 650, 700, 700], 'Fundinghistory_EducationalGrants': ['200K', '220K', '250K', '270K', '290K', '300K', '320K', '360K', '380K', '390K', '400K', '410K', '420K', '430K', '450K', '450K', '450K', '450K', '450K', '460K', '480K', '500K', '510K', '520K', '530K', '540K', '540K', '550K', '550K', '550K', '560K', '570K', '590K', '600K', '620K', '620K', '630K', '640K', '660K', '670K'], 'No_Of_Publications': [27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27], 'Trainings_Delivered': [14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14], 'Professional_Certification': [8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [0, 0, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 1, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [40, 40, 40, 40, 40, 40, 40, 40, 42, 42, 42, 42, 42, 42, 42, 42, 42, 42, 44, 44, 44, 44, 44, 44, 44, 44, 44, 44, 46, 46, 46, 46, 46, 46, 46, 46, 46, 48, 48, 48], 'National_presentations_Presented': [200, 200, 200, 200, 200, 200, 200, 200, 210, 210, 210, 210, 210, 210, 210, 210, 210, 210, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 230, 230, 230, 230, 230, 230, 230, 230, 230, 230, 230, 230], 'KOL_FollowUp': ['No', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Overview', 'Drug interactions with immunosuppressants', 'Drug interactions with antihypertensive medications', 'Drug interactions with anti-diabetic medications', 'Drug interactions with anti-inflammatory medications', 'Drug interactions with cardiovascular medications', 'Drug interactions with opioids and pain medications', 'Drug interactions with anti-anxiety medications', 'Drug interactions with antipsychotic medications', 'Role of bisphosphonates in myeloma-related bone disease', 'Cost-effectiveness of myeloma treatment strategies', 'Role of MRD (Minimal Residual Disease) in treatment decision-making', 'Treatment considerations for elderly patients with myeloma', 'Role of maintenance therapy in multiple myeloma', 'Role of CAR-T cell therapy in myeloma treatment', 'Resistance mechanisms to myeloma drugs', 'Management of treatment-related neuropathy in myeloma', 'Impact of myeloma on renal function', 'Role of supportive therapies in managing anemia in myeloma', 'Role of angiogenesis inhibitors in myeloma treatment', 'Role of immune checkpoint inhibitors in myeloma therapy', 'Role of next-generation sequencing in myeloma management', 'Role of extramedullary disease in myeloma prognosis', 'Role of immune effector cells in myeloma treatment', 'Role of epigenetic modifiers in myeloma therapy', 'Impact of myeloma on the immune system', 'Role of CD38-targeted therapies in myeloma treatment', 'Role of monoclonal antibodies in myeloma therapy', 'Role of immunomodulatory drugs in myeloma treatment', 'Role of histone deacetylase inhibitors in myeloma therapy', 'Role of the bone marrow microenvironment in myeloma progression', 'Impact of genetic abnormalities in myeloma prognosis', 'Role of autologous stem cell transplantation in myeloma treatment', 'Role of allogeneic stem cell transplantation in myeloma therapy', 'Role of minimal residual disease assessment in treatment monitoring', 'Management of extramedullary plasmacytomas in myeloma', 'Role of novel imaging techniques in myeloma diagnosis', 'Role of liquid biopsies in myeloma management', 'Impact of cytogenetic abnormalities on myeloma treatment outcomes', 'Role of drug combinations in high-risk myeloma'], 'Previous_Meeting_SubTopics': ['Finalizing the trends to focus upon', 'Interactions between the drug and medications that suppress the immune system.', 'Interactions with drugs used to lower blood pressure.', 'Interactions with medications used to manage diabetes.', 'Interactions with medications used to reduce inflammation.', 'Interactions with medications used to treat heart and vascular conditions.', 'Interactions between the drug and medications used for pain management.', 'Interactions with medications used to manage anxiety.', 'Interactions with medications used to treat psychotic disorders.', 'Prevention of skeletal-related events', 'Economic evaluations and value-based healthcare', 'Prognostic value and treatment intensity adjustment', 'Geriatric assessment and personalized treatment plans', 'Prolongation of remission and survival outcomes', 'Targeting BCMA (B-cell maturation antigen) and clinical outcomes', 'Drug efflux pumps and genomic alterations', 'Symptomatic relief and dose modifications', 'Renal impairment and management strategies', 'Erythropoiesis-stimulating agents and blood transfusions', 'Anti-VEGF (vascular endothelial growth factor) agents and clinical trials', 'PD-1/PD-L1 blockade and immune response modulation', 'Genomic profiling and treatment decision support', 'Impact on outcomes and treatment strategies', 'Natural killer (NK) cells and antibody-dependent cellular cytotoxicity (ADCC)', 'HDAC (histone deacetylase) inhibitors and gene expression regulation', 'Immunodeficiency and susceptibility to infections', 'Daratumumab and isatuximab mechanisms of action', 'Targeting specific surface antigens for immune-mediated cytotoxicity', 'Thalidomide and lenalidomide immunomodulatory effects', 'Epigenetic modulation and anti-tumor effects', 'Stromal cells and cytokine interactions', 'Chromosomal aberrations and gene mutations', 'High-dose chemotherapy and hematopoietic stem cell support', 'Graft-versus-myeloma effect and immunotherapy', 'Depth of response and treatment adjustment', 'Radiation therapy and local control strategies', 'PET/CT (positron emission tomography/computed tomography) and MRI (magnetic resonance imaging)', 'Circulating tumor DNA and minimal residual disease monitoring', 'Del(17p), t(4;14), and risk stratification', 'Intensified treatment regimens and overcoming drug resistance'], 'Current_Discussion_Topic': ['Drug interactions with immunosuppressants', 'Drug interactions with antihypertensive medications', 'Drug interactions with anti-diabetic medications', 'Drug interactions with anti-inflammatory medications', 'Drug interactions with cardiovascular medications', 'Drug interactions with opioids and pain medications', 'Drug interactions with anti-anxiety medications', 'Drug interactions with antipsychotic medications', 'Drug interactions with antiviral medications', 'Drug interactions with chemotherapy agents', 'Drug interactions with anti-rejection medications', 'Drug interactions with respiratory medications', 'Drug interactions with topical medications', 'Drug interactions with central nervous system stimulants', 'Drug interactions with anti-nausea medications', 'Drug interactions with gastrointestinal medications', 'Drug interactions with muscle relaxants', 'Drug interactions with sedatives and hypnotics', 'Drug interactions with urinary medications', 'Drug interactions with dermatological medications', 'Drug interactions with immunizations and vaccines', 'Drug interactions with herbal medications', 'Drug interactions with analgesics', 'Drug interactions with anti-infective medications', 'Drug interactions with antifungal medications', 'Drug interactions with antineoplastic medications', 'Drug interactions with diuretics', 'Drug interactions with antihistamines', 'Drug interactions with anticholinergic medications', 'Drug interactions with antivertigo medications', 'Drug interactions with anticonvulsant medications', 'Drug interactions with bronchodilators', 'Drug interactions with antiemetic medications', 'Drug interactions with antirheumatic medications', 'Drug interactions with antithrombotic medications', 'Drug interactions with antineoplastic medications', 'Drug interactions with antianemic medications', 'Drug interactions with antiparasitic medications', 'Drug interactions with antiviral medications', 'Drug interactions with antidiarrheal medications'], 'Current_Meeting_Subtopics': ['Interactions between the drug and medications that suppress the immune system.', 'Interactions with drugs used to lower blood pressure.', 'Interactions with medications used to manage diabetes.', 'Interactions with medications used to reduce inflammation.', 'Interactions with medications used to treat heart and vascular conditions.', 'Interactions between the drug and medications used for pain management.', 'Interactions with medications used to manage anxiety.', 'Interactions with medications used to treat psychotic disorders.', 'Interactions with medications used to treat viral infections.', 'Interactions with medications used in cancer treatment.', 'Interactions with medications used to prevent organ rejection after transplantation.', 'Interactions with medications used to manage respiratory conditions.', 'Interactions between the drug and medications applied to the skin.', 'Interactions with medications that stimulate the central nervous system.', 'Interactions with medications used to alleviate nausea and vomiting.', 'Interactions with medications used to treat gastrointestinal disorders.', 'Interactions with medications used to relax muscles.', 'Interactions with medications used for sleep induction or sedation.', 'Interactions with medications used for urinary tract disorders.', 'Interactions with medications used for skin conditions.', 'Interactions between the drug and the efficacy or safety of immunizations or vaccines.', 'Interactions between the drug and herbal supplements or alternative medicines.', 'Interactions between the drug and medications used for pain relief.', 'Interactions between the drug and medications used to treat infections.', 'Interactions between the drug and medications used to treat fungal infections.', 'Interactions between the drug and medications used in cancer treatment.', 'Interactions between the drug and medications used to increase urine output.', 'Interactions between the drug and medications used to manage allergies.', 'Interactions between the drug and medications that block acetylcholine receptors.', 'Interactions between the drug and medications used to treat vertigo or dizziness.', 'Interactions between the drug and medications used to control seizures.', 'Interactions between the drug and medications used to dilate the airways.', 'Interactions between the drug and medications used to prevent or treat nausea and vomiting.', 'Interactions between the drug and medications used to treat rheumatic conditions.', 'Interactions between the drug and medications used to prevent blood clots.', 'Interactions between the drug and medications used in cancer treatment.', 'Interactions between the drug and medications used to treat anemia.', 'Interactions between the drug and medications used to treat parasitic infections.', 'Interactions between the drug and medications used to treat viral infections.', 'Interactions between the drug and medications used to treat diarrhea'], 'Current_Channel_of_interaction': ['Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call'], 'Company_Event': ['Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials'], 'Interaction_intent': ['Inquire about interactions between the drug and medications that suppress the immune system.', 'Seek information on interactions between the drug and medications used to lower blood pressure.', 'Explore potential interactions between the drug and medications used to manage diabetes.', 'Inquire about interactions between the drug and medications used to reduce inflammation.', 'Seek information on interactions between the drug and medications used to treat heart and vascular conditions.', 'Explore potential interactions between the drug and medications used for pain management.', 'Inquire about interactions between the drug and medications used to manage anxiety.', 'Seek information on interactions between the drug and medications used to treat psychotic disorders.', 'Explore potential interactions between the drug and medications used to treat viral infections.', 'Inquire about interactions between the drug and medications used in cancer treatment.', 'Seek information on interactions between the drug and medications used to prevent organ rejection after transplantation.', 'Explore potential interactions between the drug and medications used to manage respiratory conditions.', 'Inquire about potential interactions between the drug and medications applied topically to the skin.', 'Seek information on interactions between the drug and medications that have stimulant effects on the central nervous system.', 'Explore potential interactions between the drug and medications used to relieve nausea and vomiting.', 'Inquire about potential interactions between the drug and medications used to treat gastrointestinal disorders.', 'Seek information on potential interactions between the drug and medications used to induce muscle relaxation.', 'Explore potential interactions between the drug and medications used to induce sleep or provide sedation.', 'Inquire about potential interactions between the drug and medications used to treat urinary tract disorders.', 'Seek information on potential interactions between the drug and medications used to treat various skin conditions.', 'Explore potential interactions between the drug and the effectiveness or safety of immunizations or vaccines.', 'Inquire about potential interactions between the drug and herbal supplements or alternative medicines.', 'Seek information on potential interactions between the drug and medications used to alleviate pain.', 'Explore potential interactions between the drug and medications used to treat various infections.', 'Inquire about potential interactions between the drug and medications used to treat fungal infections.', 'Seek information on potential interactions between the drug and medications used in cancer treatment.', 'Explore potential interactions between the drug and medications used to promote diuresis.', 'Inquire about potential interactions between the drug and medications used to treat allergic conditions.', 'Seek information on potential interactions between the drug and medications that block acetylcholine receptors.', 'Explore potential interactions between the drug and medications used to manage vertigo or dizziness.', 'Inquire about potential interactions between the drug and medications used to manage seizures.', 'Seek information on potential interactions between the drug and medications used to widen the airways.', 'Explore potential interactions between the drug and medications used to prevent or alleviate nausea and vomiting.', 'Inquire about potential interactions between the drug and medications used to manage rheumatic conditions.', 'Seek information on potential interactions between the drug and medications used to prevent blood clot formation.', 'Explore potential interactions between the drug and medications commonly used in cancer treatment, such as chemotherapy agents or targeted therapies.', 'Inquire about potential interactions between the drug and medications used to manage or treat anemia, including iron supplements or erythropoiesis-stimulating agents.', 'Seek information on potential interactions between the drug and medications used to treat various parasitic infections, such as antimalarial or antiparasitic drugs.', 'Explore potential interactions between the drug and medications commonly used to treat viral infections, including antiviral medications or vaccines.', 'Inquire about potential interactions between the drug and medications used to alleviate or manage diarrhea, such as antidiarrheal agents or probiotics.'], 'Items/topics_to_exchange': ['Interactions with medications that suppress the immune system', 'Interactions with medications used to lower blood pressure', 'Interactions with medications used to manage diabetes', 'Interactions with medications used to reduce inflammation', 'Interactions with medications used for heart and vascular conditions', 'Interactions with medications used for pain relief', 'Interactions with medications used to manage anxiety', 'Interactions with medications used to treat psychotic disorders', 'Interactions with medications used to treat viral infections', 'Interactions with medications used in cancer treatment', 'Interactions with medications used to prevent organ rejection after transplantation', 'Interactions with medications used to manage respiratory conditions', 'Interactions between the drug and medications applied to the skin', 'Interactions with medications that stimulate the central nervous system', 'Interactions with medications used to alleviate nausea', 'Interactions with medications used to treat gastrointestinal disorders', 'Interactions with medications used to relax muscles', 'Interactions with medications used for sleep induction or sedation', 'Interactions with medications used for urinary tract disorders', 'Interactions with medications used for skin conditions', 'How drugs may interfere with the effectiveness or safety of vaccinations.', 'How drugs can interact with natural herbal products, affecting their efficacy or causing adverse effects.', 'How certain drugs can interact with pain-relieving medications, potentially altering their effects or causing side effects.', 'How drugs may interact with medications used to treat or prevent infections, affecting their effectiveness or increasing the risk of side effects.', 'How drugs can interact with antifungal medications, potentially altering their efficacy or causing adverse reactions.', 'How drugs can interact with medications used in cancer treatment, affecting their effectiveness or increasing the risk of toxicity.', 'How drugs can interact with diuretic medications, potentially altering their effects on fluid balance or electrolyte levels.', 'How drugs can interact with antihistamine medications, potentially intensifying sedation or other side effects.', 'How drugs can interact with medications that have anticholinergic properties, potentially exacerbating side effects such as dry mouth, constipation, or blurred vision.', 'How drugs can interact with medications used to treat vertigo or dizziness, potentially affecting their efficacy or causing adverse effects.', 'How drugs can interact with medications used to treat seizures, potentially altering their effectiveness or increasing the risk of side effects.', 'How drugs can interact with medications that dilate the airways, potentially affecting their effectiveness or causing adverse reactions.', 'How drugs can interact with medications used to prevent or treat nausea and vomiting, potentially altering their efficacy or increasing the risk of side effects.', 'How drugs can interact with medications used to treat rheumatic conditions, potentially affecting their effectiveness or increasing the risk of adverse reactions.', 'How drugs can interact with medications used to prevent blood clotting, potentially altering their efficacy or increasing the risk of bleeding.', 'How drugs can interact with medications used in cancer treatment, affecting their effectiveness or increasing the risk of toxicity.', 'How drugs can interact with medications used to treat anemia, potentially altering their efficacy or causing adverse effects.', 'How drugs can interact with medications used to treat parasitic infections, potentially affecting their effectiveness or increasing the risk of side effects.', 'How drugs can interact with medications used to treat viral infections, potentially affecting their effectiveness or causing adverse reactions.', 'How drugs can interact with medications used to manage diarrhea, potentially altering their effects or increasing the risk of side effects.'], 'KOLMSL_Relation': ['Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good'], 'Next_Action_Items': ['Conduct a comprehensive literature review and develop a reference guide for healthcare professionals outlining potential drug interactions between the focus drug and commonly used immunosuppressant medications, including recommendations for monitoring and dose adjustments if necessary.', 'Collaborate with cardiologists and pharmacists to create educational materials for healthcare professionals and patients, highlighting potential interactions between the focus drug and antihypertensive medications, and providing guidance on monitoring blood pressure, adjusting dosages, or considering alternative therapies.', 'Develop a decision support tool or algorithm to assist healthcare professionals in managing potential drug interactions between the focus drug and anti-diabetic medications, considering factors such as glucose control, dosage adjustments, and monitoring of glycemic parameters.', 'Conduct a systematic review of the literature to identify potential interactions between the focus drug and commonly used anti-inflammatory medications, and provide healthcare professionals with evidence-based guidelines on concurrent use, dose adjustments, or alternative treatment options.', 'Establish collaborations with cardiovascular specialists to evaluate potential drug interactions between the focus drug and commonly prescribed cardiovascular medications, and develop guidelines for managing these interactions, including monitoring parameters, dose adjustments, and alternative treatment options if necessary.', 'Create educational materials and resources for healthcare professionals and patients, emphasizing potential interactions between the focus drug and opioids or other pain medications, and providing guidance on optimizing pain management, monitoring for adverse effects, and considering alternative pain management strategies.', 'Collaborate with mental health professionals to develop guidelines and educational materials for healthcare professionals regarding potential interactions between the focus drug and anti-anxiety medications, including recommendations for monitoring, dose adjustments, or alternative treatments.', 'Conduct studies and compile evidence-based guidelines for managing potential interactions between the focus drug and antipsychotic medications, considering factors such as therapeutic efficacy, dose adjustments, and monitoring parameters to ensure optimal patient outcomes.', 'Collaborate with infectious disease specialists to evaluate potential interactions between the focus drug and commonly used antiviral medications, and develop guidelines or recommendations for managing concurrent use, dosage adjustments, or alternative treatment options as needed.', 'Establish a multidisciplinary team involving oncologists, pharmacists, and supportive care specialists to review potential drug interactions between the focus drug and chemotherapy agents, and develop protocols or guidelines for managing these interactions, including considerations for supportive care and therapeutic adjustments.', 'Create educational resources and provide training to healthcare professionals involved in transplant medicine to increase awareness of potential interactions between the focus drug and anti-rejection medications, and develop guidelines for monitoring, dose adjustments, or alternative treatment options when necessary.', 'Conduct a review of the literature and develop a reference guide for healthcare professionals, outlining potential interactions between the focus drug and commonly used respiratory medications, and providing recommendations for monitoring, dosage adjustments, or alternative therapies.', 'Collaborate with dermatologists and pharmacists to develop guidelines and educational materials on potential interactions between the focus drug and commonly used topical medications, including recommendations for concurrent use, interval spacing, or alternative treatment options to minimize the risk of adverse effects.', 'Evaluate potential interactions between the focus drug and central nervous system stimulants, and collaborate with healthcare professionals to develop guidelines for managing these interactions, including monitoring for therapeutic efficacy, dose adjustments, and considering alternative treatment strategies if necessary.', 'Compile a comprehensive database or reference guide of potential interactions between the focus drug and commonly used anti-nausea medications, and provide healthcare professionals with recommendations for managing nausea, optimizing treatment outcomes, and adjusting dosages if needed.', 'Collaborate with gastroenterologists and pharmacists to develop guidelines and educational materials for healthcare professionals regarding potential interactions between the focus drug and gastrointestinal medications, including recommendations for co-administration, dose adjustments, or alternative treatment options.', 'Conduct a literature review and collaborate with pain management specialists to develop guidelines or protocols for managing potential interactions between the focus drug and muscle relaxants, including considerations for therapeutic efficacy, dose adjustments, and monitoring parameters.', 'Create educational materials and resources for healthcare professionals and patients, highlighting potential interactions between the focus drug and sedatives or hypnotic medications, and providing guidance on optimizing sedation, monitoring for adverse effects, and considering alternative sedation strategies if necessary.', 'Collaborate with urologists and pharmacists to develop guidelines and educational materials on potential interactions between the focus drug and commonly used urinary medications, including recommendations for monitoring, dosage adjustments, or alternative treatment options.', 'Conduct a review of the literature and develop a reference guide for healthcare professionals, outlining potential interactions between the focus drug and commonly used dermatological medications, and providing recommendations for monitoring, dosage adjustments, or alternative treatment options to ensure optimal dermatological care.', 'Develop an online platform or mobile application that healthcare professionals can access to quickly check for potential drug interactions with specific immunizations and vaccines, providing real-time guidance on co-administration, timing, and precautions.', 'Create an educational campaign targeting both healthcare professionals and the general public, raising awareness about potential interactions between conventional medications and herbal remedies, and encouraging patients to disclose their use of herbal medications during healthcare visits.', 'Conduct a series of educational webinars or workshops for healthcare professionals, focusing on the common analgesics used in different clinical settings and providing guidance on identifying and managing potential drug interactions, including considerations for dose adjustments and alternative analgesic options.', 'Establish a collaboration between infectious disease specialists and pharmacists to develop an online database or reference guide that provides comprehensive information on potential drug interactions between the focus drug and commonly prescribed anti-infective medications, along with recommendations for co-administration, dose adjustments, and monitoring parameters.', 'Collaborate with mycologists and clinical pharmacists to create a specialized training program for healthcare professionals, focusing on the interactions between the focus drug and antifungal medications, providing guidance on optimal treatment strategies, monitoring for efficacy and safety, and managing potential drug interactions.', 'Establish a multidisciplinary committee consisting of oncologists, pharmacists, and nurses to develop comprehensive guidelines for managing drug interactions between the focus drug and antineoplastic agents, including recommendations for dose adjustments, scheduling modifications, and monitoring protocols.', 'Develop a clinical decision support tool integrated into electronic health record systems that alerts healthcare professionals about potential drug interactions between the focus drug and commonly used diuretics, providing guidance on adjusting diuretic doses, monitoring for adverse effects, and ensuring optimal fluid and electrolyte balance.', 'Create an online learning module for healthcare professionals, featuring case-based scenarios and interactive content to enhance their understanding of potential interactions between the focus drug and antihistamines, and providing practical strategies for managing these interactions in clinical practice.', 'Collaborate with geriatric medicine specialists to develop a medication review program for elderly patients, focusing on potential interactions between the focus drug and anticholinergic medications, with the aim of minimizing anticholinergic burden and optimizing medication regimens.', 'Develop a patient-centered information pamphlet or website content that educates individuals about potential interactions between the focus drug and antivertigo medications, emphasizing the importance of disclosing all medications to healthcare providers and providing tips for managing dizziness and vertigo symptoms effectively.', 'Establish a collaboration between neurologists, psychiatrists, and clinical pharmacists to develop guidelines and educational materials on potential interactions between the focus drug and anticonvulsant medications, offering strategies for optimizing seizure control, managing therapeutic drug levels, and minimizing adverse effects.', 'Develop a mobile application for healthcare professionals that provides real-time alerts and recommendations for managing potential drug interactions between the focus drug and bronchodilators, including guidance on optimizing respiratory outcomes, adjusting medication regimens, and monitoring lung function.', 'Collaborate with oncology nurses and pharmacists to develop an evidence-based practice guideline for the management of potential drug interactions between the focus drug and antiemetic medications, offering recommendations on selecting appropriate antiemetic regimens, monitoring for efficacy and adverse effects, and adjusting doses as needed.', 'Establish a clinical consultation service staffed by rheumatologists and clinical pharmacists, providing healthcare professionals with timely advice and guidance on managing potential drug interactions between the focus drug and antirheumatic medications, including considerations for disease control, medication adjustments, and patient monitoring.', 'Develop a continuing education program for pharmacists and primary care providers, focusing on potential drug interactions between the focus drug and antithrombotic medications, providing guidelines for optimizing anticoagulation therapy, balancing thrombotic and bleeding risks, and adjusting antithrombotic regimens as necessary.', 'Collaborate with oncology pharmacists and clinical trial coordinators to establish a proactive monitoring system that captures potential drug interactions between the focus drug and other antineoplastic agents during clinical trials, ensuring timely intervention, dose adjustments, or protocol modifications to optimize safety and efficacy.', 'Develop a comprehensive educational toolkit for hematologists and healthcare professionals involved in the management of anemia, providing information on potential drug interactions between the focus drug and antianemic medications, along with evidence-based recommendations for adjusting treatment regimens and monitoring patient response.', 'Establish collaborations with infectious disease specialists and parasitologists to create a resource hub or online platform that consolidates information on potential drug interactions between the focus drug and antiparasitic medications, facilitating rapid access to guidelines, dosing recommendations, and precautions for healthcare professionals involved in parasitic disease management.', 'Develop a clinical practice guideline for healthcare professionals, addressing potential drug interactions between the focus drug and antiviral medications, including recommendations for selecting appropriate antiviral therapy, managing co-administration, adjusting doses, and monitoring viral load or therapeutic response.', 'Collaborate with gastroenterologists and pharmacists to develop educational materials and guidelines for healthcare professionals, focusing on potential drug interactions between the focus drug and antidiarrheal medications, providing recommendations for managing diarrhea symptoms, optimizing treatment outcomes, and minimizing adverse effects.'], 'Proposed_Next_Channel_Of_interaction': ['Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call']}"
8,"{'kol': 'Dr. Katherine Baker', 'Interaction_Date': ['5-Apr-19', '12-May-19', '18-Jun-19', '25-Jul-19', '31-Aug-19', '7-Oct-19', '13-Nov-19', '20-Dec-19', '26-Jan-20', '3-Mar-20', '9-Apr-20', '16-May-20', '22-Jun-20', '29-Jul-20', '4-Sep-20', '11-Oct-20', '17-Nov-20', '24-Dec-20', '30-Jan-21', '8-Mar-21', '14-Apr-21', '21-May-21', '27-Jun-21', '3-Aug-21', '9-Sep-21', '16-Oct-21', '22-Nov-21', '29-Dec-21', '4-Feb-22', '13-Mar-22', '19-Apr-22', '26-May-22', '2-Jul-22', '8-Aug-22', '14-Sep-22', '21-Oct-22', '27-Nov-22', '3-Jan-23', '9-Feb-23', '18-Mar-23'], 'Current_Tier': ['Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional'], 'KOL_Qualification': ['MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD', 'MD, PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer'], 'KOL_years_of_Experience': [29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29], 'KOL_Location': ['College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington', 'College Park, Washington'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['12656', '12656', '12656', '12656', '12656', '12656', '12656', '12656', '12656', '12656', '13004', '13004', '13004', '13004', '13004', '13004', '13004', '13004', '13004', '13004', '13212', '13212', '13212', '13212', '13212', '13212', '13212', '13212', '13212', '13212', '13343', '13343', '13343', '13343', '13343', '13343', '13343', '13343', '13343', '13343'], 'SocialMedia_Linkedin': ['8090', '8090', '8090', '8090', '8090', '8090', '8090', '8090', '8090', '8090', '8090', '8090', '8112', '8112', '8112', '8112', '8112', '8112', '8112', '8112', '8234', '8234', '8234', '8234', '8234', '8234', '8234', '8234', '8355', '8355', '8355', '8355', '8355', '8355', '8355', '8355', '8355', '8355', '8355', '8355'], 'SocialMedia_YouTube': ['4320', '4320', '4320', '4320', '4320', '4320', '4320', '4320', '4320', '4320', '4320', '4320', '4320', '4522', '4522', '4522', '4522', '4522', '4522', '4522', '4522', '4677', '4677', '4677', '4677', '4677', '4677', '4677', '4677', '4677', '4677', '4677', '4785', '4785', '4785', '4785', '4785', '4785', '4785', '4785'], 'Overall_Kol_Rating': [4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3], 'Connection_to_Advisory_Boards': [8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'Research_Participated': [11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11], 'Research_Experience': [22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22], 'Fundinghistory_researchgrants': ['580k', '580k', '580k', '580k', '580k', '580k', '580k', '580k', '580k', '580k', '580k', '580k', '612k', '612k', '612k', '612k', '612k', '612k', '612k', '612k', '643k', '643k', '643k', '643k', '643k', '643k', '643k', '643k', '678k', '678k', '678k', '678k', '678k', '678k', '678k', '678k', '678k', '678k', '678k', '678k'], 'Fundinghistory_ConsultingFees': [245, 245, 245, 245, 245, 245, 245, 245, 245, 245, 245, 245, 245, 245, 245, 245, 260, 260, 260, 260, 260, 260, 260, 260, 260, 260, 260, 260, 260, 260, 260, 260, 260, 265, 265, 265, 265, 265, 265, 265], 'Fundinghistory_EducationalGrants': ['580k', '580k', '580k', '580k', '580k', '580k', '580k', '580k', '580k', '580k', '580k', '580k', '612k', '612k', '612k', '612k', '612k', '612k', '612k', '612k', '643k', '643k', '643k', '643k', '643k', '643k', '643k', '643k', '678k', '678k', '678k', '678k', '678k', '678k', '678k', '678k', '678k', '678k', '678k', '678k'], 'No_Of_Publications': [39, 39, 39, 39, 39, 39, 39, 39, 39, 39, 39, 39, 39, 39, 39, 39, 41, 41, 41, 41, 41, 41, 41, 41, 41, 41, 42, 42, 42, 42, 42, 42, 42, 42, 42, 42, 42, 42, 42, 42], 'Trainings_Delivered': [28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 28, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29, 29], 'Professional_Certification': [24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 25, 25, 25, 25, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26], 'KOL_affiliations_academicinstitutionss': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5], 'KOL_Affiliations_Hospital_and_medical_Centres': [7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0, 5.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Government_and_Regulatory_bodies': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9], 'International_Presentations_Presented': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'National_presentations_Presented': [65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65, 65], 'KOL_FollowUp': ['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'Yes', 'No', 'No'], 'Previous_meeting_agenda': ['Share the current market trends', 'Share insights on different test conducted for impacts over different age groups', 'Molecular activity of the drug', 'Effects of the drug with different medications', 'Discuss on potential drug interactivity with various conditions', 'Drug effects during pregnancy.', 'Change of existing prescribed drug to new drug', 'Interrelativity of drug symtoms during pregnancy from mother to child', 'Risk associated with the drug during administration', 'Discuss on potential drug dosage and drug efficacy over short and long duration', 'Discussion on patient candidate requirements', 'Methods and technologies used to deliver the drug', 'Discuss on drug resistance in certain patients', 'Ideate on the drug resistance due in elderly patients', 'Discuss on the safety of the trial patient involved', 'Understand directives before sharing report to FDA for phase trials', 'Discuss on the coverage of the drug by co-pay programs', 'Insurance coverage of the drug over different patient demographics', 'On the Drug availability to patients', 'Discuss drug pricing post trials', 'Inform the KOL on drug lifespan', 'Take KOLs input on prescriptive information', 'Discuss potential Withdrawal symptoms of candidates', 'Protection of Trial patients Identity', ""Patient's Genetic Response"", 'Problems related to drug overdose', 'Consult the KOL on potential adverse events certain patients might face due to drug administration', 'Consult the KOL on potential reactions certain patients might face due to drug administration', 'Post Drug administration recovery', 'Interaction of drug with different molecules', 'How well the drug will react in non-controlled scenario', 'Updates on drug formulation', 'Discuss with KOL the new areas of action post trials', 'Discuss on the usage of sequential therapy during the trials', 'Current Drug combination in controlled environment', ""Drugs' usage along with Car-t Cell therapy"", 'Consideration as a precision medicine', 'Drugs reaction with inhibitors', 'Consideration as a maximality reduction', 'Invite the KOL to be a potential committee member for the new trials phase'], 'Previous_Meeting_SubTopics': ['Impact of drug over different age groups', 'Drug Mechanism', 'Interactions with medications for potential stimuli', 'Drug interactivity', 'Drug interations during pregnancy', 'Drug transferance', 'Understand KOLs perspective on drug interactions from pregnancy to post birth', 'Drug safety', 'Drug Efficacy', 'Identification of potential Candidates', 'Delivery of Drug and Drug administration', 'Drug resistance', 'Special case of Elderly patients', 'Patient Safety', 'Trial reports for FDA', 'Insurance Co-pay coverage', 'Insurance coverage', 'Drug Availability', 'Drug Pricing', 'Drug Lifespan', 'Prescriptive information', 'Patient Withdrawal Symptops', 'Identity Protection', 'Genetic Response', 'Drug Overdose issues', 'Adverse Events based on drug administration', 'Reactions based on drug administration', 'Drug Recovery', 'Drug Interactions', 'Drug Effectiveness', 'Drug Formulation updates', 'Emerging areas of action', 'Usage of sequential Therapy', 'Drug Combination', 'Car-t Cell Therapy', 'Precision Medicine', 'Reaction with Inhibitors', 'Maximality Reduction', 'Invitation as trials committee member', 'Plan of action'], 'Current_Discussion_Topic': ['Share insights on different test conducted for impacts over different age groups', 'Molecular activity of the drug', 'Effects of the drug with different medications', 'Discuss on potential drug interactivity with various conditions', 'Drug effects during pregnancy.', 'Change of existing prescribed drug to new drug', 'Interrelativity of drug symtoms during pregnancy from mother to child', 'Risk associated with the drug during administration', 'Discuss on potential drug dosage and drug efficacy over short and long duration', 'Discussion on patient candidate requirements', 'Methods and technologies used to deliver the drug', 'Discuss on drug resistance in certain patients', 'Ideate on the drug resistance due in elderly patients', 'Discuss on the safety of the trial patient involved', 'Understand directives before sharing report to FDA for phase trials', 'Discuss on the coverage of the drug by co-pay programs', 'Insurance coverage of the drug over different patient demographics', 'On the Drug availability to patients', 'Discuss drug pricing post trials', 'Inform the KOL on drug lifespan', 'Take KOLs input on prescriptive information', 'Discuss potential Withdrawal symptoms of candidates', 'Protection of Trial patients Identity', ""Patient's Genetic Response"", 'Problems related to drug overdose', 'Consult the KOL on potential adverse events certain patients might face due to drug administration', 'Consult the KOL on potential reactions certain patients might face due to drug administration', 'Post Drug administration recovery', 'Interaction of drug with different molecules', 'How well the drug will react in non-controlled scenario', 'Updates on drug formulation', 'Discuss with KOL the new areas of action post trials', 'Discuss on the usage of sequential therapy during the trials', 'Current Drug combination in controlled environment', ""Drugs' usage along with Car-t Cell therapy"", 'Consideration as a precision medicine', 'Drugs reaction with inhibitors', 'Consideration as a maximality reduction', 'Invite the KOL to be a potential committee member for the new trials phase', 'Discuss on company plan of action for the new phase'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'In-Person'], 'Company_Event': ['Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials'], 'Interaction_intent': ['Give a brisk overview of how the drug is reacting in test environments over artifically created test samples of different age groups', 'How the drug is targetting the required molecules and what is the effective time', 'Discuss on how the drug might have different effect with respect to different forms of ongoing medication', 'Discuss how the drug may interact with patients having different conditions', 'Seek opinions on the different drug effects and side effects during pregnancy', 'Exchange on drug transferance', 'Understand and come to a conclusion about the drug interaction', 'Seek advice on drug risks and potential mitigations', 'Seek Guidance on drug administration over variety of patient demographic', 'Understand potential candidate choices in consultation to KOL', 'Consult with the KOL on identification of drug delivery', 'Explore ways on which patients and generate drug resistance', 'Identify factors for potential drug ambiguity in elderly patients', 'Understand KOLs perspective on patient safety', 'Seek KOLs clarity and his stance post phase trials', 'Discuss exsiting norms and new items to be informed to the insurance firms for the addition of the drug to the co-pay programs', 'Share with KOL current insurance vetted programs that might cover the drug cost', 'Discuss with the KOL on the current drug availability scenrio to patients', 'Share with KOL the current vision on the price of drugs', ""Share company outlook of the drug's vision"", 'Understand the core prescriptive information to be adhered to', 'Understand different kinds of patient withdrawal symptoms from the KOL', 'Guidance on protection of identity of patient trials', 'Understanding Genetic responses to drug', 'Discuss on the scenarios of drug overdose and its effect', 'Root cause discussion over molecularity of Adverse effects', 'Proper understanding on side effects and reactions after drug administration', 'Discuss on the drug recovery phase', 'Discuss on how the drug is reacting to different molecules', 'Seek KOLs opinion and guidance on the study of drug effectiveness in real world scenario', 'Share with KOL updates on drug formulation for better site activity', 'Understand and report the new areas of action to KOL', 'Seek from KOL his opinion on Sequential drug therapy for the trials', 'How is the drug being combined in current controlled environment', 'Understand KOLs standpoint of Car-t cell therapy and its usage as a potential accelator for the drug', 'Drugs standpoint interms of usage as a precision medicine', 'Share the trial report on how the drug is reacting with inhibitors', 'Whether the drug can be considered as a maximality reduction', 'Share with KOL the overall plans and his role as a committee member for the new phase trials', 'Seek advice on the plan of action'], 'Items/topics_to_exchange': ['Test sample procurement, drug dosage, drug reaction, possible side effects, possible ressuciations', 'Reports generated during drug discovery', 'Reports on existing identified drug reactions', 'List of key identified factors', 'Drug interaction reports and studies', 'Drug analysis, fall throughs', 'Reports of drug administration, lab sheets, and moleular reports', 'Molecular report, drug dynamics, and drug delivery methods', 'Drug interaction study', 'Closed case study suiting the patient demographic', 'How to deliver drug to the human body and potential target site', 'Abalation study over previous records of similar compounds', 'Causesheet of existing drug apenditures', 'Regulatory checks, and guidelines on patient safety', 'Share all premtive documents and reports', 'Insurance co-pay programs report for drug coverage', 'Insurance plantiffs report for drug coverage', 'Redaction reports encompassing the drug availability', 'Share the development cost sheet and expected return', 'Current Vision Statements', 'share current drug labels', 'List of essential practices used for patient wellness', 'Previous trial methodicals', 'Drug induced genetic responses', 'Potential patient fall through reports, expected behaviour, consolidation reports of patient recovery', 'Labs reports of first cases', 'Drug administration related reactions', 'Preliminary study reports and patient transripts', 'Test Reports of patient criterion', 'Current phase trial reports', 'New formula supportive documents', 'Share suggestive documents', 'Existing literature and counter arguments', 'Lab reports', 'Current stochastic reports from different exhibitions', 'Genesis articles for the following', 'Drug test report', 'Phase trial report capturing best cases and their study', 'Target reports and expected outcomes', 'Share extensive checklist and memorandum'], 'KOLMSL_Relation': ['Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Address impact of children', 'Share the potantial drug usage charts', 'Inquire about drug reactions during pregnancy', 'Create a repository of existing and future reports of drug interactivity for easy referrals', 'Create a consolidation of interactiosn ranging from early pregnancy to early infacy post birth', ""Do a survey with HCO's on understanding existing dynamics"", 'Create a reference guide', 'Consultation report with HCPs', 'Identify groups of candidates for clinical studies currently consulting with KOL', 'Referendum', 'Create comparative study', 'Seek clarity and generate report with the help of biochemists', 'Study existing reports and create abalation report', 'Create a study on different levels of patient involvement through different stages of the trials', 'Compile all the reports and feedbacks from KOL', 'Seek information from Insurance companies and seek advisory chairs extension', 'Research on whatnew items checklist might need to be added', 'Updation of factsheets', 'Take KOL feedback report for adjustment if needed', 'Include KOLs feedback', 'Incorporate the feedback into a decadence report for the internal teams', 'Seek incidents and reports during past trials of drug', 'Liability report', 'Study on genetic mutation', 'Create a short report on different patient groups', 'Send extended study reports', 'Share with KOL a report of existing understanding and prolific study', 'Consult and create report with phase trial officers', 'Relative summary from previous trials', 'Adjunct report', 'Consolidated factsheet', 'Create and share a report of the study', 'Share KOLs understanding to respective stakeholders', 'Understand from trial holders on drug inhibition', 'Case Study of the diagnostics', 'Compile a report on the benchmarks of Precision medicine', 'Granular study guidance', 'Referendum from patients post trials ops', 'Share KOLs intention with advisory body', 'Include KOLs feedback'], 'Proposed_Next_Channel_Of_interaction': ['In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'In-Person']}"
9,"{'kol': 'Dr. Rachel Dunphy', 'Interaction_Date': ['3-Apr-19', '10-May-19', '16-Jun-19', '23-Jul-19', '29-Aug-19', '5-Oct-19', '11-Nov-19', '18-Dec-19', '24-Jan-20', '1-Mar-20', '7-Apr-20', '14-May-20', '20-Jun-20', '27-Jul-20', '2-Sep-20', '9-Oct-20', '15-Nov-20', '22-Dec-20', '28-Jan-21', '6-Mar-21', '12-Apr-21', '19-May-21', '25-Jun-21', '1-Aug-21', '7-Sep-21', '14-Oct-21', '20-Nov-21', '27-Dec-21', '2-Feb-22', '11-Mar-22', '17-Apr-22', '24-May-22', '30-Jun-22', '6-Aug-22', '12-Sep-22', '19-Oct-22', '25-Nov-22', '1-Jan-23', '7-Feb-23', '16-Mar-23'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.', 'MD, Ph.D.'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer'], 'KOL_years_of_Experience': [20, 20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23, 23, 23, 23, 24, 24, 24], 'KOL_Location': ['California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California'], 'KOL_Territory': ['Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA', 'Western USA'], 'SocialMedia_Twitter': ['18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732', '18732'], 'SocialMedia_Linkedin': ['4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352', '4352'], 'SocialMedia_YouTube': ['14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432', '14432'], 'Overall_Kol_Rating': [4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8, 4.8], 'Connection_to_Advisory_Boards': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'Research_Participated': [7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7], 'Research_Experience': [16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16], 'Fundinghistory_researchgrants': ['30.7K', '43.3K', '44K', '50K', '52K', '58K', '70K', '80K', '80K', '81K', '82K', '83K', '84K', '90K', '92K', '94K', '98K', '100K', '105K', '110K', '115K', '117K', '127K', '130K', '132K', '134K', '138K', '140K', '142K', '144K', '150K', '155K', '156K', '157K', '159K', '165K', '175K', '180K', '190K', '200K'], 'Fundinghistory_ConsultingFees': [400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 500, 500, 500, 500], 'Fundinghistory_EducationalGrants': ['30.7K', '43.3K', '44K', '50K', '52K', '58K', '70K', '80K', '80K', '81K', '82K', '83K', '84K', '90K', '92K', '94K', '98K', '100K', '105K', '110K', '115K', '117K', '127K', '130K', '132K', '134K', '138K', '140K', '142K', '144K', '150K', '155K', '156K', '157K', '159K', '165K', '175K', '180K', '190K', '200K'], 'No_Of_Publications': [27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27], 'Trainings_Delivered': [14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14], 'Professional_Certification': [8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [0, 0, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 1, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [20, 20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23, 23, 23, 23, 24, 24, 24], 'National_presentations_Presented': [100, 100, 100, 100, 100, 100, 100, 100, 105, 105, 105, 105, 105, 105, 105, 105, 105, 105, 110, 110, 110, 110, 110, 110, 110, 110, 110, 110, 115, 115, 115, 115, 115, 115, 115, 115, 115, 120, 120, 120], 'KOL_FollowUp': ['No', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Overview', 'Introduction to the medical drug', 'Mechanism of action', 'Clinical uses and indications', 'Dosage and administration', 'Pharmacokinetics of the drug', 'Pharmacodynamics of the drug', 'Drug interactions', 'Adverse effects and side effects', 'Introduction to multiple myeloma', 'Pathophysiology of multiple myeloma', 'Current treatment options for multiple myeloma', 'Mechanism of action of myeloma drugs', 'Clinical trials in multiple myeloma', 'Side effects and adverse reactions of myeloma drugs', 'Novel therapies for multiple myeloma', 'Targeted therapies in myeloma treatment', 'Immunotherapy for multiple myeloma', 'Role of stem cell transplantation in myeloma treatment', 'Management of bone disease in multiple myeloma', 'Supportive care in myeloma treatment', 'Genomic profiling in multiple myeloma', 'Role of molecular diagnostics in myeloma management', 'Precision medicine in multiple myeloma', 'Early detection and screening for multiple myeloma', 'Treatment options for relapsed or refractory multiple myeloma', 'Minimal residual disease assessment in myeloma', 'Imaging techniques in myeloma diagnosis and monitoring', 'Role of radiation therapy in myeloma treatment', 'Psychosocial support for patients with multiple myeloma', 'Palliative care for advanced multiple myeloma', 'Impact of myeloma on quality of life', 'Emerging therapies for myeloma treatment', 'Combination therapies in multiple myeloma', 'Role of proteasome inhibitors in myeloma treatment', 'Novel immunomodulatory drugs in myeloma therapy', 'Biomarkers in myeloma prognosis and treatment response', 'Risk stratification in multiple myeloma', 'Impact of myeloma on bone marrow function', 'Role of supportive therapies in managing treatment-related complications'], 'Previous_Meeting_SubTopics': ['Finalizing the trends to focus upon', 'Historical background and discovery process.', 'Specific molecular targets and signaling pathways affected by the drug.', 'Approved medical conditions and off-label uses.', 'Recommended dosing regimens and considerations for different patient populations.', 'Absorption, distribution, metabolism, and excretion of the drug in the body.', 'Biological effects and mechanisms of action at the cellular level.', 'Interactions with specific classes of medications or substances.', 'Common and rare adverse reactions associated with the drug.', 'Staging and classification systems', 'Role of abnormal plasma cell proliferation', 'Combination therapies and maintenance strategies', 'Inhibition of proteasome function', 'Phase I/II trials for novel agents', 'Hematological toxicities', 'Immune checkpoint inhibitors', 'Monoclonal antibodies targeting surface antigens', 'Adoptive T-cell therapy', 'Allogeneic transplant in high-risk cases', 'Bisphosphonate treatment guidelines', 'Management of treatment-related neuropathy', 'Identification of genetic abnormalities and prognostic markers', 'Detection of chromosomal aberrations', 'Targeting specific genetic mutations', 'Role of serum protein electrophoresis', 'CAR-T cell therapy in salvage settings', 'Next-generation sequencing techniques', 'Whole-body MRI for disease evaluation', 'Palliative irradiation for bone pain relief', 'Support groups and counseling services', 'Symptom management and end-of-life care', 'Physical, emotional, and social well-being', 'CAR-T cell therapy and bispecific antibodies', 'Triple-drug regimens and treatment sequencing', 'Bortezomib and carfilzomib mechanisms of action', 'Pomalidomide and lenalidomide in combination regimens', 'Serum and genetic markers', 'Revised International Staging System (R-ISS) criteria', 'Cytopenias and risk of infection', 'Growth factors and antimicrobial prophylaxis'], 'Current_Discussion_Topic': ['Introduction to the medical drug', 'Mechanism of action', 'Clinical uses and indications', 'Dosage and administration', 'Pharmacokinetics of the drug', 'Pharmacodynamics of the drug', 'Drug interactions', 'Adverse effects and side effects', 'Contraindications for the drug', 'Drug-drug interactions', 'Drug-food interactions', 'Drug metabolism and elimination', 'Pharmacogenomics and personalized medicine', 'Drug delivery systems', 'Drug development process', 'Preclinical studies and animal testing', 'Clinical trials and phases', 'Drug safety and efficacy', 'Drug discovery and design', 'Drug formulation and manufacturing', 'Drug patents and intellectual property', 'Drug regulations and approvals', 'Drug pricing and access', 'Off-label drug use', 'Drug resistance and mechanisms', 'Drug toxicity and overdose', 'Drug monitoring and therapeutic drug levels', 'Drug adherence and compliance', 'Drug withdrawal and discontinuation', 'Drug interactions with herbal supplements', 'Drug interactions with over-the-counter medications', 'Drug interactions with alcohol', 'Drug interactions with specific populations (e.g., elderly, pediatric)', 'Drug interactions with specific medical conditions (e.g., renal impairment)', 'Drug interactions with pregnancy and lactation', 'Drug interactions with hormonal contraceptives', 'Drug interactions with antibiotics', 'Drug interactions with anticoagulants', 'Drug interactions with antidepressants', 'Drug interactions with antiepileptic medications'], 'Current_Meeting_Subtopics': ['Historical background and discovery process.', 'Specific molecular targets and signaling pathways affected by the drug.', 'Approved medical conditions and off-label uses.', 'Recommended dosing regimens and considerations for different patient populations.', 'Absorption, distribution, metabolism, and excretion of the drug in the body.', 'Biological effects and mechanisms of action at the cellular level.', 'Interactions with specific classes of medications or substances.', 'Common and rare adverse reactions associated with the drug.', ""Medical conditions or patient characteristics that warrant avoiding the drug's use."", 'Examples of significant interactions with other specific drugs.', 'Effects of food or specific nutrients on drug absorption or metabolism.', ""Enzymes and pathways involved in the drug's metabolism and elimination from the body."", 'Genetic factors influencing individual response to the drug.', 'Different methods and technologies used to deliver the drug to the target site.', 'Stages from initial research to market approval, including preclinical and clinical studies.', ""Assessing the drug's safety and efficacy in animal models before human trials."", 'Phases of human trials and the design and objectives of each phase.', 'Assessing the balance between beneficial effects and potential risks.', 'Approaches and methods used to identify and develop new drugs.', 'Processes involved in creating the final drug product and ensuring quality and stability.', ""Legal aspects and protection of the drug's intellectual property rights."", 'Government regulations and processes for drug evaluation and market authorization.', 'Factors influencing drug pricing and availability to patients.', 'Non-approved uses of the drug and associated considerations.', 'Development of resistance to the drug and underlying mechanisms.', 'Potential harmful effects of the drug and management of overdose cases.', 'Monitoring drug levels in the blood to ensure optimal therapeutic effects.', 'Factors influencing patient adherence to prescribed drug regimens.', 'Safe and appropriate strategies for discontinuing the drug.', 'Interactions between the drug and specific herbal supplements.', 'Potential interactions between the drug and commonly used non-prescription medications.', 'Effects of combining the drug with alcohol consumption.', 'Considerations and potential interactions specific to certain age groups.', 'Interactions and adjustments needed for patients with specific medical conditions.', 'Effects of the drug on pregnant and breastfeeding women.', 'Interactions between the drug and hormonal birth control methods.', 'Interactions between the drug and commonly used antibiotics.', 'Interactions with medications used to prevent blood clotting.', 'Potential interactions between the drug and medications used to treat depression.', 'Interactions with drugs used to manage epilepsy.'], 'Current_Channel_of_interaction': ['Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call'], 'Company_Event': ['Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials'], 'Interaction_intent': [""Inquire about the timeline and key milestones in the drug's development."", 'Seek information on how the drug interacts with specific cellular targets and modulates signaling pathways.', ""Explore the drug's approved uses and potential off-label applications."", 'Request guidance on appropriate dosage and any specific considerations for different patient groups.', 'Understand how the drug is absorbed, distributed, metabolized, and eliminated in the body.', ""Learn about the drug's specific biological effects and its mechanisms of action within cells."", 'Identify potential interactions between the drug and other specific medications or substances.', ""Inquire about the known side effects and adverse reactions linked to the drug's use."", 'Seek information on the contraindications or precautions associated with specific medical conditions or patient characteristics.', 'Request details on notable interactions between the drug and other specific medications.', ""Explore how food or certain nutrients may affect the drug's absorption or metabolism."", ""Understand the enzymes and pathways responsible for the drug's metabolism and elimination."", ""Discover how genetic variations can impact an individual's response to the drug."", 'Explore various drug delivery systems and technologies employed to target specific sites in the body.', 'Gain insights into the drug development process, including preclinical and clinical trial phases.', ""Inquire about the use of animal models to evaluate the drug's safety and efficacy prior to human trials."", 'Learn about the different phases of human clinical trials and the objectives of each phase.', ""Understand how the drug's potential benefits are weighed against its associated risks."", 'Explore the techniques and strategies employed in the discovery and development of novel drugs.', 'Inquire about the manufacturing processes and quality control measures involved in producing the drug.', ""Seek information on the legal framework and measures in place to protect the drug's intellectual property rights."", 'Understand the regulatory requirements and processes involved in evaluating and authorizing the drug for the market.', 'Explore the factors that impact drug pricing and patient access to the medication.', 'Inquire about the potential off-label uses of the drug and the considerations associated with such use.', 'Understand how resistance to the drug can develop and the mechanisms involved.', 'Inquire about the potential adverse effects associated with the drug and how to manage cases of overdose or toxicity.', 'Seek information on the importance of monitoring drug levels in the blood to ensure the drug is within the therapeutic range.', 'Understand the various factors that can influence patient adherence to the prescribed drug regimen.', 'Inquire about the recommended approaches and strategies for safely discontinuing the use of the drug.', 'Seek information on potential interactions between the drug and specific herbal supplements.', 'Explore possible interactions between the drug and commonly used non-prescription medications.', 'Inquire about the effects and potential risks of combining the drug with alcohol.', 'Understand the specific considerations and potential interactions that may arise in different age groups.', 'Seek information on how the drug may interact with specific medical conditions and the adjustments required.', 'Inquire about the effects of the drug on pregnant and breastfeeding women and any precautions to be taken.', 'Explore potential interactions between the drug and hormonal birth control methods.', 'Understand potential interactions between the drug and commonly used antibiotics.', 'Inquire about interactions between the drug and medications used to prevent blood clotting.', 'Seek information on potential interactions between the drug and medications used to treat depression.', 'Explore potential interactions between the drug and medications used to manage epilepsy.'], 'Items/topics_to_exchange': ['Basics of the medication explained', 'How the drug works in the body', 'Conditions for which the drug is prescribed', 'Proper way to take and use the drug', 'How the body processes and absorbs the drug', 'The effects the drug has on the body', 'Interactions between the drug and other substances', 'Unwanted reactions or effects of the drug', 'Situations where the drug should not be used', 'Drug interactions', 'Food interactions', 'How the body breaks down and eliminates the drug', 'Tailoring treatment based on genetic factors', 'Different methods of delivering the drug to the body', 'The stages involved in creating a new drug', ""Testing the drug's safety and effectiveness in animals"", 'Testing the drug in human volunteers in different stages', ""Assessing the drug's safety and effectiveness"", 'The process of identifying and designing new drugs', 'Creating the final product and ensuring quality', ""Legal protection for the drug's invention"", 'Government regulations and authorizations for the drug', 'Factors influencing the cost and availability of the drug', 'label drug use', 'How the body can become resistant to the drug', 'Harmful effects and excessive use of the drug', 'Monitoring drug levels for optimal treatment', 'Following prescribed treatment plans', 'Safely stopping the use of the drug', 'Interactions between the drug and natural remedies', 'Interactions between the drug and non-prescription medications', 'Effects of combining the drug with alcoholic beverages', 'Interactions specific to certain age groups or populations', 'Interactions related to specific health conditions like kidney problems', 'Effects of the drug on pregnant and breastfeeding women', 'Interactions between the drug and birth control methods', 'Interactions with medications used to treat bacterial infections', 'Interactions with medications used to prevent blood clotting', 'Interactions with medications used to treat depression', 'Interactions with medications used to manage epilepsy'], 'KOLMSL_Relation': ['Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good'], 'Next_Action_Items': ['Prepare a comprehensive presentation highlighting the key features, benefits, and indications of the drug for educational purposes.', ""Conduct a literature review and present a summary of the latest research on the drug's mechanism of action, including any recent discoveries or updates."", 'Organize a training session for healthcare professionals to educate them about the clinical uses and indications of the drug, focusing on specific patient populations and conditions.', 'Develop clear and concise guidelines for the appropriate dosage and administration of the drug, ensuring that healthcare professionals have easy access to this information.', ""Collaborate with a pharmacokinetics expert to conduct a study on the drug's pharmacokinetic profile, aiming to optimize dosing regimens and improve therapeutic outcomes."", ""Design and implement in vitro and in vivo experiments to explore the drug's pharmacodynamics, providing insights into its interactions with cellular targets and the resulting physiological effects."", 'Create an online resource or reference guide that lists potential drug interactions with the focus drug, highlighting the importance of monitoring and managing these interactions.', 'Develop a comprehensive adverse effects and side effects profile for the drug, including a system for reporting and monitoring adverse events in patients.', 'Create a checklist or decision support tool to help healthcare professionals identify contraindications and ensure safe and appropriate use of the drug.', 'Develop an educational module or training session to increase awareness among healthcare professionals about potential drug-drug interactions involving the focus drug, emphasizing the need for vigilance.', 'Collaborate with a nutrition expert to identify and document potential drug-food interactions, providing guidelines and recommendations for patients on how to manage these interactions.', ""Conduct studies to investigate the drug's metabolism and elimination pathways, with the aim of optimizing dosing regimens and minimizing the risk of accumulation or toxicity."", ""Initiate a research project to explore the relationship between the drug's efficacy and genetic variations in patients, with the goal of developing personalized treatment approaches."", 'Evaluate and compare different drug delivery systems to determine the most suitable one for the focus drug, considering factors such as bioavailability, patient compliance, and ease of administration.', 'Establish a multidisciplinary team to review and optimize the drug development process, identifying potential bottlenecks, and implementing strategies for improved efficiency and timeline management.', ""Design and conduct preclinical studies and animal testing to assess the drug's safety, efficacy, and potential toxicities, ensuring compliance with regulatory requirements."", 'Plan and initiate the necessary clinical trials for the drug, ensuring proper study design, patient recruitment, and adherence to ethical guidelines and regulatory requirements.', 'Establish a comprehensive pharmacovigilance program to monitor the safety and efficacy of the drug after its market release, including mechanisms for adverse event reporting and continuous evaluation.', 'Collaborate with researchers and utilize computational approaches to identify potential targets and design new drug candidates, with the aim of expanding the drug portfolio and therapeutic options.', ""Optimize the drug's formulation and manufacturing processes, focusing on factors such as stability, bioavailability, and scalability, to ensure consistent quality and supply for commercial distribution."", 'Evaluate the current patent portfolio and conduct a patent landscape analysis to identify potential opportunities for patent extension or additional intellectual property protection.', ""Develop a regulatory strategy and timeline for the drug's approval process, including compiling necessary documentation, engaging with regulatory agencies, and ensuring compliance with regulatory requirements."", 'Conduct a comprehensive pricing analysis to determine an optimal pricing strategy that balances affordability and sustainability, considering factors such as manufacturing costs, market demand, and access programs.', 'Conduct a systematic review of published literature and compile evidence-based guidelines or recommendations for healthcare professionals regarding the safe and appropriate use of the drug in off-label indications.', 'Initiate research studies to investigate the mechanisms of drug resistance, including genetic mutations or acquired resistance pathways, aiming to develop strategies to overcome or prevent resistance.', 'Develop educational materials and training programs to increase awareness among healthcare professionals and patients about the signs, symptoms, and management of drug toxicity and overdose, including appropriate interventions and supportive care.', 'Establish guidelines and protocols for monitoring drug levels in patients, including the frequency and methods of monitoring, as well as defining therapeutic ranges and actions to be taken based on the results.', 'Design and implement patient education programs and interventions to improve medication adherence and compliance, utilizing techniques such as patient counseling, reminder systems, and adherence monitoring tools.', 'Develop evidence-based guidelines and protocols for tapering and discontinuing the drug, including monitoring for withdrawal symptoms, managing withdrawal effects, and providing appropriate patient support during the process.', 'Compile a comprehensive database or reference guide of potential interactions between the drug and commonly used herbal supplements, highlighting the need for caution and appropriate monitoring.', 'Collaborate with pharmacists and healthcare professionals to create educational materials for patients, providing information on potential interactions between the drug and commonly used over-the-counter medications, and recommending precautions or alternatives.', 'Develop educational campaigns and materials targeting healthcare professionals and patients to raise awareness about the potential adverse effects and interactions between the drug and alcohol consumption, emphasizing the importance of avoiding or limiting alcohol intake.', ""Conduct targeted studies or retrospective analyses to evaluate the drug's pharmacokinetics, efficacy, and safety in specific populations, and generate evidence-based dosing guidelines and recommendations."", 'Collaborate with specialists and experts in relevant medical conditions to establish guidelines for drug use in patients with specific medical conditions, taking into account dose adjustments, monitoring parameters, and potential interactions.', ""Conduct preclinical and clinical studies to assess the drug's safety and potential risks during pregnancy and lactation, and develop evidence-based guidelines for healthcare professionals on the appropriate use of the drug in these populations."", 'Collaborate with reproductive health experts to evaluate potential interactions between the drug and hormonal contraceptives, and provide healthcare professionals with guidance on alternative contraceptive methods or dosage adjustments if necessary.', 'Create educational materials and resources for healthcare professionals to educate them about potential drug interactions between the focus drug and commonly prescribed antibiotics, including recommendations for timing, dose adjustments, or alternative therapies.', 'Develop guidelines and protocols for managing drug interactions between the focus drug and anticoagulants, including recommendations for monitoring coagulation parameters, adjusting anticoagulant dosages, and assessing the risk-benefit ratio.', 'Collaborate with psychiatrists and mental health experts to develop guidelines and resources for managing potential interactions between the focus drug and antidepressant medications, including recommendations for monitoring, dosage adjustments, or alternative treatments.', 'Conduct studies and compile evidence-based guidelines for managing drug interactions between the focus drug and antiepileptic medications, considering potential changes in seizure control, dosage adjustments, or therapeutic drug monitoring.'], 'Proposed_Next_Channel_Of_interaction': ['Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Video Call']}"
10,"{'kol': 'Dr. Simanth Chintala', 'Interaction_Date': ['9-Apr-19', '16-May-19', '22-Jun-19', '29-Jul-19', '4-Sep-19', '11-Oct-19', '17-Nov-19', '24-Dec-19', '30-Jan-20', '7-Mar-20', '13-Apr-20', '20-May-20', '26-Jun-20', '2-Aug-20', '8-Sep-20', '15-Oct-20', '21-Nov-20', '28-Dec-20', '3-Feb-21', '12-Mar-21', '18-Apr-21', '25-May-21', '1-Jul-21', '7-Aug-21', '13-Sep-21', '20-Oct-21', '26-Nov-21', '2-Jan-22', '8-Feb-22', '17-Mar-22', '23-Apr-22', '30-May-22', '6-Jul-22', '12-Aug-22', '18-Sep-22', '25-Oct-22', '1-Dec-22', '7-Jan-23', '13-Feb-23', '22-Mar-23'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer', 'Myleoma cancer'], 'KOL_years_of_Experience': [17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17], 'KOL_Location': ['Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia', 'Trenton, Philadelphia'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['5634', '5634', '5634', '5634', '5634', '5634', '5634', '5634', '5634', '5634', '5634', '5634', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5711', '5808', '5808', '5808', '5808', '5808'], 'SocialMedia_Linkedin': ['7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7650', '7804', '7804', '7804', '7804', '7804', '7804', '7804', '7804', '7804', '7804', '7804', '7945', '7945', '7945', '7945', '7945'], 'SocialMedia_YouTube': ['3665', '3665', '3665', '3665', '3665', '3665', '3665', '3665', '3665', '3665', '3665', '3665', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3690', '3718', '3718', '3718', '3718', '3718', '3822', '3822', '3822', '3822', '3822', '3822'], 'Overall_Kol_Rating': [4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3], 'Connection_to_Advisory_Boards': [6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6], 'Research_Participated': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5], 'Research_Experience': [12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12], 'Fundinghistory_researchgrants': ['425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '512k', '512k', '512k', '512k', '512k', '512k', '512k', '512k', '512k', '512k', '512k', '512k'], 'Fundinghistory_ConsultingFees': [180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180, 180], 'Fundinghistory_EducationalGrants': ['425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '425k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '477k', '512k', '512k', '512k', '512k', '512k', '512k', '512k', '512k', '512k', '512k', '512k', '512k'], 'No_Of_Publications': [24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25], 'Trainings_Delivered': [16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17], 'Professional_Certification': [18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18], 'KOL_affiliations_academicinstitutionss': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'KOL_Affiliations_Government_and_Regulatory_bodies': [6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'International_Presentations_Presented': [3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'National_presentations_Presented': [73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73, 73], 'KOL_FollowUp': ['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No'], 'Previous_meeting_agenda': ['Share a market study on the target drug area', 'Share insights on different test conducted for impacts over different age groups', 'Interaction of drug with different molecules', 'How well the drug will react in non-controlled scenario', 'Molecular activity of the drug', 'Effects of the drug with different medications', 'Discuss on potential drug interactivity with various conditions', 'Updates on drug formulation', 'Discuss with KOL the new areas of action post trials', 'Drug effects during pregnancy.', 'Change of existing prescribed drug to new drug', 'Interrelativity of drug symtoms during pregnancy from mother to child', 'Risk associated with the drug during administration', 'Discuss on the usage of sequential therapy during the trials', 'Current Drug combination in controlled environment', 'Discuss on potential drug dosage and drug efficacy over short and long duration', 'Discussion on patient candidate requirements', 'Methods and technologies used to deliver the drug', ""Drugs' usage along with Car-t Cell therapy"", 'Consideration as a precision medicine', 'Discuss on drug resistance in certain patients', 'Ideate on the drug resistance due in elderly patients', 'Discuss on the safety of the trial patient involved', 'Understand directives before sharing report to FDA for phase trials', 'Drugs reaction with inhibitors', 'Discuss on the coverage of the drug by co-pay programs', 'Insurance coverage of the drug over different patient demographics', 'On the Drug availability to patients', 'Discuss drug pricing post trials', 'Inform the KOL on drug lifespan', 'Take KOLs input on prescriptive information', 'Discuss potential Withdrawal symptoms of candidates', 'Protection of Trial patients Identity', ""Patient's Genetic Response"", 'Problems related to drug overdose', 'Consult the KOL on potential adverse events certain patients might face due to drug administration', 'Consult the KOL on potential reactions certain patients might face due to drug administration', 'Post Drug administration recovery', 'Consideration as a maximality reduction', 'Invite the KOL to be a potential committee member for the new trials phase'], 'Previous_Meeting_SubTopics': ['Impact of drug over different age groups', 'Drug Interactions', 'Drug Effectiveness', 'Drug Mechanism', 'Interactions with medications for potential stimuli', 'Drug interactivity', 'Drug Formulation updates', 'Emerging areas of action', 'Drug interations during pregnancy', 'Drug transferance', 'Understand KOLs perspective on drug interactions from pregnancy to post birth', 'Drug safety', 'Usage of sequential Therapy', 'Drug Combination', 'Drug Efficacy', 'Identification of potential Candidates', 'Delivery of Drug and Drug administration', 'Car-t Cell Therapy', 'Precision Medicine', 'Drug resistance', 'Special case of Elderly patients', 'Patient Safety', 'Trial reports for FDA', 'Reaction with Inhibitors', 'Insurance Co-pay coverage', 'Insurance coverage', 'Drug Availability', 'Drug Pricing', 'Drug Lifespan', 'Prescriptive information', 'Patient Withdrawal Symptops', 'Identity Protection', 'Genetic Response', 'Drug Overdose issues', 'Adverse Events based on drug administration', 'Reactions based on drug administration', 'Drug Recovery', 'Maximality Reduction', 'Invitation as trials committee member', 'Plan of action'], 'Current_Discussion_Topic': ['Share insights on different test conducted for impacts over different age groups', 'Interaction of drug with different molecules', 'How well the drug will react in non-controlled scenario', 'Molecular activity of the drug', 'Effects of the drug with different medications', 'Discuss on potential drug interactivity with various conditions', 'Updates on drug formulation', 'Discuss with KOL the new areas of action post trials', 'Drug effects during pregnancy.', 'Change of existing prescribed drug to new drug', 'Interrelativity of drug symtoms during pregnancy from mother to child', 'Risk associated with the drug during administration', 'Discuss on the usage of sequential therapy during the trials', 'Current Drug combination in controlled environment', 'Discuss on potential drug dosage and drug efficacy over short and long duration', 'Discussion on patient candidate requirements', 'Methods and technologies used to deliver the drug', ""Drugs' usage along with Car-t Cell therapy"", 'Consideration as a precision medicine', 'Discuss on drug resistance in certain patients', 'Ideate on the drug resistance due in elderly patients', 'Discuss on the safety of the trial patient involved', 'Understand directives before sharing report to FDA for phase trials', 'Drugs reaction with inhibitors', 'Discuss on the coverage of the drug by co-pay programs', 'Insurance coverage of the drug over different patient demographics', 'On the Drug availability to patients', 'Discuss drug pricing post trials', 'Inform the KOL on drug lifespan', 'Take KOLs input on prescriptive information', 'Discuss potential Withdrawal symptoms of candidates', 'Protection of Trial patients Identity', ""Patient's Genetic Response"", 'Problems related to drug overdose', 'Consult the KOL on potential adverse events certain patients might face due to drug administration', 'Consult the KOL on potential reactions certain patients might face due to drug administration', 'Post Drug administration recovery', 'Consideration as a maximality reduction', 'Invite the KOL to be a potential committee member for the new trials phase', 'Discuss on company plan of action for the new phase'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'In-Person'], 'Company_Event': ['Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials', 'Clinical Trials'], 'Interaction_intent': ['Give a brisk overview of how the drug is reacting in test environments over artifically created test samples of different age groups', 'Discuss on how the drug is reacting to different molecules', 'Seek KOLs opinion and guidance on the study of drug effectiveness in real world scenario', 'How the drug is targetting the required molecules and what is the effective time', 'Discuss on how the drug might have different effect with respect to different forms of ongoing medication', 'Discuss how the drug may interact with patients having different conditions', 'Share with KOL updates on drug formulation for better site activity', 'Understand and report the new areas of action to KOL', 'Seek opinions on the different drug effects and side effects during pregnancy', 'Exchange on drug transferance', 'Understand and come to a conclusion about the drug interaction', 'Seek advice on drug risks and potential mitigations', 'Seek from KOL his opinion on Sequential drug therapy for the trials', 'How is the drug being combined in current controlled environment', 'Seek Guidance on drug administration over variety of patient demographic', 'Understand potential candidate choices in consultation to KOL', 'Consult with the KOL on identification of drug delivery', 'Understand KOLs standpoint of Car-t cell therapy and its usage as a potential accelator for the drug', 'Drugs standpoint interms of usage as a precision medicine', 'Explore ways on which patients and generate drug resistance', 'Identify factors for potential drug ambiguity in elderly patients', 'Understand KOLs perspective on patient safety', 'Seek KOLs clarity and his stance post phase trials', 'Share the trial report on how the drug is reacting with inhibitors', 'Discuss exsiting norms and new items to be informed to the insurance firms for the addition of the drug to the co-pay programs', 'Share with KOL current insurance vetted programs that might cover the drug cost', 'Discuss with the KOL on the current drug availability scenrio to patients', 'Share with KOL the current vision on the price of drugs', ""Share company outlook of the drug's vision"", 'Understand the core prescriptive information to be adhered to', 'Understand different kinds of patient withdrawal symptoms from the KOL', 'Guidance on protection of identity of patient trials', 'Understanding Genetic responses to drug', 'Discuss on the scenarios of drug overdose and its effect', 'Root cause discussion over molecularity of Adverse effects', 'Proper understanding on side effects and reactions after drug administration', 'Discuss on the drug recovery phase', 'Whether the drug can be considered as a maximality reduction', 'Share with KOL the overall plans and his role as a committee member for the new phase trials', 'Seek advice on the plan of action'], 'Items/topics_to_exchange': ['Test sample procurement, drug dosage, drug reaction, possible side effects, possible ressuciations', 'Test Reports of patient criterion', 'Current phase trial reports', 'Reports generated during drug discovery', 'Reports on existing identified drug reactions', 'List of key identified factors', 'New formula supportive documents', 'Share suggestive documents', 'Drug interaction reports and studies', 'Drug analysis, fall throughs', 'Reports of drug administration, lab sheets, and moleular reports', 'Molecular report, drug dynamics, and drug delivery methods', 'Existing literature and counter arguments', 'Lab reports', 'Drug interaction study', 'Closed case study suiting the patient demographic', 'How to deliver drug to the human body and potential target site', 'Current stochastic reports from different exhibitions', 'Genesis articles for the following', 'Abalation study over previous records of similar compounds', 'Causesheet of existing drug apenditures', 'Regulatory checks, and guidelines on patient safety', 'Share all premtive documents and reports', 'Drug test report', 'Insurance co-pay programs report for drug coverage', 'Insurance plantiffs report for drug coverage', 'Redaction reports encompassing the drug availability', 'Share the development cost sheet and expected return', 'Current Vision Statements', 'share current drug labels', 'List of essential practices used for patient wellness', 'Previous trial methodicals', 'Drug induced genetic responses', 'Potential patient fall through reports, expected behaviour, consolidation reports of patient recovery', 'Labs reports of first cases', 'Drug administration related reactions', 'Preliminary study reports and patient transripts', 'Phase trial report capturing best cases and their study', 'Target reports and expected outcomes', 'Share extensive checklist and memorandum'], 'KOLMSL_Relation': ['Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Address impact of children', 'Relative summary from previous trials', 'Adjunct report', 'Share the potantial drug usage charts', 'Inquire about drug reactions during pregnancy', 'Create a repository of existing and future reports of drug interactivity for easy referrals', 'Consolidated factsheet', 'Create and share a report of the study', 'Create a consolidation of interactiosn ranging from early pregnancy to early infacy post birth', ""Do a survey with HCO's on understanding existing dynamics"", 'Create a reference guide', 'Consultation report with HCPs', 'Share KOLs understanding to respective stakeholders', 'Understand from trial holders on drug inhibition', 'Identify groups of candidates for clinical studies currently consulting with KOL', 'Referendum', 'Create comparative study', 'Case Study of the diagnostics', 'Compile a report on the benchmarks of Precision medicine', 'Seek clarity and generate report with the help of biochemists', 'Study existing reports and create abalation report', 'Create a study on different levels of patient involvement through different stages of the trials', 'Compile all the reports and feedbacks from KOL', 'Granular study guidance', 'Seek information from Insurance companies and seek advisory chairs extension', 'Research on whatnew items checklist might need to be added', 'Updation of factsheets', 'Take KOL feedback report for adjustment if needed', 'Include KOLs feedback', 'Incorporate the feedback into a decadence report for the internal teams', 'Seek incidents and reports during past trials of drug', 'Liability report', 'Study on genetic mutation', 'Create a short report on different patient groups', 'Send extended study reports', 'Share with KOL a report of existing understanding and prolific study', 'Consult and create report with phase trial officers', 'Referendum from patients post trials ops', 'Share KOLs intention with advisory body', 'Include KOLs feedback'], 'Proposed_Next_Channel_Of_interaction': ['In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Phone Call', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'In-Person']}"
11,"{'kol': 'Jacob Schiller', 'Interaction_Date': ['19-Sep-19', '22-Mar-20', '6-May-20', '28-May-20', '1-Jun-20', '7-Jul-20', '19-Sep-20', '22-Dec-20', '6-Feb-21', '19-Apr-21', '22-Jun-21', '6-Aug-21', '19-Oct-21', '22-Dec-21', '6-Mar-22', '19-May-22', '22-Jul-22', '6-Sep-22', '19-Nov-22', '22-Jan-23', '6-Mar-23', '7-May-23', '8-Jul-23', '10-Oct-23', '10-Dec-23'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer'], 'KOL_years_of_Experience': [20, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'KOL_Location': ['New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['20.2K', '20.4K', '20.6K', '20.6K', '20.6K', '20.6K', '20.8K', '20.8K', '20.9K', '20.9K', '20.9K', '20.9K', '21K', '21K', '21K', '21K', '21.2K', '21.6K', '21.6K', '22K', '22K', '22K', '22K', '22K', '22K'], 'SocialMedia_Linkedin': ['17K', '17.2K', '17.5K', '17.5K', '17.5K', '17.5K', '17.8K', '17.8K', '17.8K', '17.8K', '17.8K', '17.8K', '19K', '19K', '19K', '19K', '20K', '20.4K', '20.4K', '21K', '21K', '21K', '21K', '21K', '21K'], 'SocialMedia_YouTube': ['15.2K', '15.5K', '15.7K', '15.7K', '15.7K', '15.7K', '15.8K', '15.8K', '15.9K', '15.9K', '15.9K', '15.9K', '17K', '17K', '17K', '17K', '17.3K', '17.7K', '17.7K', '18.4K', '18.4K', '18.4K', '18.4K', '18.4K', '18.4K'], 'Overall_Kol_Rating': [3.7, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'Research_Participated': [15, 16, 16, 16, 16, 16, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 19], 'Research_Experience': [17, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 20, 20, 20, 20, 20, 20], 'Fundinghistory_researchgrants': ['120000', '130000', '130000', '130000', '130000', '130000', '140000', '140000', '140000', '140000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '170000', '170000', '170000', '170000', '170000', '170000'], 'Fundinghistory_ConsultingFees': [300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 400], 'Fundinghistory_EducationalGrants': ['120000', '130000', '130000', '130000', '130000', '130000', '140000', '140000', '140000', '140000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '160000', '170000', '170000', '170000', '170000', '170000', '170000'], 'No_Of_Publications': [16, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 21, 21, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'Trainings_Delivered': [20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'Professional_Certification': [7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'KOL_affiliations_academicinstitutionss': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'National_presentations_Presented': [300, 315, 315, 315, 315, 315, 315, 315, 330, 330, 330, 330, 330, 330, 330, 330, 330, 330, 330, 345, 345, 345, 345, 345, 345], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the clinical trial', 'Safety measures of the drug on general patients', 'Efficacy & Accuracy of Drug', 'Patient Safety during Clinical Trial', 'To discuss regarding \n Procedures\n Risks and benefits and the rights of patients , treatment options in case of adverse events', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Product overview and its differentiating way', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Finding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug'], 'Previous_Meeting_SubTopics': ['Discussion on Principal Investigator Support', 'Safety', 'Efficacy & Accuracy of Drug', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'Discussion regarding claims/insurance and copay programs', 'Technical feasibility', 'Financial feasibility', 'Market feasibility', 'Operational feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Current_Discussion_Topic': ['Indentifying Principal Investigator for the clinical trial', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Finding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'Video Conference', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person'], 'Company_Event': ['Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug'], 'Interaction_intent': ['Indentifying Principal Investigator for the Clinical trial who has substantial experience as PI in past and how much support he can provide in Clinical Trial', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'To discuss about the claims,insurance and copay programs', 'Technical feasibility', 'Financial feasibility', 'Market feasibility', 'Operational feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Items/topics_to_exchange': ['Indentifying Principal Investigator for the Clinical trial who has substantial experience as PI in past', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Are there risks to taking part in the trial?\n Who is watching out for any problems?\n Who is making sure that people who take part are safe?\n Is the trial trying to answer an important research question?', 'To discuss regarding \n Procedures\n Risks and benefits and the rights of patients , treatment options in case of adverse events', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Findiding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Safety : Discussion on Safety Measures', 'Safety : discussion regarding efficay and accuracy of drug', 'Safety : Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discussion regarding submitting application for investigational new drug', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'Discuss compliance and ethical practices', 'Technical feasibility', 'Financial feasibility', 'Market Feasibility', 'Operational Feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.', 'Discussion regarding rare side effects.'], 'Proposed_Next_Channel_Of_interaction': ['Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'Phone Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'In-Person']}"
12,"{'kol': 'Jane Lee', 'Interaction_Date': ['1-Mar-21', '20-Mar-21', '1-May-21', '22-May-21', '6-Jun-21', '21-Jun-21', '2-Jul-21', '16-Jul-21', '1-Aug-21', '21-Aug-21', '2-Sep-21', '21-Sep-21', '2-Jan-22', '26-Jan-22', '1-Feb-22', '22-Feb-22', '6-Mar-22', '19-Mar-22', '2-Apr-22', '16-Apr-22', '1-May-22', '22-May-22', '6-Jun-22', '19-Jun-22', '2-Jul-22', '26-Jul-22', '1-Aug-22', '22-Aug-22', '6-Sep-22', '19-Sep-22', '2-Oct-22', '26-Oct-22', '1-Nov-22', '22-Nov-22', '2-Dec-22', '19-Dec-22', '2-Jan-23', '26-Jan-23', '1-Feb-23', '22-Feb-23'], 'Current_Tier': ['Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional'], 'KOL_Qualification': ['MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer'], 'KOL_years_of_Experience': [17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18], 'KOL_Location': ['New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['10K', '10K', '10K', '10K', '10K', '10K', '10K', '10.5K', '10.5K', '10.5K', '10.5K', '10.5K', '10.5K', '10.5K', '10.5K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '13K', '13K', '13K', '13K', '13K', '13K', '13K', '13K', '13K', '13K', '13K', '13K', '13K', '13K', '13K', '13K', '13K'], 'SocialMedia_Linkedin': ['8.1K', '8.1K', '8.1K', '8.1K', '8.1K', '8.1K', '8.1K', '9.1K', '9.1K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K'], 'SocialMedia_YouTube': ['7.5K', '7.5K', '7.5K', '7.5K', '7.5K', '7.5K', '7.5K', '8.5K', '8.5K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K'], 'Overall_Kol_Rating': [3.7, 3.8, 3.9, 3.9, 3.9, 3.9, 4.1, 4.1, 4.0, 4.2, 4.4, 4.4, 4.3, 4.2, 4.2, 4.6, 4.6, 4.6, 4.6, 4.7, 4.71, 4.72, 4.8, 4.83, 4.7, 4.65, 4.54, 4.57, 4.58, 4.6, 4.3, 4.3, 4.3, 4.3, 4.3, 4.35, 4.3, 4.3, 4.4, 4.6], 'Connection_to_Advisory_Boards': [2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6], 'Research_Participated': [12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 15, 15, 15, 15, 15, 15, 15], 'Research_Experience': [9, 9, 9, 10, 10, 10, 10, 10, 10, 11, 11, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 13, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14], 'Fundinghistory_researchgrants': ['20000', '20000', '20000', '20000', '20000', '20000', '20000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000'], 'Fundinghistory_ConsultingFees': [0, 0, 0, 0, 0, 0, 0, 0, 0, 100, 100, 100, 100, 100, 100, 200, 200, 200, 200, 200, 200, 200, 300, 300, 300, 400, 400, 400, 500, 500, 500, 500, 500, 600, 600, 600, 600, 600, 600, 600], 'Fundinghistory_EducationalGrants': ['20000', '20000', '20000', '20000', '20000', '20000', '20000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000'], 'No_Of_Publications': [12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13], 'Trainings_Delivered': [8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 13, 13, 13, 13, 13], 'Professional_Certification': [8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 2, 2, 2, 3, 4], 'National_presentations_Presented': [85, 85, 85, 85, 85, 85, 85, 85, 85, 85, 85, 85, 85, 85, 85, 85, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['New drug launch initiation', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Cancer Awareness', 'Cost Analysis', 'Campaigns', 'Safety measures of the drug on general patients', 'Product overview and its differentiating way', 'Awareness Campaigns', 'Target receptor of drug', 'Efficacy and effectivenes of drug', 'Target receptor of drug', 'Product overview and its differentiating way', 'Product overview and its differentiating way', 'Efficacy and effectivenes of drug', 'Safety measures of the drug on general patients', 'New drug launch initiation', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Intro and overview of marketing strategy', 'New Insurance policy', 'Product overview and its differentiating way', 'Awareness Campaigns', 'Target receptor of drug', 'Intro and overview of claims procedure', 'Target receptor of drug', 'Product overview and its differentiating way', 'Discuss conference themes,outline session objectives,explore potential subtopics for Dr David Kim presenatation', 'Competitive Analysis of the drug', 'Study Design and Protocol Development,Regulatory Compliance,Site Selection', 'Awareness Campaigns', 'New drug launch initiation', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Intro and overview of copay programs', 'Intro and onvview of clinical safety'], 'Previous_Meeting_SubTopics': ['Introduction and overview of drug', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Address Problems regarding cost and usage of Verzenio brand', 'Public Outreach awareness', 'Share information on upcoming brand Verzenio launch', 'Sponsored patient programs', 'Discuss the event objectives,agenda and topics to be covered', 'Marketing Startegy', 'Patient Demographics', 'Discussion regarding claims/insurance and copay programs', 'Safety', 'Discussion regarding claims/insurance and copay programs', 'Discussion regarding claims/insurance and copay programs', 'Discuss the event objectives,agenda and topics to be covered', 'Sponsored patient programs', 'Introduction and overview of drug', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Into and overview of market strategy', 'Into and overview of Insurance policy', 'Discuss the event objectives,agenda and topics to be covered', 'Marketing Startegy', 'Patient Demographics', 'Discussion regarding claims/insurance and copay programs', 'Safety', 'Discussion regarding claims/insurance and copay programs', 'Competitive Analysis\u200b', 'Principal Investigator Support', 'Safety', 'Safety', 'Introduction and overview of drug', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Discussion regarding claims/insurance and copay programs', 'share information on upcoming clinical safety'], 'Current_Discussion_Topic': ['Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Cost Analysis', 'Campaigns', 'Verzenio Brand attributes', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Event agenda,subtopics,objectives', 'Advertisments,brand reach', 'Health Status,Origin ,age,race,gender of patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Safety measures of the drug on general patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Event agenda,subtopics,objectives', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Into and overview of Insurance policy', 'Event agenda,subtopics,objectives', 'Advertisments,brand reach', 'Health Status,Origin ,age,race,gender of patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Safety measures of the drug on general patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Competitive Analysis of the drug', 'Study Design and Protocol Development,Regulatory Compliance,Site Selection', 'Safety measures of the drug on general patients', 'Safety measures of the drug on general patients', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Discussion about clinical safety'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In Person', 'In Person', 'email', 'Email', 'Video Conference', 'In-Person', 'In -Person', 'Video Conference', 'Video Call', 'Video Conference', 'Video Conference', 'Video Conference', 'Email', 'In-Person', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In -Person', 'Video Conference', 'In-Person', 'In -Person', 'Video Conference', 'Video Call', 'Video Conference', 'In -Person', 'Video Conference', 'Email', 'Video Call', 'In-Person', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In -Person'], 'Company_Event': ['Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim'], 'Interaction_intent': ['To get acquanitance of the drug', 'To know about drug action and how it works', 'To spread the awareness of the talim drug', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'Engagement', 'Awareness to mass', 'Launch of new Verzenio brand', 'Discussion on supporting patients with access to medicine,education and other programs', 'Discussion on event agenda,topics so that they align with company objectives', 'Discussion about how to market the product to increase its reach', 'To study the patient demographics on which the drug is tested before launch', 'To discuss about the claims,insurance and copay programs', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss about the claims,insurance and copay programs', 'To discuss about the claims,insurance and copay programs', 'Discussion on event agenda,topics so that they align with company objectives', 'Discussion on supporting patients with access to medicine,education and other programs', 'To get acquanitance of the drug', 'To know about drug action and how it works', 'To spread the awareness of the talim drug', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'To get acquanitance of the Insurance policy', 'Discussion on event agenda,topics so that they align with company objectives', 'Discussion about how to market the product to increase its reach', 'To study the patient demographics on which the drug is tested before launch', 'To discuss about the claims,insurance and copay programs', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss about the claims,insurance and copay programs', 'Discussion about competitive analysis to get overview of market', 'Oversseeing the entire study,ensuring compliance with rights and guidelines and protecting rights and welfare of participants', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To get acquanitance of the drug', 'To know about drug action and how it works', 'To spread the awareness of the talim drug', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss about the claims,insurance and copay programs', 'To discuss the safety measures of drug on general patients and discuss complications if any'], 'Items/topics_to_exchange': ['Introduction and overview of drug', 'Target interaction of drug', 'Spreading awareness about talim drug', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Early detection methods and awareness', 'Spreading awareness through mediums', 'Verzenio Brand launch details and impact of brand launch', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Event Agenda,Topics', 'Promotion channels and tactics,Pharmacovigilance and safety monitoring', 'Health Status,Origin ,age,race,gender of patients', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Safety measures and its complications', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Event Agenda,Topics', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Introduction and overview of drug', 'Target interaction of drug', 'Spreading awareness about talim drug', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Intro and overview of Insurance policy', 'Event Agenda,Topics', 'Promotion channels and tactics,Pharmacovigilance and safety monitoring', 'Health Status,Origin ,age,race,gender of patients', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Safety measures and its complications', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Competitor drugs,their advantages and disadvantages', 'Study Design and Protocol Development,Regulatory Compliance,Site Selection,Participant Recruitment,Safety and Adverse Event Monitoring', 'Safety measures and its complications', 'Safety measures and its complications', 'Introduction and overview of drug', 'Target interaction of drug', 'Spreading awareness about talim drug', 'Safety measures and its complications', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Health Status,Origin ,age,race,gender of patients'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral'], 'Next_Action_Items': ['Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Patient Demographics', 'Public Outreach awareness', 'Share information on upcoming brand launch', 'Verzenio Brand Endorsement collaterals for upcoming launch event', 'Review and provide feedback on campaign designs', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss compliance and ethical practices', 'Efficacy', 'Discuss compliance and ethical practices', 'Discuss compliance and ethical practices', 'Scientific communication materials', 'Review and provide feedback on campaign designs', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Patient Demographics', 'Discuss various phases of Insurance policy', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss compliance and ethical practices', 'Efficacy', 'Discuss compliance and ethical practices', 'Principal Investigator Support', 'Safety', 'Efficacy', 'Efficacy', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Discuss compliance and ethical practices', 'Discuss various phases of testing in patients'], 'Proposed_Next_Channel_Of_interaction': ['In-Person', 'Email', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'email', 'Video Call', 'Video Conference', 'Video Conference', 'Email', 'Video Conference', 'Phone Call', 'Video Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Video Conference', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In-Person', 'Video Conference', 'Video Conference', 'Email', 'Video Conference', 'Phone Call', 'Video Call', 'Phone Call', 'Video Conference', 'Email', 'Video Call', 'Video Call', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In-Person', 'Video Conference']}"
13,"{'kol': 'Jenna Jackson', 'Interaction_Date': ['3-Apr-19', '1-May-19', '10-Jun-19', '7-Jul-19', '14-Aug-19', '20-Sep-19', '10-Oct-19', '4-Nov-19', '4-Dec-19', '10-Jan-20', '12-Feb-20', '1-Mar-20', '1-Apr-20', '5-May-20', '13-Jun-20', '9-Jul-20', '4-Aug-20', '4-Sep-20', '10-Oct-20', '16-Nov-21', '11-Dec-21', '8-Jan-21', '10-Feb-21', '1-Mar-21', '5-Apr-21', '3-May-21', '15-Jun-21', '11-Jul-21', '2-Aug-21', '6-Sep-21', '1-Oct-21', '20-Nov-21', '17-Dec-21', '22-Jan-22', '10-Feb-22', '1-Mar-22', '5-Apr-22', '7-May-22', '16-Jun-22', '1-Jul-22'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer', 'Brain cancer'], 'KOL_years_of_Experience': [20, 20, 20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23, 23], 'KOL_Location': ['Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida', 'Florida'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['20k', '21k', '21k', '21k', '21k', '21k', '22k', '22k', '22k', '23k', '23k', '23k', '26k', '26k', '26k', '26k', '27k', '27k', '27k', '28k', '28k', '28k', '28k', '28k', '29k', '29k', '29k', '29k', '29k', '29k', '29k', '29k', '29k', '29k', '30k', '30k', '30k', '30k', '30k', '30k'], 'SocialMedia_Linkedin': ['10k', '10k', '10k', '11k', '11k', '11k', '11k', '12k', '12k', '12k', '12k', '12k', '14k', '14k', '14k', '14k', '14k', '15k', '15k', '15k', '16k', '16k', '16k', '16k', '16k', '16k', '16k', '16k', '16k', '16k', '16k', '16k', '16k', '16k', '17k', '17k', '17k', '17k', '17k', '17k'], 'SocialMedia_YouTube': ['8k', '8k', '8k', '9k', '9k', '9k', '9k', '9k', '9k', '10k', '10k', '10k', '13k', '13k', '13k', '13k', '14k', '14k', '14k', '15k', '15k', '15k', '15k', '15k', '15k', '15k', '16k', '16k', '16k', '16k', '16k', '16k', '16k', '16k', '17k', '17k', '17k', '17k', '17k', '17k'], 'Overall_Kol_Rating': [3.5, 3.5, 3.5, 3.5, 3.6, 3.6, 3.6, 3.6, 3.65, 3.65, 3.65, 3.65, 3.8, 3.8, 3.8, 3.8, 3.8, 3.85, 3.85, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.7, 3.7, 3.7, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 4, 4, 4, 4, 4, 5, 5, 5, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 4, 4, 4, 3, 3, 4, 4, 4, 4, 4, 4], 'Research_Participated': [12, 14, 16, 16, 16, 18, 18, 18, 18, 18, 18, 18, 20, 20, 20, 20, 20, 20, 22, 22, 22, 22, 22, 22, 22, 22, 22, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24], 'Research_Experience': [6, 7, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 11, 11, 11, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12], 'Fundinghistory_researchgrants': ['30000', '30000', '30000', '40000', '40000', '40000', '40000', '40000', '50000', '50000', '50000', '50000', '50000', '60000', '60000', '60000', '60000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '8000', '8000', '8000', '9000', '9000', '9000', '9000', '9000', '10000', '10000', '10000', '10000', '10000', '10000', '10000'], 'Fundinghistory_ConsultingFees': [0, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 400, 400, 400, 400], 'Fundinghistory_EducationalGrants': ['30000', '30000', '30000', '40000', '40000', '40000', '40000', '40000', '50000', '50000', '50000', '50000', '50000', '60000', '60000', '60000', '60000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '8000', '8000', '8000', '9000', '9000', '9000', '9000', '9000', '10000', '10000', '10000', '10000', '10000', '10000', '10000'], 'No_Of_Publications': [10, 10, 10, 10, 10, 10, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 13, 14, 14, 14, 14, 14, 15, 15, 15, 15], 'Trainings_Delivered': [5, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10, 10, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12], 'Professional_Certification': [5, 5, 5, 5, 6, 6, 6, 6, 7, 7, 7, 7, 7, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 11], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'National_presentations_Presented': [8, 8, 8, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12], 'KOL_FollowUp': ['No', 'No', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['No', 'No', 'Regulatory compliance and quality control measures for medical assets.', 'Ensuring safety and effectiveness in medical asset production.', 'Strategies for scaling up manufacturing of medical assets.', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Adapting medical assets to the needs of different healthcare settings.', 'Supply chain management for medical assets.', 'International collaboration in medical asset generation.', 'Public-private partnerships in medical asset development.', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Adapting medical assets to the needs of diverse patient populations.', 'No', 'No', 'No', 'No'], 'Previous_Meeting_SubTopics': ['No', 'No', 'Discussing regulations and measures regarding the medical assets', 'Safety mesures need to be taken', 'How to scale up the manufacturing process', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'How medical assets overcoming different challenges', 'Discussing how raw material being processed to get finished product', 'How International colaboration made event easier', 'Diffrent collaboration in asset development', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'How assets are developed for diversity of pateints', 'No', 'No', 'No', 'No'], 'Current_Discussion_Topic': ['Prioritizing research and development areas for medical assets.', 'Regulatory compliance and quality control measures for medical assets.', 'Ensuring safety and effectiveness in medical asset production.', 'Strategies for scaling up manufacturing of medical assets.', 'Optimizing production costs while maintaining quality.', 'Affordable pricing models for medical assets.', 'Distribution strategies for equitable access to medical assets.', 'Overcoming barriers to access in underserved areas.', 'Addressing regional disparities in medical asset availability.', 'Emergency preparedness and response in medical asset generation.', 'Role of technology and innovation in medical asset development.', 'Leveraging digital health solutions in medical asset generation.', 'Incorporating artificial intelligence (AI) in medical asset production.', 'Telemedicine and remote monitoring in medical asset utilization.', 'Sustainable manufacturing practices for medical assets.', 'Environmental impact mitigation in medical asset generation.', 'Waste management and disposal of medical assets.', 'Strategies for recycling and repurposing medical assets.', 'Intellectual property rights and patent considerations in medical asset development.', 'Ethics and accountability in medical asset generation.', 'Safety and efficacy considerations for medical equipment.', 'Developing specialized medical assets for specific diseases or conditions.', 'Personal protective equipment (PPE) development and distribution.', 'Adapting medical assets to the needs of different healthcare settings.', 'Supply chain management for medical assets.', 'International collaboration in medical asset generation.', 'Public-private partnerships in medical asset development.', 'Bridging the gap between research and implementation of medical assets.', 'Addressing challenges in clinical trials for medical assets.', 'Optimizing the use of data and analytics in medical asset development.', 'Training and education for healthcare professionals on using new medical assets.', 'User-centered design and patient feedback in medical asset development.', 'Regulatory pathways and approvals for new medical assets.', 'Post-market surveillance and monitoring of medical asset performance.', 'Adapting medical assets to the needs of diverse patient populations.', 'Cultural considerations in medical asset development and utilization.', 'Ethical considerations in the use of emerging medical technologies.', 'Addressing cybersecurity risks in medical asset generation.', 'Evaluating the economic impact of medical asset generation on healthcare systems.', 'Assessing the impact of medical asset generation on healthcare infrastructure.'], 'Current_Meeting_Subtopics': ['why prioritize research and decvelopment', 'Discussing regulations and measures regarding the medical assets', 'Safety mesures need to be taken', 'How to scale up the manufacturing process', 'How to reduce the cost of the assets', 'Research regarding cost effective models for medical assets', 'Distribution plans', 'Research to overcome probelms regarding access in underserved areas', 'Discussion regarding diffrence in treatment in regional areas', 'How well prepared for emergency situations', 'How innovation is involved in asset generation', 'Collaboration', 'How Ai being used for asset production', 'How remotely medical assets will be utilized', 'How are we achieving the idea of sustainable manufacturing', 'Report regarding the impact on nature', 'Report on waste management', 'Disucssing recycling strategies', 'Discussing Rights regarding medical asset development', 'Responsibilty of asset generation', 'safety measures regarding the medical equipment, Efficiancy of the equipments', 'How medical assets are being developed for targeting particular conditions', 'How ensuring safety of users', 'How medical assets overcoming different challenges', 'Discussing how raw material being processed to get finished product', 'How International colaboration made event easier', 'Diffrent collaboration in asset development', 'Discussing Steps regarding develpment according to research', 'Discussing challenges in clinical trials', 'use of limited data and analytics', 'Discussing Training that needs to be given for using new assets', 'Discussion on asset design', 'discussing Preclinical Development', 'Discussing the performance of assets', 'How assets are developed for diversity of pateints', 'Discuss Clinical Research and Trials', 'Discussing Patient Autonomy and Informed Consent', 'Disucssing cybersecurity risks in medical assets', 'Report on Cost of Development', 'key considerations for assessing the impact'], 'Current_Channel_of_interaction': ['In Person', 'In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'Video', 'In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person'], 'Company_Event': ['Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation'], 'Interaction_intent': ['Discussing how reasearch and development can help in medical asset generation', 'Why quality control measures are necessary', 'How implementing safety measures', 'How increasing medical asset manufacturing', 'How to keep the cost in check of assets', 'Discussing pricing so assets available for all healthcare facilities', 'Discussing distribution strategies', 'measures to overcome roadblocks in underserved areas', 'Why regional disparities', 'Measures to be taken in case of emergency', 'How innovation helping in asset generation', 'Digital health solutions in asset generation', 'Discussing use of AI in medical asset generation', 'Discussion about Telemedicine and remote monitoring', 'How sustainable manufacturing practices are being implemented', 'Report on Impact on enviornment', 'How is wasste management going on', 'How medical assets are being recycled', 'Ip rights and patent rights in asset developemt', 'accountability in medical asset generation', 'Safety measures being taken while asset generation', 'How developing specialized medical asset targeting specific conditions', 'How safe ppe kits being developed are', 'Report on how well medical assets adapt to diffrent healthcare settings', 'Supply chain management for medical assets', 'How Collaboration helping in asset generation', 'Discussion about partnerships in asset development', 'How reducing the gap between research and implementation', 'challenges during clinical trials', 'Optimizing used of data and analytics', 'Training and education for healthcare proffesionals', 'Design of asset being generated', 'Approval required for medical assets', 'Market surveillance and monitoring of medical asset performance', 'How assets are adapting to diverse patient populations', 'Discussing cultural considerations in medical asset development', 'Ethical considerations in use for asset generation', 'Discussing cybersecurity risks', 'Report evaluating ecnomic impact', 'How is the impact of medical asset generation on healthcare infrastructure'], 'Items/topics_to_exchange': ['Impact of research on asset generation', 'How quality control mesures can help, why quality control measures', 'Steps being taken for increased safety', 'Measures to be taken for Increasing the maufacturing', 'Steps to ensure quality is maintained while reducing cost', 'How can prices of assets can be reduced, what should be the initial prices', 'How distribution of medical assets is planned', 'roadblocks in underserved areas, ways to overcome the problems', 'Discussing how can this be lowered', 'How prepared for diffrent emergencies', 'with technology and innovation what problems are being solved', 'Research related to digital health solutions', 'Diffrent ways in which AI is being used in asset generation', 'Report on Telemedicine and remote monitoring', 'why sustainable manufacturing practices', 'Steps being taken fot reducing impact', 'Steps being taken for low generation of waste', 'Report on recycling and repurposing of medical assets', 'Discussing Intellectual property rights and patent considerations', 'Responsibility of asset geenration', 'What al safety measures being taken', 'What all conditions assets targeting', 'Report on the safety of the ppe', 'How assets are able to adapt to changes', 'Process to get final product', 'Report on how International collaboration has changed medical asset generation', 'How partnerships helping with asset development', 'Things to akecare of to reduce the gap between research and implementation', 'How overcoming clinical trial challenges', 'Report how can use of data and analytics be reduced', 'why training and education is required', 'Design accuracy according to users needs', 'What all preclinical developments are required', 'Discussion about Monitoring the performance of medical assets', 'Report on assets adapting to diffrent pateints', 'Important things to consider with cultural consideration perspective', 'Discussing why ethical considertions in use for emerging medical technologies', 'Measures being taken to handle cybersecurity risks', 'Discussing How ecnomic impact because of medical asset generation', 'Discussing key considerations of the impact'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Regulatory compliance and quality control measures for medical assets.', 'Ensuring safety and effectiveness in medical asset production.', 'Strategies for scaling up manufacturing of medical assets.', 'Optimizing production costs while maintaining quality.', 'Affordable pricing models for medical assets.', 'Distribution strategies for equitable access to medical assets.', 'Overcoming barriers to access in underserved areas.', 'Addressing regional disparities in medical asset availability.', 'Emergency preparedness and response in medical asset generation.', 'Role of technology and innovation in medical asset development.', 'Leveraging digital health solutions in medical asset generation.', 'Incorporating artificial intelligence (AI) in medical asset production.', 'Telemedicine and remote monitoring in medical asset utilization.', 'Sustainable manufacturing practices for medical assets.', 'Environmental impact mitigation in medical asset generation.', 'Waste management and disposal of medical assets.', 'Strategies for recycling and repurposing medical assets.', 'Intellectual property rights and patent considerations in medical asset development.', 'Ethics and accountability in medical asset generation.', 'Safety and efficacy considerations for medical equipment.', 'Developing specialized medical assets for specific diseases or conditions.', 'Personal protective equipment (PPE) development and distribution.', 'Adapting medical assets to the needs of different healthcare settings.', 'Supply chain management for medical assets.', 'International collaboration in medical asset generation.', 'Public-private partnerships in medical asset development.', 'Bridging the gap between research and implementation of medical assets.', 'Addressing challenges in clinical trials for medical assets.', 'Optimizing the use of data and analytics in medical asset development.', 'Training and education for healthcare professionals on using new medical assets.', 'User-centered design and patient feedback in medical asset development.', 'Regulatory pathways and approvals for new medical assets.', 'Post-market surveillance and monitoring of medical asset performance.', 'Adapting medical assets to the needs of diverse patient populations.', 'Cultural considerations in medical asset development and utilization.', 'Ethical considerations in the use of emerging medical technologies.', 'Addressing cybersecurity risks in medical asset generation.', 'Evaluating the economic impact of medical asset generation on healthcare systems.', 'Assessing the impact of medical asset generation on healthcare infrastructure.', 'Addressing global health disparities through medical asset generation.'], 'Proposed_Next_Channel_Of_interaction': ['In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'Video', 'In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person', 'Video']}"
14,"{'kol': 'John Doe', 'Interaction_Date': ['1-Apr-19', '20-Apr-19', '1-May-19', '22-May-19', '6-Jun-19', '21-Jun-19', '2-Jul-19', '16-Jul-19', '1-Aug-19', '21-Aug-19', '2-Sep-19', '21-Sep-19', '2-Jan-20', '26-Jan-20', '1-Feb-20', '22-Feb-20', '6-Mar-20', '19-Mar-20', '2-Apr-20', '16-Apr-20', '1-May-20', '22-May-20', '6-Jun-20', '19-Jun-20', '2-Jul-20', '26-Jul-20', '1-Aug-20', '22-Aug-20', '6-Sep-20', '19-Sep-20', '2-Oct-20', '26-Oct-20', '1-Nov-20', '22-Nov-20', '2-Dec-20', '19-Dec-20', '2-Jan-21', '26-Jan-21', '1-Feb-21', '22-Feb-21'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer'], 'KOL_years_of_Experience': [21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22], 'KOL_Location': ['New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['11.2K', '11.2K', '11.2K', '11.2K', '11.2K', '11.2K', '11.2K', '11.2K', '11.2K', '12.4K', '12.4K', '12.4K', '12.4K', '12.4K', '14.9K', '14.9K', '14.9K', '14.9K', '14.9K', '14.9K', '14.9K', '14.9K', '14.9K', '14.9K', '14.9K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K', '15.2K'], 'SocialMedia_Linkedin': ['9.1K', '9.1K', '9.1K', '9.1K', '9.1K', '9.1K', '9.1K', '9.1K', '9.1K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '10.3K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K', '11.7K'], 'SocialMedia_YouTube': ['8.5K', '8.5K', '8.5K', '8.5K', '8.5K', '8.5K', '8.5K', '8.5K', '8.5K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K', '9.4K'], 'Overall_Kol_Rating': [3.7, 3.8, 3.9, 3.9, 3.9, 3.9, 4.1, 4.1, 4.0, 4.2, 4.4, 4.4, 4.3, 4.2, 4.2, 4.6, 4.6, 4.6, 4.6, 4.7, 4.71, 4.72, 4.8, 4.83, 4.7, 4.65, 4.54, 4.57, 4.58, 4.6, 4.3, 4.3, 4.3, 4.3, 4.3, 4.35, 4.3, 4.3, 4.4, 4.6], 'Connection_to_Advisory_Boards': [2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6], 'Research_Participated': [15, 15, 15, 15, 15, 15, 15, 15, 15, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21], 'Research_Experience': [10, 10, 10, 10, 10, 10, 10, 10, 10, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14], 'Fundinghistory_researchgrants': ['20000', '20000', '20000', '20000', '20000', '20000', '20000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000'], 'Fundinghistory_ConsultingFees': [0, 0, 0, 0, 0, 0, 0, 0, 0, 100, 100, 100, 100, 100, 100, 200, 200, 200, 200, 200, 200, 200, 300, 300, 300, 400, 400, 400, 500, 500, 500, 500, 500, 600, 600, 600, 600, 600, 600, 600], 'Fundinghistory_EducationalGrants': ['20000', '20000', '20000', '20000', '20000', '20000', '20000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '30000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000', '1,00,000'], 'No_Of_Publications': [13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 22, 22, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 24, 24, 24], 'Trainings_Delivered': [10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 13, 13, 13, 13, 14, 14, 14, 14, 14, 14, 15, 15, 15, 15, 15, 16, 16, 16, 19, 19, 19, 19, 22, 23, 23, 23, 24, 26], 'Professional_Certification': [8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 13, 13, 13, 13, 13, 13, 13, 13, 15, 15, 15, 15, 15], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'National_presentations_Presented': [210, 210, 210, 210, 210, 210, 210, 210, 210, 210, 210, 210, 210, 210, 210, 210, 210, 210, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220, 220], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['New drug launch initiation', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Cancer Awareness', 'Cost Analysis', 'Campaigns', 'Safety measures of the drug on general patients', 'Product overview and its differentiating way', 'Awareness Campaigns', 'Target receptor of drug', 'Efficacy and effectivenes of drug', 'Target receptor of drug', 'Product overview and its differentiating way', 'Product overview and its differentiating way', 'Efficacy and effectivenes of drug', 'Safety measures of the drug on general patients', 'New drug launch initiation', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Intro and overview of marketing strategy', 'New Insurance policy', 'Product overview and its differentiating way', 'Awareness Campaigns', 'Target receptor of drug', 'Intro and overview of claims procedure', 'Target receptor of drug', 'Product overview and its differentiating way', 'Discuss conference themes,outline session objectives,explore potential subtopics for Dr David Kim presenatation', 'Competitive Analysis of the drug', 'Study Design and Protocol Development,Regulatory Compliance,Site Selection', 'Awareness Campaigns', 'New drug launch initiation', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Intro and overview of copay programs', 'Intro and onvview of clinical safety'], 'Previous_Meeting_SubTopics': ['Introduction and overview of drug', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Address Problems regarding cost and usage of Verzenio brand', 'Public Outreach awareness', 'Share information on upcoming brand Verzenio launch', 'Sponsored patient programs', 'Discuss the event objectives,agenda and topics to be covered', 'Marketing Startegy', 'Patient Demographics', 'Discussion regarding claims/insurance and copay programs', 'Safety', 'Discussion regarding claims/insurance and copay programs', 'Discussion regarding claims/insurance and copay programs', 'Discuss the event objectives,agenda and topics to be covered', 'Sponsored patient programs', 'Introduction and overview of drug', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Into and overview of market strategy', 'Into and overview of Insurance policy', 'Discuss the event objectives,agenda and topics to be covered', 'Marketing Startegy', 'Patient Demographics', 'Discussion regarding claims/insurance and copay programs', 'Safety', 'Discussion regarding claims/insurance and copay programs', 'Competitive Analysis\u200b', 'Principal Investigator Support', 'Safety', 'Safety', 'Introduction and overview of drug', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Discussion regarding claims/insurance and copay programs', 'share information on upcoming clinical safety'], 'Current_Discussion_Topic': ['Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Cost Analysis', 'Campaigns', 'Verzenio Brand attributes', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Event agenda,subtopics,objectives', 'Advertisments,brand reach', 'Health Status,Origin ,age,race,gender of patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Safety measures of the drug on general patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Event agenda,subtopics,objectives', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Into and overview of Insurance policy', 'Event agenda,subtopics,objectives', 'Advertisments,brand reach', 'Health Status,Origin ,age,race,gender of patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Safety measures of the drug on general patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Competitive Analysis of the drug', 'Study Design and Protocol Development,Regulatory Compliance,Site Selection', 'Safety measures of the drug on general patients', 'Safety measures of the drug on general patients', 'Intro and overview of drug', 'Target receptor of drug', 'Awareness Campaigns', 'Safety measures of the drug on general patients', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Discussion about clinical safety'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In Person', 'In Person', 'email', 'Email', 'Video Conference', 'In-Person', 'In -Person', 'Video Conference', 'Video Call', 'Video Conference', 'Video Conference', 'Video Conference', 'Email', 'In-Person', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In -Person', 'Video Conference', 'In-Person', 'In -Person', 'Video Conference', 'Video Call', 'Video Conference', 'In -Person', 'Video Conference', 'Email', 'Video Call', 'In-Person', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In -Person'], 'Company_Event': ['Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim', 'Product Launch - Talim'], 'Interaction_intent': ['To get acquanitance of the drug', 'To know about drug action and how it works', 'To spread the awareness of the talim drug', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'Engagement', 'Awareness to mass', 'Launch of new Verzenio brand', 'Discussion on supporting patients with access to medicine,education and other programs', 'Discussion on event agenda,topics so that they align with company objectives', 'Discussion about how to market the product to increase its reach', 'To study the patient demographics on which the drug is tested before launch', 'To discuss about the claims,insurance and copay programs', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss about the claims,insurance and copay programs', 'To discuss about the claims,insurance and copay programs', 'Discussion on event agenda,topics so that they align with company objectives', 'Discussion on supporting patients with access to medicine,education and other programs', 'To get acquanitance of the drug', 'To know about drug action and how it works', 'To spread the awareness of the talim drug', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'To get acquanitance of the Insurance policy', 'Discussion on event agenda,topics so that they align with company objectives', 'Discussion about how to market the product to increase its reach', 'To study the patient demographics on which the drug is tested before launch', 'To discuss about the claims,insurance and copay programs', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss about the claims,insurance and copay programs', 'Discussion about competitive analysis to get overview of market', 'Oversseeing the entire study,ensuring compliance with rights and guidelines and protecting rights and welfare of participants', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To get acquanitance of the drug', 'To know about drug action and how it works', 'To spread the awareness of the talim drug', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'To discuss about the claims,insurance and copay programs', 'To discuss the safety measures of drug on general patients and discuss complications if any'], 'Items/topics_to_exchange': ['Introduction and overview of drug', 'Target interaction of drug', 'Spreading awareness about talim drug', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Early detection methods and awareness', 'Spreading awareness through mediums', 'Verzenio Brand launch details and impact of brand launch', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Event Agenda,Topics', 'Promotion channels and tactics,Pharmacovigilance and safety monitoring', 'Health Status,Origin ,age,race,gender of patients', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Safety measures and its complications', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Event Agenda,Topics', 'Access to medicine,patient education and support ,treatment adherance and monitoring', 'Introduction and overview of drug', 'Target interaction of drug', 'Spreading awareness about talim drug', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Intro and overview of Insurance policy', 'Event Agenda,Topics', 'Promotion channels and tactics,Pharmacovigilance and safety monitoring', 'Health Status,Origin ,age,race,gender of patients', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Safety measures and its complications', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Competitor drugs,their advantages and disadvantages', 'Study Design and Protocol Development,Regulatory Compliance,Site Selection,Participant Recruitment,Safety and Adverse Event Monitoring', 'Safety measures and its complications', 'Safety measures and its complications', 'Introduction and overview of drug', 'Target interaction of drug', 'Spreading awareness about talim drug', 'Safety measures and its complications', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Health Status,Origin ,age,race,gender of patients'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral'], 'Next_Action_Items': ['Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Patient Demographics', 'Public Outreach awareness', 'Share information on upcoming brand launch', 'Verzenio Brand Endorsement collaterals for upcoming launch event', 'Review and provide feedback on campaign designs', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss compliance and ethical practices', 'Efficacy', 'Discuss compliance and ethical practices', 'Discuss compliance and ethical practices', 'Scientific communication materials', 'Review and provide feedback on campaign designs', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Patient Demographics', 'Discuss various phases of Insurance policy', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss various phases of testing in patients', 'Discuss compliance and ethical practices', 'Efficacy', 'Discuss compliance and ethical practices', 'Principal Investigator Support', 'Safety', 'Efficacy', 'Efficacy', 'Discuss mechanism of action of drug', 'Conferences for Product awareness', 'Safety', 'Efficacy', 'Discuss compliance and ethical practices', 'Discuss various phases of testing in patients'], 'Proposed_Next_Channel_Of_interaction': ['In-Person', 'Email', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'email', 'Video Call', 'Video Conference', 'Video Conference', 'Email', 'Video Conference', 'Phone Call', 'Video Call', 'Phone Call', 'Phone Call', 'Phone Call', 'Video Conference', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In-Person', 'Video Conference', 'Video Conference', 'Email', 'Video Conference', 'Phone Call', 'Video Call', 'Phone Call', 'Video Conference', 'Email', 'Video Call', 'Video Call', 'In-Person', 'Email', 'Video Call', 'Video Call', 'In-Person', 'Video Conference']}"
15,"{'kol': 'Johnson charles', 'Interaction_Date': ['1-Apr-19', '1-May-19', '1-Jun-19', '1-Jul-19', '1-Aug-19', '1-Sep-19', '1-Oct-19', '1-Nov-19', '1-Dec-19', '1-Jan-20', '1-Feb-20', '1-Mar-20', '1-Apr-20', '1-May-20', '1-Jun-20', '1-Jul-20', '1-Aug-20', '1-Sep-20', '1-Oct-20', '1-Nov-20', '1-Dec-20', '1-Jan-21', '1-Feb-21', '1-Mar-21', '1-Apr-21', '1-May-21', '1-Jun-21', '1-Jul-21', '1-Aug-21', '1-Sep-21', '1-Oct-21', '1-Nov-21', '1-Dec-21', '1-Jan-22', '1-Feb-22', '1-Mar-22', '1-Apr-22', '1-May-22', '1-Jun-22', '1-Jul-22'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD', 'MD,PHD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer'], 'KOL_years_of_Experience': [11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 14, 14, 14, 14], 'KOL_Location': ['Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston', 'Boston'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['30K', '30.1K', '30.1K', '30.1K', '30.2K', '30.3K', '30.5K', '30.5K', '32K', '32.2K', '32.2K', '33K', '33.3K', '33.8K', '34K', '34.4K', '35K', '35.5K', '35.5K', '35.5K', '36K', '36K', '36.2K', '36.3K', '37K', '37.3K', '37.8K', '38K', '38.2K', '38.5K', '38.5K', '38.5K', '39K', '40K', '40.5K', '40.8K', '41K', '41.1K', '41.3K', '41.8K'], 'SocialMedia_Linkedin': ['15K', '15.1K', '15.1K', '15.1K', '15.3K', '15.5K', '15.9K', '15.9K', '16K', '16.3K', '16.3K', '17K', '17.3K', '17.8K', '18K', '18.5K', '19K', '19.3K', '19.3K', '19.3K', '20K', '20K', '20.3K', '20.5K', '21K', '21.2K', '22K', '23K', '23.4K', '23.7K', '23.7K', '23.7K', '24K', '24.8K', '25K', '25.3K', '26K', '26.3K', '26.5K', '26.9K'], 'SocialMedia_YouTube': ['10K', '10.2K', '10.2K', '10.2K', '10.4K', '10.6K', '11K', '11K', '11.5K', '11.7K', '11.7K', '12K', '12.2K', '12.9K', '13.4K', '13.9K', '14K', '14.3K', '14.3K', '14.3K', '15K', '15.3K', '15.5K', '16K', '16.3K', '17K', '17.5K', '18K', '18.3K', '19K', '19K', '19K', '19.5K', '20K', '21K', '21.4K', '22K', '22.2K', '22.8K', '23K'], 'Overall_Kol_Rating': [4.66, 4.64, 4.7, 4.7, 4.71, 4.73, 4.75, 4.75, 4.8, 4.82, 4.82, 4.83, 4.79, 4.81, 4.89, 4.9, 4.9, 4.9, 4.91, 4.93, 4.95, 4.96, 4.96, 4.96, 4.96, 4.96, 4.96, 4.96, 4.97, 4.96, 4.96, 4.96, 4.96, 4.96, 4.96, 4.96, 4.96, 4.96, 4.96, 4.96], 'Connection_to_Advisory_Boards': [2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5], 'Research_Participated': [10, 10, 10, 10, 10, 11, 11, 12, 12, 13, 13, 13, 13, 14, 14, 14, 14, 15, 15, 15, 15, 16, 16, 16, 16, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18], 'Research_Experience': [5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'Fundinghistory_researchgrants': ['15000', '16000', '18000', '18000', '20000', '24000', '26000', '30000', '35000', '35000', '35000', '35000', '35000', '40000', '40000', '50000', '60000', '80000', '100000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '170000', '180000', '180000', '180000', '180000', '200000', '200000', '200000', '200000'], 'Fundinghistory_ConsultingFees': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 20000, 30000, 40000, 50000, 60000, 80000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 100000, 140000, 140000, 140000, 140000, 140000, 140000, 140000, 140000, 140000, 140000, 140000, 140000], 'Fundinghistory_EducationalGrants': ['15000', '16000', '18000', '18000', '20000', '24000', '26000', '30000', '35000', '35000', '35000', '35000', '35000', '40000', '40000', '50000', '60000', '80000', '100000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '150000', '170000', '180000', '180000', '180000', '180000', '200000', '200000', '200000', '200000'], 'No_Of_Publications': [2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5], 'Trainings_Delivered': [5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 8, 8, 8, 8, 9, 9, 9, 9, 10, 10, 10, 10, 10, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12, 12], 'Professional_Certification': [3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10], 'KOL_affiliations_academicinstitutionss': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'International_Presentations_Presented': [1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4], 'National_presentations_Presented': [6, 6, 6, 6, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 10, 10, 10, 11, 11, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13], 'KOL_FollowUp': ['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Business model and revenue generation', 'Scalability and growth potential', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Team Expertise and execution plan in start up pitch competitions', 'Regulatory and compliance considerations in startup pitch competitions', 'Impact and sustainability in startup pitch competitons', 'Digital Health Innovations in stratup pitch competitions', 'Health Tech Infrastructure', 'Personalized medicine in startup pitch competitions', 'Healthcare analytics and insights in startup pitch competition', 'Patient experience enhacement in startup pitch competitions', 'Health care supply chain optimization in startup pitch competitions', 'Events have the potential for collaboration and innovation', 'Patients invloved in the development process can lead to increased patient engagement and empowerment', 'Patient insights can help us identify unmet needs,design patient interventions and improve patient outcomes', 'Discuss about how these events provide a platform for cross-pollination between patients,healthcare professionals and innovators', 'How to effectively capture and utilize patient feedback', 'Capturing patient feedbacks', 'Event provide insights on best practices and guidelines for implementing patient driven solutions', 'Ethical considerations and privacy protection are paramount', 'Educating and empowering healthcare professionals to embrace patient driven appraoches', 'Impact of collaborative partnerships on medical asset generation', 'Sustainable practice in medical asset generation in research presentations', 'Implementation of technology in medical asset management in research presentations', 'Evaluation of training programs for medical asset management', 'Financial Analysis of medical asset generation in research presentations', 'Role of regulatory compliance in medical asset generation in research presentations', 'Future trends and innovations in medical asset generations in research presentations', 'Problem identification in startup pitch competition', 'Innovative medical asset solutions in medical asset generation event', 'Market potential and target audience in startup pitch competitions', 'Unique value proposition in medical asset generation', 'Business model and revenue generation', 'Scalability and growth potential', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Team Expertise and execution plan in start up pitch competitions', 'Regulatory and compliance considerations in startup pitch competitions', 'Impact and sustainability in startup pitch competitons', 'Digital Health Innovations in stratup pitch competitions', 'Health Tech Infrastructure'], 'Previous_Meeting_SubTopics': ['Pricing strategies,potential partnerships and revenue streams', 'Expansion plans,target markets beyond the initial launch', 'Patents,trademarks or proprietary technologies', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal', 'Patient safety,operational efficiency and cost savings', 'Mobile apps,wearables or remote devices to improve heakthcare delivery', 'Robust health tech infrastructure,secure data storage or telecommnunication networks', 'AI driven diagnostics,or precision therapies', 'AI-driven solutions,improve clinical trial decision making,optimize resource allocation', 'Patient experience,solutions for patient scheduling,appointment reminders,virtual consultations or patient feedback platforms', 'Healthcare supply chain,inventory management solutions,appointment reminders,virtual consultations', 'Potential for innovation and collaboration,Opportunity to bridge the gap', 'Patients become partners rather than recepients of healthcare', 'Patients are no longer passive recipients,patients become active participants and decision-makers,enhance the adoption and acceptance of new medical assets', ""Cross-pollination of ideas between patients,healthcare professional and innovators.Everyone's and expertise contribute to development of patient driven solutions"", ""Patient's perspectives and experiences"", 'Implementing appropriate channels and mechanism.Survey and focus groups.Incorporating patient advisory boards', 'Privacy,data security and informed consent are protected.Striking the right balance between patient involvment and safeguarding rights', ""To discuss abour fostering a collaborative and ethical ethical enviroment by establishing frameworks that respect patient's automony and addressing potential biases and ensuring diversity and inclusivity in patient represenations"", 'Integrating patient perspectives into practice,culture of patient centered care,collaboration between patient and heakthcare professional', 'Impact of collaborative partnerships between healthcare organizations,manufacturers', 'Sustainable practices in medical asset generation,including environment friendly procurement,energy-efficient equipment', 'IOT,RFID,asset management .Impact of technology on asset tracking,maintainence and optimization', 'Asset utilization,maintainence practices and overall operational efficiency', 'Total cost of ownership,return on investment and cost-benefit analysis of various asset acquisition and management strategies', 'Standards for equipment safety,quality control and legal requirements', 'Robotics,ai,advanced imaging techniques and virtual reality', 'High cost,limited access,equipment maintainence or supply chain bottlenecks', 'Technologies,software programs or business models', 'Target audience such as hospitals,clincics,research facilities and healthcare organizations', 'Solution stand out,competitive advantage', 'Pricing strategies,potential partnerships and revenue streams', 'Expansion plans,target markets beyond the initial launch', 'Patents,trademarks or proprietary technologies', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal', 'Patient safety,operational efficiency and cost savings', 'Mobile apps,wearables or remote devices to improve heakthcare delivery', 'Robust health tech infrastructure,secure data storage or telecommnunication networks'], 'Current_Discussion_Topic': ['Scalability and growth potential', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Team Expertise and execution plan in start up pitch competitions', 'Regulatory and compliance considerations in startup pitch competitions', 'Impact and sustainability in startup pitch competitons', 'Digital Health Innovations in startup pitch competitions', 'Health Tech Infrastructure', 'Personalized medicine in startup pitch competitions', 'Healthcare analytics and insights in startup pitch competition', 'Patient experience enhacement in startup pitch competitions', 'Health care supply chain optimization in startup pitch competitions', 'Events have the potential for collaboration and innovation', 'Patients invloved in the development process can lead to increased patient engagement and empowerment', 'Patient insights can help us identify unmet needs,design patient interventions and improve patient outcomes', 'Discuss about how these events provide a platform for cross-pollination between patients,healthcare professionals and innovators', 'How to effectively capture and utilize patient feedback', 'Capturing patient feedbacks', 'Event provide insights on best practices and guidelines for implementing patient driven solutions', 'Ethical considerations and privacy protection are paramount', 'Educating and empowering healthcare professionals to embrace patient driven appraoches', 'Impact of collaborative partnerships on medical asset generation', 'Sustainable practice in medical asset generation in research presentations', 'Implementation of technology in medical asset management in research presentations', 'Evaluation of training programs for medical asset management', 'Financial Analysis of medical asset generation in research presentations', 'Role of regulatory compliance in medical asset generation in research presentations', 'Future trends and innovations in medical asset generations in research presentations', 'Problem identification in startup pitch competition', 'Innovative medical asset solutions in medical asset generation event', 'Market potential and target audience in startup pitch competitions', 'Unique value proposition in medical asset generation', 'Business model and revenue generation', 'Scalability and growth potential', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Team Expertise and execution plan in start up pitch competitions', 'Regulatory and compliance considerations in startup pitch competitions', 'Impact and sustainability in startup pitch competitons', 'Digital Health Innovations in stratup pitch competitions', 'Health Tech Infrastructure', 'Need for workshop and training session'], 'Current_Meeting_Subtopics': ['Expansion plans,target markets beyond the initial launch', 'Patents,trademarks or proprietary technologies', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal', 'Patient safety,operational efficiency and cost savings', 'Mobile apps,wearables or remote devices to improve heakthcare delivery', 'Robust health tech infrastructure,secure data storage or telecommnunication networks', 'AI driven diagnostics,or precision therapies', 'AI-driven solutions,improve clinical trial decision making,optimize resource allocation', 'Patient experience,solutions for patient scheduling,appointment reminders,virtual consultations or patient feedback platforms', 'Healthcare supply chain,inventory management solutions,appointment reminders,virtual consultations', 'Potential for innovation and collaboration,Opportunity to bridge the gap', 'Patients become partners rather than recepients of healthcare', 'Patients are no longer passive recipients,patients become active participants and decision-makers,enhance the adoption and acceptance of new medical assets', ""Cross-pollination of ideas between patients,healthcare professional and innovators.Everyone's and expertise contribute to development of patient driven solutions"", ""Patient's perspectives and experiences"", 'Implementing appropriate channels and mechanism.Survey and focus groups.Incorporating patient advisory boards', 'Privacy,data security and informed consent are protected.Striking the right balance between patient involvment and safeguarding rights', ""To discuss abour fostering a collaborative and ethical ethical enviroment by establishing frameworks that respect patient's automony and addressing potential biases and ensuring diversity and inclusivity in patient represenations"", 'Integrating patient perspectives into practice,culture of patient centered care,collaboration between patient and heakthcare professional', 'Impact of collaborative partnerships between healthcare organizations,manufacturers', 'Sustainable practices in medical asset generation,including environment friendly procurement,energy-efficient equipment', 'IOT,RFID,asset management .Impact of technology on asset tracking,maintainence and optimization', 'Asset utilization,maintainence practices and overall operational efficiency', 'Total cost of ownership,return on investment and cost-benefit analysis of various asset acquisition and management strategies', 'Standards for equipment safety,quality control and legal requirements', 'Robotics,ai,advanced imaging techniques and virtual reality', 'High cost,limited access,equipment maintainence or supply chain bottlenecks', 'Technologies,software programs or business models', 'Target audience such as hospitals,clincics,research facilities and healthcare organizations', 'Solution stand out,competitive advantage', 'Pricing strategies,potential partnerships and revenue streams', 'Expansion plans,target markets beyond the initial launch', 'Patents,trademarks or proprietary technologies', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal', 'Patient safety,operational efficiency and cost savings', 'Mobile apps,wearables or remote devices to improve heakthcare delivery', 'Robust health tech infrastructure,secure data storage or telecommnunication networks', 'Medical asset generation becoming important,healthcare professionals to stay updated,educate and empower participants'], 'Current_Channel_of_interaction': ['Email', 'InPerson', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'In Person', 'Phone', 'In Person', 'Phone', 'Email', 'Email', 'In Person', 'In Person', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Email', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'Email', 'Phone', 'Email', 'InPerson', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'In Person'], 'Company_Event': ['Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions'], 'Interaction_intent': ['To discuss the expansion plans,target markets beyond the initial launc,and the ability to adapt the solution to different healthcare or geographic locations', 'To discuss about any patents,trademarks or proprietary technologies that provide a competitive advantage and barriers to entry to potential competitors', ""To discuss about team's execution plans,milestones and strategies for market penetration,customer acquisition and product development"", 'To discuss how the startup ensure adherance to regulatory standards,certifications and any potential legal or ethical implications', 'To emphasize on the sustainability aspect of the solutions,such as reducing waste,energy efficiency or environmental considerations', 'To discuss about startups that leverage digital health technologies such as mobile apps,wearable or remote devices to improve haleathcare delivery', 'To discuss about startups that focus on robust health tech infrastructure including data storage,interoperability solutions to enable seamless healthcare data exchange and communication', 'To discuss about startups that offer personalized medical solutions such as genetic testing platform,AI-driven diagnostics or precision therapies tailored to unique genetic makeup or medical history', 'To discuss about startups that provide analytics platform or AI-driven solutions for healthcare providers to extract meaningful insights from patient data', 'To discuss about startups that aim to enhance overall patient experience,including solutions for patient scheduling,appointment reminders etc.', 'To discuss and highlight about the startups that aim to enhance the overall patient experience,including solutions for patient scheduling,appointment reminders,virtual consultations or patient feedback forms', 'To discuss about event having potential for innovation and collaboration', 'To discuss about involving patients in healthcare can lead to increased patient enagagement and empowerment', 'To discuss about how patient insights can help identify unmet needs,design patient interventions and improve patient outcome.By involving them ,we can enhance the acceptance and adoption of new medical assets', ""These events provides platform for cross pollination of ideas between different stakeholders where everyone's experience contribute to development of patient driven solutions"", 'To discuss one of key aspect to consider while event is how to effectively capture and utilize patient feedback', 'To discuss about capturing patient feedback requires implementing appropriate channels and mechanism for communication.Traditional methods such as surveys and focus groups can be useful,but more innovative approaches need to be explored', 'To discuss these events should provide insights into best practice and guidelines for implementing patient deriven solutions', 'To discuss about steps and challenges to be addressed to foster a collaborative and ethical environment that promptes patient-driven innovation', 'To explore the role of health care professionals in patient-driven solutions', 'To discuss about benefits,challenges and outcome of partnerships', 'To discuss the enviromental impact and cost-effectiveness of adopting sustainable practices in healthcare settings', 'To discuss the impact of technology on asset tracking,maintenence and optimization', 'To discuss about effectiveness of training programs in improving asset utilization,maintainence practices and overall operational efficiency', 'To discuss about insights into optimizing financial outcomes in medical asset generation', 'To discuss about research findings on the impact of compliance on asset acquisition,utilization and patient safety outcomes', 'To discuss about potential impact of innovation on healthcare deliveryv,asset management and patient care', 'To discuss about emphasizing the need for innovative solutions to address these problems', 'To discuss about startups giving pitches that offer innovative solutions to improve medical asset generation', 'To discuss about the market research and insights of the demand,competition and growth prospects for the proposed solutions', 'To discuss how a particular solution offers and addresses specifica pain points in asset generation', 'To discuss about the business models of the startups and their plans for revenue generation', 'To discuss the expansion plans,target markets beyond the initial launc,and the ability to adapt the solution to different healthcare or geographic locations', 'To discuss about any patents,trademarks or proprietary technologies that provide a competitive advantage and barriers to entry to potential competitors', ""To discuss about team's execution plans,milestones and strategies for market penetration,customer acquisition and product development"", 'To discuss how the startup ensure adherance to regulatory standards,certifications and any potential legal or ethical implications', 'To emphasize on the sustainability aspect of the solutions,such as reducing waste,energy efficiency or environmental considerations', 'To discuss about startups that leverage digital health technologies such as mobile apps,wearable or remote devices to improve haleathcare delivery', 'To discuss about startups that focus on robust health tech infrastructure including data storage,interoperability solutions to enable seamless healthcare data exchange and communication', 'To discuss the importance of medical asset generation and need of organizing training and workshop sessions to educate and empower participants'], 'Items/topics_to_exchange': ['Expansion plans,target markets beyond the initial launch', 'Patents,trademarks or proprietary technologies', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal imlications', 'Patient safety,operational efficiency and cost savings', 'Mobile apps,wearables or remote devices to improve heakthcare delivery,patient engagement', 'Robust health tech infrastructure,secure data storage or telecommnunication networks', 'AI driven diagnostics,or precision therapies,Personalized medical solutions', 'AI-driven solutions,improve clinical trial decision making,optimize resource allocation', 'Patient experience,solutions for patient scheduling,appointment reminders,virtual consultations or patient feedback platforms', 'Healthcare supply chain,inventory management solutions,appointment reminders,virtual consultations', 'Patients involved in generation of medical assets,we can tap into unique insights and perspectives.Event provides opportunity to bridge the gap and create solutions that are tailored to the need', 'Patients invloved in the development process can lead to increased patient engagement and empowerment.Patients become partner rather than receipients', 'Patient insights can help us identify unmet needs,design patient interventions and improve patient outcomes,acceptance and adoption of new medical assets', ""Cross-pollination of ideas between patients,healthcare professional and innovators.Everyone's and expertise contribute to development of patient driven solutions"", 'Patient experiences and perspectives are invaluable', 'Implementing appropriate channels and mechanism.Survey and focus groups.Incorporating patient advisory boards', 'Privacy,data security and informed consent are protected.Striking the right balance between patient involvment and safeguarding rights', ""To discuss abour fostering a collaborative and ethical ethical enviroment by establishing frameworks that respect patient's automony and addressing potential biases and ensuring diversity and inclusivity in patient represenations"", 'Integrating patient perspectives into practice,culture of patient centered care,collaboration between patient and heakthcare professional', 'Impact of collaborative partnerships between healthcare organizations,manufacturers', 'Sustainable practices in medical asset generation,including environment friendly procurement,energy-efficient equipment', 'IOT,RFID,asset management .Impact of technology on asset tracking,maintainence and optimization', 'Asset utilization,maintainence practices and overall operational efficiency', 'Asset utilization,maintainence practices and overall operational efficiency', 'Standards for equipment safety,quality control and legal requirements', 'Robotics,ai,advanced imaging techniques and virtual reality', 'High cost,limited access,equipment maintainence or supply chain bottlenecks', 'Technologies,software programs or business models', 'Technologies,software programs or business models', 'Solution stand out,competitive advantage', 'Pricing strategies,potential partnerships and revenue streams', 'Expansion plans,target markets beyond the initial launch', 'Patents,trademarks or proprietary technologies', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal imlications', 'Patient safety,operational efficiency and cost savings', 'Mobile apps,wearables or remote devices to improve heakthcare delivery,patient engagement', 'Robust health tech infrastructure,secure data storage or telecommnunication networks', 'Medical asset generation becoming important,healthcare professionals to stay updated,educate and empower participants'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good'], 'Next_Action_Items': ['How these events can revolutionize healthcare', 'Financial Analysis of medical asset generation in research presentations', 'Regulatory frameworks,intellectual property rights and responsible innovation', 'Networking oppurtunities and programs', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Team Expertise and execution plan in start up pitch competitions', 'Impact and sustainability in startup pitch competitons', 'Digital Health Innovations in startup pitch competitions', 'Regulatory and compliance considerations in startup pitch competitions', 'Digital Health Innovations in startup pitch competitions', 'Patients invloved in the development process can lead to increased patient engagement and empowerment', 'Patient insights can help us identify unmet needs,design patient interventions and improve patient outcomes', 'Discuss about how these events provide a platform for cross-pollination between patients,healthcare professionals and innovators', 'How to effectively capture and utilize patient feedback', 'Capturing patient feedbacks', 'Event provide insights on best practices and guidelines for implementing patient driven solutions', 'Ethical considerations and privacy protection are paramount', 'Educating and empowering healthcare professionals to embrace patient driven appraoches', 'How collaboration and open communication can be the key', 'How connections can help people', 'To discuss about how these events can provide a platform for discussion on regulatory frameworks and IP rights', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'Discussion about how these events can address pressing healthcare challenges', 'Marketing startegy', 'Discussion about how these events can address pressing healthcare challenges', 'How these events can revolutionize healthcare', 'Topic about key note speeches', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'Future trends in asset generation', 'How connections can help people', 'How these events can revolutionize healthcare', 'Financial Analysis of medical asset generation in research presentations', 'Regulatory frameworks,intellectual property rights and responsible innovation', 'Networking oppurtunities and programs', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Team Expertise and execution plan in start up pitch competitions', 'Importance of patient driven solutions'], 'Proposed_Next_Channel_Of_interaction': ['In Person', 'Phone', 'Email', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'Email', 'In Person', 'In Person', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Phone', 'Phone', 'Email', 'In Person', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'In Person', 'Phone', 'Email', 'Phone', 'Email']}"
16,"{'kol': 'Kim Kang Ho', 'Interaction_Date': ['10-Apr-19', '1-May-19', '1-Jun-19', '5-Jul-19', '10-Aug-19', '2-Sep-19', '1-Oct-19', '9-Nov-19', '10-Dec-19', '20-Jan-20', '10-Feb-20', '1-Mar-20', '1-Apr-20', '4-May-20', '10-Jun-20', '13-Jul-20', '1-Aug-20', '2-Sep-20', '5-Oct-20', '11-Nov-20', '1-Dec-20', '17-Jan-21', '11-Feb-21', '19-Apr-21', '1-May-21', '5-Jun-21', '4-Jul-21', '10-Aug-21', '1-Sep-21', '1-Oct-21', '3-Nov-21', '12-Dec-21', '20-Jan-22', '10-Feb-22', '1-Mar-22', '1-Apr-22', '4-May-22', '1-Jun-22', '5-Jul-22', '1-Aug-22'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer', 'Lung Cancer'], 'KOL_years_of_Experience': [25, 25, 25, 25, 25, 25, 25, 25, 25, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 27, 28, 28, 28, 28, 28, 28, 28, 28], 'KOL_Location': ['New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york', 'New york'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['27k', '27k', '27k', '27k', '27k', '27k', '28k', '28k', '28k', '28k', '28k', '28k', '28k', '28k', '28k', '29k', '29k', '29k', '29k', '29k', '29k', '29k', '30k', '30k', '30k', '30k', '30k', '30k', '30k', '31k', '31k', '31k', '31k', '31k', '31k', '31k', '32k', '32k', '32k', '32k'], 'SocialMedia_Linkedin': ['20k', '20k', '20k', '20k', '21k', '21k', '21k', '21k', '21k', '21k', '21k', '21k', '22k', '22k', '22k', '22k', '22k', '22k', '23k', '23k', '23k', '23k', '23k', '23k', '23k', '24k', '24k', '24k', '24k', '24k', '24k', '24k', '24k', '25k', '25k', '25k', '25k', '25k', '25k', '25k'], 'SocialMedia_YouTube': ['17k', '17k', '17k', '17k', '17k', '17k', '17k', '18k', '18k', '18k', '18k', '18k', '18k', '18k', '18k', '18k', '19k', '19k', '19k', '19k', '19k', '19k', '19k', '19k', '19k', '20k', '20k', '20k', '20k', '20k', '20k', '20k', '21k', '21k', '21k', '21k', '21k', '21k', '22k', '22k'], 'Overall_Kol_Rating': [4.3, 4.3, 4.3, 4.3, 4.3, 4.2, 4.2, 4.2, 4.0, 4.0, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'Research_Participated': [22, 22, 22, 22, 22, 22, 22, 22, 22, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 28, 28, 28, 28, 28, 28, 28, 30, 30], 'Research_Experience': [11, 11, 11, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 14, 14, 14, 14, 14, 14, 14, 15, 15], 'Fundinghistory_researchgrants': ['8000', '8000', '8000', '8000', '8000', '8000', '9000', '9000', '9000', '9000', '9000', '9000', '10000', '10000', '10000', '10000', '11000', '11000', '11000', '11000', '11000', '11000', '11000', '12000', '12000', '12000', '12000', '12000', '12000', '12000', '12000', '12000', '12000', '13000', '13000', '13000', '13000', '13000', '13000', '13000'], 'Fundinghistory_ConsultingFees': [600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 900], 'Fundinghistory_EducationalGrants': ['8000', '8000', '8000', '8000', '8000', '8000', '9000', '9000', '9000', '9000', '9000', '9000', '10000', '10000', '10000', '10000', '11000', '11000', '11000', '11000', '11000', '11000', '11000', '12000', '12000', '12000', '12000', '12000', '12000', '12000', '12000', '12000', '12000', '13000', '13000', '13000', '13000', '13000', '13000', '13000'], 'No_Of_Publications': [14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 15, 15, 15, 15, 15, 15, 15, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18], 'Trainings_Delivered': [12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 15, 15, 15, 15, 15, 15, 15, 15, 15, 16], 'Professional_Certification': [15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 17], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'National_presentations_Presented': [14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 14, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15], 'KOL_FollowUp': ['No', 'No', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['No', 'No', 'Ensuring inclusivity and accessibility of medical assets for individuals with disabilities.', 'Evaluating the role of public funding in supporting medical asset generation.', 'Balancing innovation and safety in the development of cutting-edge medical assets.', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Developing guidelines and standards for the safe and responsible use of medical assets.', 'Exploring the potential of regenerative medicine in medical asset generation.', 'Addressing the challenges of integrating telehealth technologies with existing medical assets.', 'Discussing the ethical considerations in the use of medical assets for genetic testing and gene therapy.', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Exploring strategies for effective inventory management of medical assets in healthcare facilities.', 'No', 'No', 'No', 'No'], 'Previous_Meeting_SubTopics': ['No', 'No', 'Ensuring inclusivity and accessibility of medical assets for individuals with disabilities.', 'Research and Development (R&D) Investment, Bridging the Funding Gap', 'key aspects to consider balancing, Risk Assessment and Management', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'key considerations when developing guidelines and standards', 'aspects to consider when exploring the potential of regenerative medicine', 'key areas to focus on when integrating telehealth technologies', 'ethical considerations associated', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'strategies for effective inventory management', 'No', 'No', 'No', 'No'], 'Current_Discussion_Topic': ['Addressing global health disparities through medical asset generation.', 'Ensuring inclusivity and accessibility of medical assets for individuals with disabilities.', 'Evaluating the role of public funding in supporting medical asset generation.', 'Balancing innovation and safety in the development of cutting-edge medical assets.', 'Strategies for incorporating patient perspectives in medical asset design and development.', 'Overcoming regulatory challenges in the international market for medical assets.', 'Exploring alternative financing models for medical asset generation.', 'Addressing counterfeit and substandard medical assets in the market.', 'Enhancing interoperability among different medical assets and healthcare systems.', 'The role of artificial intelligence and machine learning in medical asset optimization.', 'Exploring the potential of 3D printing in the production of customized medical assets.', 'Adapting medical assets to meet the unique needs of pediatric patients.', 'Discussing the potential impact of nanotechnology in medical asset development.', 'Addressing the shortage of skilled personnel in medical asset manufacturing.', 'Exploring the ethical implications of outsourcing medical asset production to low-income countries.', 'Strategies for effective post-market surveillance and adverse event reporting for medical assets.', 'Integrating medical asset generation with disaster preparedness and response efforts.', 'Exploring the use of robotics and automation in medical asset manufacturing.', 'Addressing the challenges of intellectual property protection in medical asset generation.', 'Promoting transparency and accountability in the pricing of medical assets.', 'Assessing the environmental impact of medical asset disposal and exploring sustainable alternatives.', 'Incorporating user experience design principles in medical asset development.', 'Discussing the role of artificial intelligence in medical asset diagnosis and decision-making.', 'Developing guidelines and standards for the safe and responsible use of medical assets.', 'Exploring the potential of regenerative medicine in medical asset generation.', 'Addressing the challenges of integrating telehealth technologies with existing medical assets.', 'Discussing the ethical considerations in the use of medical assets for genetic testing and gene therapy.', 'Enhancing collaboration between academic institutions and industry in medical asset generation.', 'Exploring the potential of blockchain technology in enhancing supply chain traceability for medical assets.', 'Addressing the impact of medical asset shortages on global health emergencies.', 'Assessing the role of medical asset generation in personalized medicine.', 'Exploring the potential of wearable technologies in medical asset development.', 'Discussing the challenges and opportunities in repurposing existing medical assets for new applications.', 'Evaluating the impact of medical asset generation on healthcare workforce training and skill requirements.', 'Exploring strategies for effective inventory management of medical assets in healthcare facilities.', 'Addressing the challenges of ensuring data privacy and security in connected medical assets.', 'Discussing the potential of biomaterials and tissue engineering in medical asset development.', 'Enhancing collaboration between manufacturers and healthcare providers in optimizing medical asset utilization.', 'Evaluating the social and economic implications of medical asset generation on healthcare systems.', 'Strategies for integrating artificial intelligence and machine learning algorithms into medical asset generation.'], 'Current_Meeting_Subtopics': ['ways in which medical asset generation can contribute to addressing global health disparities', 'Ensuring inclusivity and accessibility of medical assets for individuals with disabilities.', 'Research and Development (R&D) Investment, Bridging the Funding Gap', 'key aspects to consider balancing, Risk Assessment and Management', 'Patient Engagement,Conduct User Research', 'Early Regulatory Planning', 'Venture Capital (VC) Funding, Crowdfunding', 'strategies to combat counterfeit', 'Standards and Interoperability Frameworks', 'key areas where AI and ML contribute to medical asset optimization', 'some areas where 3D printing is being used', 'considerations for developing and adapting medical assets', 'key areas where nanotechnology can have a significant impact', 'strategies to tackle the issue of shortage of skilled personnel', 'key ethical implications', 'Discussing strategies and Why is it crucial', 'strategies to facilitate the integration', 'How robotics and automation can be used', 'challenges related to IP protection in the field of medical asset generation', 'strategies to promote transparency and accountability', 'considerations and strategies to address the environmental impact', 'integrate UX design principles in medical asset development', ""key aspects of AI's role"", 'key considerations when developing guidelines and standards', 'aspects to consider when exploring the potential of regenerative medicine', 'key areas to focus on when integrating telehealth technologies', 'ethical considerations associated', 'strategies to enhance collaboration between academic institutions and industry', 'ways in which blockchain technology can be utilized', 'significant impact on global health emergencies, strategies to address the problem', 'ways medical asset generation contributes to personalized medicine', 'wearable technologies contribute to medical asset development', 'key challenges and opportunities involved', 'aspects to consider when evaluating the impact', 'strategies for effective inventory management', 'strategies to address challenges of ensuring data privacy', 'Biomaterials for Medical Devices, Tissue Engineering for Regenerative Medicine', 'strategies to foster collaboration between stakeholders', 'key aspects to consider while evaluating social and ecnomic implications', 'Discussion on Data Collection and Preparation'], 'Current_Channel_of_interaction': ['In Person', 'In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'Video', 'In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person'], 'Company_Event': ['Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation', 'Medical Asset Generation'], 'Interaction_intent': ['Report on global health disparities', 'key considerations and strategies', 'key aspects to evaluate the role of public funding', 'key considerations for striking a balance between innovation and safety', 'strategies for integrating patient perspectives into the process', 'strategies to help overcome challenges related to medical assets in international market', 'Discussing alternative financing models', 'strategies to combat the issue', 'strategies to promote interoperability', 'key areas where AI and ML are applied in medical asset optimization', 'key aspects highlighting the potential of 3D printing in this context', 'key considerations and strategies for adapting medical assets for pediatric use', 'areas where nanotechnology can have a significant impact', 'strategies to tackle the issue of shortage of skilled personnel', 'Discussing alternative financing models', 'Measures for effective post market surveillance', 'Discussing asset generation with disaster preparedness', 'Discussing how robotics and automation can help with medical asset manufacturing', 'Measures for challenges regardng intellectual property protection', 'Keeping teh medical asset generation process transparent', 'Report on the enviornmental impact because of asset disposal', 'Discussing how can design principles can be implemented in medical asset development', 'How Ai helping in medical asset diagnosis', 'Discussing guidelines to maintain safety', 'Discussing potential of regenerative medicine', 'Discussing challenges for integrating telehealth technologies', 'key ethical considerations for genetic testing and gene therapy', 'strategies to foster collaboration', 'ways in which blockchain can contribute to improving transparency, security, and efficiency in the medical supply chain', 'key considerations for addressing the impact of medical asset shortages', 'key aspects of the role of medical asset generation in personalized medicine', 'areas where wearables can make a significant impact', 'areas where wearables can make a significant impact', 'ways in which medical asset generation influences healthcare workforce training', 'strategies for effective inventory management:', 'challenges to consider and strategies to address them', 'key aspects highlighting the potential of biomaterials and tissue engineering in medical asset development', 'some strategies to foster collaboration', 'key aspects to consider when evaluating these implications', 'strategies for effectively integrating AI and ML algorithms into the process of medical asset generation'], 'Items/topics_to_exchange': ['How medical asset generation address these disparities', 'promote inclusivity and accessibility in medical assets', 'Discussing the role of public funding', 'How to bring balance in innovation and safetry', 'Discussing pateint perspectives in medical asset design', 'Measures to be taken to overcome the challenges in international market', 'Report on major alternative financing models', 'Regulatory Measures for substandard medical assets', 'Discussing interoperability among diffrent medical assets', 'How can Ai and Ml be applied in medical asset optimization', 'Discussing how 3d printing can be used for production', 'Disucssing how medical assets can be used for adapting for pediatric use', 'Discussing how nanotechnology can have impact on medical asset generation', 'Investment in Education and Training', 'Report on alternatve financng models', 'Discussing adverse event reporting for medical asset and measures for effectve post market survellance', 'Report on disaster preparedness and response efforts', 'Report on robotics and automation', 'Dscussing the challenges', 'Discussing how we can maintain transparency', 'Strategies to reduce the impact of envornmental mpact', 'Measures to be taken to implement design principles in medical assets', 'Report on medical asset diagnosis', 'Report on use of safe and responsible use of medical assets', 'Report on regenerative medicine', 'several challenges that need be addressed to ensure successful integration', 'Discussing use of medical assets for genetic testing and gene therapy', 'Discussing significant advancements in healthcare', 'Report how blockchain can contribute to improving security and efficiency in the medical supply chain', 'Discussing consequences on the ability to effectively respond to crises and provide essential healthcare services', 'Discussing role of medical asset generation in personalized medicine', 'discussing potential of wearable technologies in medical asset development', 'Discussing potential of wearable technologies in medical asset development', 'Discussing impact of medical asset generation on healthcare workforce training and skill requirements', 'Discussing strategies for effective inventory management:', 'Discussing challenges of ensuring data privacy and security in connected medical assets', 'Report on potential of biomaterials and tissue engineering in medical asset development', 'How to enhance collaboration between manufacturers and healthcare', 'discussing implications of medical asset generation on healthcare systems.', 'Discussion how integrating artificial intelligence and machine learning algorithms into medical asset generation'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Ensuring inclusivity and accessibility of medical assets for individuals with disabilities.', 'Evaluating the role of public funding in supporting medical asset generation.', 'Balancing innovation and safety in the development of cutting-edge medical assets.', 'Strategies for incorporating patient perspectives in medical asset design and development.', 'Overcoming regulatory challenges in the international market for medical assets.', 'Exploring alternative financing models for medical asset generation.', 'Addressing counterfeit and substandard medical assets in the market.', 'Enhancing interoperability among different medical assets and healthcare systems.', 'The role of artificial intelligence and machine learning in medical asset optimization.', 'Exploring the potential of 3D printing in the production of customized medical assets.', 'Adapting medical assets to meet the unique needs of pediatric patients.', 'Discussing the potential impact of nanotechnology in medical asset development.', 'Addressing the shortage of skilled personnel in medical asset manufacturing.', 'Exploring the ethical implications of outsourcing medical asset production to low-income countries.', 'Strategies for effective post-market surveillance and adverse event reporting for medical assets.', 'Integrating medical asset generation with disaster preparedness and response efforts.', 'Exploring the use of robotics and automation in medical asset manufacturing.', 'Addressing the challenges of intellectual property protection in medical asset generation.', 'Promoting transparency and accountability in the pricing of medical assets.', 'Assessing the environmental impact of medical asset disposal and exploring sustainable alternatives.', 'Incorporating user experience design principles in medical asset development.', 'Discussing the role of artificial intelligence in medical asset diagnosis and decision-making.', 'Developing guidelines and standards for the safe and responsible use of medical assets.', 'Exploring the potential of regenerative medicine in medical asset generation.', 'Addressing the challenges of integrating telehealth technologies with existing medical assets.', 'Discussing the ethical considerations in the use of medical assets for genetic testing and gene therapy.', 'Enhancing collaboration between academic institutions and industry in medical asset generation.', 'Exploring the potential of blockchain technology in enhancing supply chain traceability for medical assets.', 'Addressing the impact of medical asset shortages on global health emergencies.', 'Assessing the role of medical asset generation in personalized medicine.', 'Exploring the potential of wearable technologies in medical asset development.', 'Discussing the challenges and opportunities in repurposing existing medical assets for new applications.', 'Evaluating the impact of medical asset generation on healthcare workforce training and skill requirements.', 'Exploring strategies for effective inventory management of medical assets in healthcare facilities.', 'Addressing the challenges of ensuring data privacy and security in connected medical assets.', 'Discussing the potential of biomaterials and tissue engineering in medical asset development.', 'Enhancing collaboration between manufacturers and healthcare providers in optimizing medical asset utilization.', 'Evaluating the social and economic implications of medical asset generation on healthcare systems.', 'Strategies for integrating artificial intelligence and machine learning algorithms into medical asset generation.', 'Exploring the use of virtual reality and augmented reality in medical asset training and simulation.'], 'Proposed_Next_Channel_Of_interaction': ['In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'Video', 'In Person', 'In Person', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'In Person', 'In Person', 'Video']}"
17,"{'kol': 'Leigh Legros', 'Interaction_Date': ['21-Apr-19', '13-May-19', '21-Jul-19', '22-Oct-19', '6-Dec-19', '28-Jan-20', '28-Mar-20', '30-Apr-20', '1-Jun-20', '22-Aug-20', '22-Sep-20', '19-Oct-20', '22-Nov-20', '12-Dec-20', '19-Oct-20', '22-Dec-20', '6-Mar-21', '19-May-21', '22-Jul-21', '6-Sep-21', '19-Nov-21', '22-Jan-22', '6-Mar-22', '7-May-22', '8-Jul-22', '10-Oct-22', '10-Dec-22'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer'], 'KOL_years_of_Experience': [25, 25, 25, 25, 25, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 27, 27, 27, 27, 27, 28, 28, 28, 28, 28, 28], 'KOL_Location': ['Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon', 'Oregon'], 'KOL_Territory': ['West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast'], 'SocialMedia_Twitter': ['10K', '10K', '10.2K', '10.4K', '10.6K', '10.6K', '10.6K', '10.6K', '10.8K', '10.8K', '10.9K', '10.9K', '10.9K', '10.9K', '11K', '11K', '11K', '11K', '11.2K', '11.6K', '11.6K', '12K', '12K', '12K', '12K', '12K', '12K'], 'SocialMedia_Linkedin': ['15K', '15K', '15K', '15.2K', '15.5K', '15.5K', '15.5K', '15.5K', '15.8K', '15.8K', '15.8K', '15.8K', '15.8K', '15.8K', '16K', '16K', '16K', '16K', '17K', '17.4K', '17.4K', '18K', '18K', '18K', '18K', '18K', '18K'], 'SocialMedia_YouTube': ['15K', '15K', '15.2K', '15.5K', '15.7K', '15.7K', '15.7K', '15.7K', '15.8K', '15.8K', '15.9K', '15.9K', '15.9K', '15.9K', '17K', '17K', '17K', '17K', '17.3K', '17.7K', '17.7K', '18.4K', '18.4K', '18.4K', '18.4K', '18.4K', '18.4K'], 'Overall_Kol_Rating': [3.6, 3.6, 3.7, 3.7, 3.7, 3.7, 3.7, 3.7, 3.7, 3.7, 3.7, 3.7, 3.7, 3.7, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'Research_Participated': [15, 15, 15, 16, 16, 16, 16, 16, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 19], 'Research_Experience': [18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 19, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21], 'Fundinghistory_researchgrants': ['11000', '11000', '11000', '13000', '13000', '13000', '13000', '13000', '14000', '14000', '14000', '14000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '25000', '25000', '25000', '25000', '25000', '25000'], 'Fundinghistory_ConsultingFees': [550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 550, 600, 600, 600, 600, 600], 'Fundinghistory_EducationalGrants': ['11000', '11000', '11000', '13000', '13000', '13000', '13000', '13000', '14000', '14000', '14000', '14000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '25000', '25000', '25000', '25000', '25000', '25000'], 'No_Of_Publications': [15, 15, 16, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 21, 21, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'Trainings_Delivered': [20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'Professional_Certification': [6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6], 'KOL_affiliations_academicinstitutionss': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'National_presentations_Presented': [250, 250, 250, 250, 250, 260, 260, 260, 260, 260, 260, 260, 260, 260, 260, 260, 270, 270, 270, 270, 270, 280, 280, 280, 280, 280, 280], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Discussion regarding long-term risks and benefits of using the drug', 'Identifying various competators and gather information about them', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the clinical trial', 'Safety measures of the drug on general patients', 'Efficacy & Accuracy of Drug', 'Patient Safety during Clinical Trial', 'To discuss regarding \n Procedures\n Risks and benefits and the rights of patients , treatment options in case of adverse events', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Product overview and its differentiating way', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Finding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug'], 'Previous_Meeting_SubTopics': ['Analysis of various competators in industry', 'Analysis of various competators in industry', 'Discussion on Principal Investigator Support', 'Safety', 'Efficacy & Accuracy of Drug', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'Discussion regarding claims/insurance and copay programs', 'Technical feasibility', 'Financial feasibility', 'Market feasibility', 'Operational feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Current_Discussion_Topic': ['Identifying various competators and gather information about them', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the clinical trial', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Finding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'Email', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'Video Conference', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person'], 'Company_Event': ['Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug'], 'Interaction_intent': ['identifying competitors in industry', 'To determine competative advantage by analysing strengths and weaknesses of Competators', 'Indentifying Principal Investigator for the Clinical trial who has substantial experience as PI in past and how much support he can provide in Clinical Trial', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'To discuss about the claims,insurance and copay programs', 'Technical feasibility', 'Financial feasibility', 'Market feasibility', 'Operational feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Items/topics_to_exchange': ['Analysis of various competators in industry', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the Clinical trial who has substantial experience as PI in past', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Are there risks to taking part in the trial?\n Who is watching out for any problems?\n Who is making sure that people who take part are safe?\n Is the trial trying to answer an important research question?', 'To discuss regarding \n Procedures\n Risks and benefits and the rights of patients , treatment options in case of adverse events', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Findiding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Analyse competators strengths & weaknesses and determine your competative advange', 'Discussion on Principal Investigator Support', 'Safety : Discussion on Safety Measures', 'Safety : discussion regarding efficay and accuracy of drug', 'Safety : Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discussion regarding submitting application for investigational new drug', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'Discuss compliance and ethical practices', 'Technical feasibility', 'Financial feasibility', 'Market Feasibility', 'Operational Feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.', 'Discussion regarding rare side effects.'], 'Proposed_Next_Channel_Of_interaction': ['Phone Call', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'Phone Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'In-Person']}"
18,"{'kol': 'Meredith', 'Interaction_Date': ['19-Jun-19', '17-Jul-19', '13-Aug-19', '9-Sep-19', '3-Oct-19', '31-Oct-19', '26-Nov-19', '18-Dec-19', '16-Jan-20', '12-Feb-20', '12-Feb-20', '10-Mar-20', '3-Apr-20', '30-Apr-20', '25-May-20', '20-Jun-20', '12-Jul-20', '12-Aug-20', '11-Sep-20', '8-Oct-20', '5-Nov-20', '2-Dec-20', '29-Dec-20', '21-Jan-21', '18-Feb-21', '13-Mar-21', '9-Apr-21', '5-May-21', '31-May-21', '28-Jun-21', '27-Jul-21', '21-Aug-21', '15-Sep-21', '12-Oct-21', '2-Nov-21', '19-Dec-21', '16-Jan-22', '14-Feb-22', '12-Mar-22', '10-Apr-22'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer'], 'KOL_years_of_Experience': [21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23, 23], 'KOL_Location': ['New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['21K', '21.4K', '21.6K', '22.3K', '23.1K', '23.3K', '24.1k', '24.3K', '25.2K', '25.9K', '26.2K', '26.5K', '27.1K', '27.4K', '28.1K', '28.5K', '29.3K', '29.7K', '30.3K', '30.5K', '31.1K', '31.5K', '32K', '33.6K', '34.5K', '34.6K', '35.1K', '36.2K', '37.4K', '39K', '40.1K', '41.4K', '41.8K', '43.4K', '44.1K', '46.4K', '47.1K', '48.4K', '51.5K', '53.7K'], 'SocialMedia_Linkedin': ['13.1K', '13.2K', '13.7K', '14K', '14.6K', '14.6K', '14.8K', '15K', '15.4K', '15.6K', '15.7K', '15.9K', '16.3K', '16.5K', '17K', '17.3K', '18.1K', '18.3K', '18.5K', '18.7K', '19.1K', '19.3K', '19.5K', '20.1K', '20.6K', '21K', '21.7K', '22.4K', '22.6K', '23.2K', '23.7K', '24.3K', '24.9K', '25.7K', '26.2K', '28.2K', '28.5K', '29.4K', '31.4K', '32.7K'], 'SocialMedia_YouTube': ['4.2K', '4.3K', '4.5K', '4.8K', '5.1K', '5.3K', '5.3K', '5.7K', '6.1K', '6.3K', '6.5k', '6.7k', '7K', '7.2K', '7.6K', '8.1K', '8.2K', '8.4K', '8.6K', '8.9K', '9.4K', '9.6K', '9.8K', '11K', '11.3K', '11.6K', '11.9K', '12.4K', '13.1K', '13.7K', '14.2K', '14.8K', '15.6K', '16.8K', '17.5K', '18.3K', '19K', '19.8K', '21.1K', '22K'], 'Overall_Kol_Rating': [4.0, 4.0, 4.0, 4.1, 4.1, 4.1, 4.1, 4.1, 4.1, 4.1, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4, 4.4], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5], 'Research_Participated': [9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13], 'Research_Experience': [18, 18, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 19, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20], 'Fundinghistory_researchgrants': ['700000', '700000', '700000', '700000', '750000', '750000', '750000', '750000', '750000', '750000', '750000', '825000', '825000', '825000', '825000', '825000', '825000', '825000', '825000', '825000', '825000', '825000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '975000', '975000', '975000', '975000', '975000'], 'Fundinghistory_ConsultingFees': [500, 500, 500, 500, 500, 500, 500, 500, 500, 500, 500, 500, 500, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 700, 800, 800, 800, 800, 800, 800], 'Fundinghistory_EducationalGrants': ['700000', '700000', '700000', '700000', '750000', '750000', '750000', '750000', '750000', '750000', '750000', '825000', '825000', '825000', '825000', '825000', '825000', '825000', '825000', '825000', '825000', '825000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '925000', '975000', '975000', '975000', '975000', '975000'], 'No_Of_Publications': [11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13], 'Trainings_Delivered': [21, 21, 21, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 24, 24, 24, 24, 25, 25, 25, 26, 26, 26, 26, 26, 26, 26, 27, 27, 27, 27, 27, 28, 28, 28, 28, 29, 29, 29], 'Professional_Certification': [9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Hospital_and_medical_Centres': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'National_presentations_Presented': [134, 135, 136, 137, 139, 141, 142, 143, 144, 146, 147, 148, 149, 149, 150, 150, 150, 151, 152, 153, 154, 155, 155, 156, 157, 158, 159, 160, 160, 161, 161, 161, 162, 162, 163, 163, 164, 164, 166, 167], 'KOL_FollowUp': ['No', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Introduction to new drug Research', 'Feasibility of Study', 'Discussion about effectivness of study.', 'Time line of study', 'Competition of drug in market', 'Discussion on Regulatory guidlines for the research', 'Claims/Insurance/Copay Programs', 'Principal Investigator support role', 'Regulatory guidlined for trial', 'Trial Start guidlines', 'Competition drug performance', 'Insurance Plan', 'To get KoL onboaded for the role', 'Patient Demographics for clinical trial sites', 'Guidlines for trial sites', 'Sites for clinical trial', 'Safety for trials', 'Trial start report', 'Claims program', 'Insurance plan for drug', 'Copay for drug', 'Competiter drug comparision', 'Trial Progress report', 'Guidlines review', 'Safety of volunteer', 'Direction of research', 'Efficacy of drug', 'Drug effectivness compare to competitor', 'Trial Progress report', 'Guidlines for post trial', 'Safety procedure review', 'Post Trial Follow Up of volunteer', 'Post Trial Implementation', 'Post Trial Report', 'Guidlines for trial closure', 'Claims/Insurance/Copay Programs', 'Cost of competitve drug', 'Volunteer Condition post trial', 'Claims/Insurance/Copay Programs Review', 'Efficiency w.r.t competitve drug'], 'Previous_Meeting_SubTopics': ['Feasibility of Study', 'Feasibility of Study', 'Feasibility of Study', 'Competitive Analysis', 'Regulatory guidlines', 'Claims/Insurance/Copay Programs', 'Principal Investigator support\u200b', 'Regulatory guidlines', 'Regulatory guidlines', 'Competitive Analysis', 'Claims/Insurance/Copay Programs', 'Principal Investigator support\u200b', 'Patient Demographics for clinical trial sites', 'Regulatory guidlines', 'Patient Demographics for clinical trial sites', 'Safety', 'Trial Start', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Competitive Analysis', 'Trial Progress', 'Regulatory guidlines', 'Safety', 'Feasibility of Study', 'Feasibility of Study', 'Competitive Analysis', 'Trial Progress', 'Regulatory guidlines', 'Safety', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Regulatory guidlines', 'Claims/Insurance/Copay Programs', 'Competitive Analysis', 'Safety', 'Claims/Insurance/Copay Programs', 'Competitive Analysis', 'Post Trial Follow Up and Implementation'], 'Current_Discussion_Topic': ['Feasibility of Study', 'Discussion about effectivness of study.', 'Time line of study', 'Competition of drug in market', 'Discussion on Regulatory guidlines for the research', 'Claims/Insurance/Copay Programs', 'Principal Investigator support role', 'Regulatory guidlines for trial', 'Trial Start guidlines', 'Competition drug performance', 'Insurance Plan', 'To get KoL onboaded for the role', 'Patient Demographics for clinical trial sites', 'Guidlines for trial sites', 'Sites for clinical trial', 'Safety for trials', 'Trial start report', 'Claims program', 'Insurance plan for drug', 'Copay for drug', 'Competiter drug comparision', 'Trial Progress report', 'Guidlines review', 'Adverse Reaction', 'Direction of research', 'Efficacy of drug', 'Drug effectivness compare to competitor', 'Trial Progress report', 'Guidlines for post trial', 'Side effects', 'Post Trial Follow Up of volunteer', 'Post Trial Implementation', 'Post Trial Report', 'Guidlines for trial closure', 'Claims/Insurance/Copay Programs', 'Cost of competitve drug', 'Side effects', 'Claims/Insurance/Copay Programs Review', 'Efficiency w.r.t competitve drug', 'Report on Efficiency of drug post trial'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Video Conference', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Conference', 'E-mail', 'In-Person', 'Video Conference', 'Video Call', 'Video Call', 'Video Conference', 'Video Conference', 'Video Conference', 'Video Conference', 'In-Person', 'Video Conference', 'Video Call', 'Video Call', 'In-Person', 'Video Conference', 'In-Person', 'Video Call', 'E-mail', 'In-Person', 'Video Conference', 'Video Conference', 'Video Conference', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Conference', 'In-Person', 'Video Conference'], 'Company_Event': ['Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug'], 'Interaction_intent': ['To check feasibility of study', 'Feasibility of Study', 'Feasibility of Study', 'Competitive Analysis', 'Regulatory guidlines', 'Claims/Insurance/Copay Programs', 'Principal Investigator support\u200b', 'Regulatory guidlines', 'Regulatory guidlines', 'Competitive Analysis', 'Claims/Insurance/Copay Programs', 'Principal Investigator support\u200b', 'Patient Demographics for clinical trial sites', 'Regulatory guidlines', 'Patient Demographics for clinical trial sites', 'Safety', 'Trial Start', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Competitive Analysis', 'Trial Progress', 'Regulatory guidlines', 'Safety', 'Feasibility of Study', 'Feasibility of Study', 'Competitive Analysis', 'Trial Progress', 'Regulatory guidlines', 'Safety', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Regulatory guidlines', 'Draft for Claims/Insurance/Copay Programs', 'Competitive Analysis', 'Safety', 'Claims/Insurance/Copay Programs', 'Competitive Analysis', 'Post Trial Follow Up and Implementation'], 'Items/topics_to_exchange': ['discussion about new research to be started', 'Discussion about effectivness of study.', 'Time line of study', 'Competition of drug in market', 'Discussion on Regulatory guidlines for the research', 'Claims/Insurance/Copay Programs', 'To get KoL agrrement for the role of Principal Investigator support', 'Regulatory guidlined for trial', 'Guidlines and procedure for the trial', 'Competition drug performance', 'For Insurance Plan', 'To get KoL onboaded for the role', 'To select clinical trial sites according to patient demography', 'Guidlines for trial sites', 'Finalizing sites for clinical trial', 'Safety for trials', 'Trial start report', 'Claims program', 'Insurance plan for drug', 'Copay for drug', 'How our drug is performing w.r.t competition.', 'Trial Progress report', 'Review all the guildlines followed in trial', 'Adverse Reaction in volunteer', 'Direction of research', 'Efficacy of drug in trial', 'Drug effectivness compare to competitor', 'Trial Progress report', 'Guidlines for post trial', 'Side effects of drug', 'Post Trial Follow Up of volunteer', 'Post Trial Implementation', 'Post Trial Report', 'Guidlines for trial closure', 'Finalizining draft for Claims/Insurance/Copay Programs', 'Cost of competitve drug', 'Side effects of drug', 'Claims/Insurance/Copay Programs Review', 'Efficiency w.r.t competitve drug', 'Report on Efficiency of drug post trial'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Feasibility of Study', 'Feasibility of Study', 'Feasibility of Study', 'Competitive Analysis', 'Regulatory guidlines', 'Competitive Analysis', 'Principal Investigator support\u200b', 'Regulatory guidlines', 'Regulatory guidlines', 'Competitive Analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Patient Demographics for clinical trial sites', 'Regulatory guidlines', 'Regulatory guidlines', 'Regulatory guidlines', 'Competitive Analysis', 'Clinical Trial-Zortobombib Drug', 'Claims/Insurance/Copay Programs', 'Regulatory guidlines', 'Competitive Analysis', 'Competitive Analysis', 'Regulatory guidlines', 'Regulatory guidlines', 'Feasibility of Study', 'Feasibility of Study', 'Competitive Analysis', 'Feasibility of Study', 'Regulatory guidlines', 'Regulatory guidlines', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation', 'Regulatory guidlines', 'Claims/Insurance/Copay Programs', 'Competitive Analysis', 'Competitive Analysis', 'Claims/Insurance/Copay Programs', 'Competitive Analysis', 'Competitive Analysis'], 'Proposed_Next_Channel_Of_interaction': ['In-Person', 'Video Call', 'Video Call', 'Video Call', 'Video Conference', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Conference', 'E-mail', 'In-Person', 'Video Conference', 'Video Call', 'Video Call', 'Video Conference', 'Video Conference', 'Video Conference', 'Video Conference', 'In-Person', 'Video Conference', 'Video Call', 'Video Call', 'In-Person', 'Video Conference', 'In-Person', 'Video Call', 'E-mail', 'In-Person', 'Video Conference', 'Video Conference', 'Video Conference', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Conference', 'In-Person', 'Video Conference', 'In-Person']}"
19,"{'kol': 'Michael stark', 'Interaction_Date': ['2-Apr-19', '23-May-19', '2-Jun-19', '12-Aug-19', '30-Sep-19', '4-Oct-19', '16-Nov-19', '9-Dec-19', '3-Jan-20', '12-Feb-20', '3-Mar-20', '20-Apr-20', '30-May-20', '4-Jun-20', '12-Jul-20', '1-Aug-20', '17-Oct-20', '5-Nov-20', '23-Dec-20', '2-Jan-21', '10-Feb-21', '13-Mar-21', '1-Apr-21', '6-Jun-21', '22-Aug-21', '15-Sep-21', '28-Oct-21', '1-Dec-21', '10-Jan-22', '4-Feb-22', '9-Mar-22', '13-Apr-22', '12-May-22', '7-Jun-22', '22-Jul-22', '13-Aug-22', '5-Sep-22', '6-Oct-22', '10-Nov-22', '13-Dec-22'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer'], 'KOL_years_of_Experience': [6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9], 'KOL_Location': ['Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver', 'Denver'], 'KOL_Territory': ['Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado', 'Colorado'], 'SocialMedia_Twitter': ['9K', '9K', '9K', '10K', '11K', '11K', '11K', '15K', '15K', '15K', '15K', '15K', '13.5K', '14K', '14K', '16K', '17K', '20K', '20K', '20K', '20K', '20K', '20K', '19K', '19K', '19K', '19K', '19K', '22K', '26K', '26K', '26K', '26K', '26K', '26K', '28K', '30K', '30K', '30K', '30K'], 'SocialMedia_Linkedin': ['6K', '6K', '6K', '8K', '10K', '10K', '10K', '10K', '10K', '13K', '13K', '13K', '13K', '13K', '15K', '15K', '15K', '15K', '15K', '14K', '14.5K', '15K', '15K', '15K', '15K', '15K', '16K', '17K', '17K', '17K', '17K', '19K', '20K', '22K', '22K', '22K', '25K', '25K', '25K', '25K'], 'SocialMedia_YouTube': ['10K', '10K', '10K', '12K', '12K', '12K', '12K', '14K', '14K', '14K', '14K', '15K', '14K', '15K', '17K', '16.5K', '16K', '15.5K', '16K', '16K', '16K', '16K', '16K', '18K', '18K', '18K', '18K', '17.5K', '17.5K', '17.5K', '17.5K', '17.5K', '18K', '18K', '18K', '18K', '19K', '20K', '22K', '25K'], 'Overall_Kol_Rating': [4.1, 3.9, 4.0, 3.8, 3.8, 4.1, 3.8, 3.9, 3.9, 4.0, 3.8, 3.8, 4.1, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.1, 4.2, 4.3, 4.3, 4.3, 4.3, 4.5, 4.5, 4.5, 4.1, 4.2, 4.0, 3.9, 4.1, 4.3, 4.5, 4.6, 4.4, 4.7, 4.8], 'Connection_to_Advisory_Boards': [5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'Research_Participated': [5, 5, 5, 5, 5, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10], 'Research_Experience': [4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10], 'Fundinghistory_researchgrants': ['32000', '33000', '33000', '33000', '33000', '34000', '34000', '34000', '34000', '34000', '36000', '36000', '36000', '38000', '40000', '40000', '40000', '40000', '40000', '41000', '41000', '41000', '43000', '43000', '43000', '43000', '45000', '45000', '45000', '45000', '45000', '45000', '45000', '47000', '47500', '48000', '48000', '48000', '50000', '50000'], 'Fundinghistory_ConsultingFees': [100, 100, 100, 100, 125, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 150, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 225, 225, 225, 225, 225, 250, 250], 'Fundinghistory_EducationalGrants': ['32000', '33000', '33000', '33000', '33000', '34000', '34000', '34000', '34000', '34000', '36000', '36000', '36000', '38000', '40000', '40000', '40000', '40000', '40000', '41000', '41000', '41000', '43000', '43000', '43000', '43000', '45000', '45000', '45000', '45000', '45000', '45000', '45000', '47000', '47500', '48000', '48000', '48000', '50000', '50000'], 'No_Of_Publications': [4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 7, 7, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10], 'Trainings_Delivered': [4, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 9, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 11, 12, 12, 12, 12, 12, 14, 14, 14, 14], 'Professional_Certification': [3, 3, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 8, 9, 10, 10, 10, 10], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'KOL_Affiliations_Government_and_Regulatory_bodies': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'National_presentations_Presented': [60, 60, 60, 60, 60, 60, 60, 60, 60, 70, 70, 70, 70, 70, 70, 70, 70, 70, 70, 80, 80, 80, 80, 80, 80, 80, 80, 80, 80, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90], 'KOL_FollowUp': ['Yes', 'No', 'Yes', 'Yes', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['No', 'No', 'Introduction to Lymphoma Cancer', 'Types of Lymphoma', 'No', 'No', 'Staging and Prognosis', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Introduction to Personalized Medicine in Blood Cancer', 'Molecular Profiling in Blood Cancer', 'Targeted Therapies in Blood Cancer', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Rehabilitation and Physical Therapy', 'No', 'No', 'Late Effects of Cancer Treatment', 'No', 'No', 'No', 'No'], 'Previous_Meeting_SubTopics': ['No', 'No', 'Brief information about Lymphoma', 'Discussing the two main types of lymphoma', 'No', 'No', 'Describing the staging system used for lymphoma', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Providing an overview of personalized medicine and its application in the field of blood cancer', 'Exploring the role of molecular profiling techniques,', 'Discussing the use of targeted therapies', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Role of rehabilitation and physical therapy in cancer survivorship', 'No', 'No', 'Exploring the potential long-term effects and complications', 'No', 'No', 'No', 'No'], 'Current_Discussion_Topic': [""aspects of a survivor's physical, mental, psychosocial, and spiritual health"", 'Introduction to Lymphoma Cancer', 'Types of Lymphoma', 'Causes and Risk Factors', 'Symptoms and Diagnosis', 'Staging and Prognosis', 'Treatment Options of Lymphoma', 'Use of chemotherapy as a treatment', 'Discussing the role of radiation therapy in cancer treatment', 'Importance of surgery as a treatment modality', 'Field of immunotherapy', 'Targeted Therapy', 'Hormonal Therapy', 'Stem Cell Transplantation', 'Palliative Care', 'Introduction to Personalized Medicine in Blood Cancer', 'Molecular Profiling in Blood Cancer', 'Targeted Therapies in Blood Cancer', 'Genomic Testing in Blood Cancer', 'Liquid Biopsies in Blood Cancer', 'Immunotherapy in Blood Cancer', 'Prognostic and Predictive Biomarkers', 'Challenges and limitations associated with personalized medicine in blood cancer', 'Future Perspectives and Clinical Trials', 'Importance of Supportive Care in Cancer Treatment', 'Managing Treatment Side Effects', 'Psychological Support for Cancer Patients', 'Nutritional Support during and after Cancer Treatment', 'Pain Management in Cancer', 'Survivorship Care Plans', 'Fertility Preservation', 'Rehabilitation and Physical Therapy', 'Managing Fear of Recurrence', 'Support for Caregivers and Family Members', 'Late Effects of Cancer Treatment', 'Cardiac Complications', 'Cognitive Dysfunction', 'Second Primary Cancers', 'Endocrine Dysfunction', 'Quality of Life and Survivorship'], 'Current_Meeting_Subtopics': ['Different aspects of survivor', 'Brief information about Lymphoma', 'Discussing the two main types of lymphoma', 'Exploring the potential causes and risk factors associated with lymphoma', 'Highlighting the common symptoms of lymphoma,', 'Describing the staging system used for lymphoma', 'Providing an overview of the various treatment', 'Exploring the use of chemotherapy as a treatment modality for various types of cancer', 'Radiation therapy in cancer treatment', 'Highlighting the importance of surgery as a treatment modality', ""Exploring the field of immunotherapy, which harnesses the body's immune system to fight cancer."", 'Discussing targeted therapy, which involves using drugs that specifically target cancer cells', 'Exploring hormonal therapy as a treatment option for hormone-sensitive cancers, such as breast or prostate cancer.', 'Exploring the use of stem cell transplantation', 'Highlighting the importance of palliative care', 'Providing an overview of personalized medicine and its application in the field of blood cancer', 'Exploring the role of molecular profiling techniques,', 'Discussing the use of targeted therapies', 'Exploring the use of genomic testing to identify specific genetic mutations or rearrangements in the genome of blood cancer cells.', 'Discussing the emerging role of liquid biopsies', 'Exploring the use of immune-based therapies', 'Discussing the importance of prognostic and predictive biomarkers in blood cancer', 'the need for comprehensive molecular profiling, heterogeneity of cancer cells, and the cost and accessibility of targeted therapies.', 'Highlighting ongoing research efforts and clinical trials in personalized medicine for blood cancer', 'Details and definations of Supportive Care', 'Exploring common treatment-related side effects', 'Discussion on the Psychological Support for Cancer Patients', 'Discussing the importance of proper nutrition for cancer patients, addressing dietary challenges,', 'Exploring approaches to pain management in cancer patients', 'Discussing the development and implementation of survivorship care plans', 'Exploring the importance of fertility preservation options for cancer patients', 'Role of rehabilitation and physical therapy in cancer survivorship', 'Addressing the common fear of cancer recurrence among survivors', 'Recognizing the vital role of caregivers and family members in the support network of cancer patients', 'Exploring the potential long-term effects and complications', 'Discussing the increased risk of cardiovascular issues,', 'Exploring the phenomenon commonly referred to as ""chemo brain"" or ""cancer-related cognitive impairment,', 'Discussing the risk of developing secondary cancers', 'Exploring the potential impact of cancer treatments on the endocrine system', ""Addressing the overall impact of long-term effects and late complications on cancer survivors' quality of life.""], 'Current_Channel_of_interaction': ['email', 'In-Person', 'In-Person', 'email', 'Video', 'In-Person', 'Video', 'In-Person', 'Video', 'email', 'email', 'email', 'email', 'email', 'email', 'Video', 'Video', 'Video', 'In-Person', 'In-Person', 'Video', 'Video', 'email', 'email', 'In-Person', 'In-Person', 'email', 'Video', 'Video', 'Video', 'Video', 'In-Person', 'In-Person', 'In-Person', 'Video', 'Video', 'Video', 'Video', 'In-Person', 'In-Person'], 'Company_Event': ['Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer'], 'Interaction_intent': ['Discussion aspects of a survivor', 'General overview of lymphoma cancer, its definition, and its classification.', 'Discussing the two main types of lymphoma, namely Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), along with their subtypes, characteristics, and differences.', 'potential causes and risk factors associated with lymphoma, including genetic predisposition, viral infections (such as Epstein-Barr virus), immune system disorders, and environmental factors.', 'The common symptoms of lymphoma, such as enlarged lymph nodes, fatigue, night sweats, and unexplained weight loss. Additionally, discussing the diagnostic procedures used to identify and confirm lymphoma, such as biopsies, imaging tests, and blood tests.', 'Describing the staging system used for lymphoma to determine the extent and spread of the disease.', 'Treatment options available for lymphoma, including chemotherapy, radiation therapy, immunotherapy, targeted therapy, and stem cell transplantation.', 'Chemotherapy treatment for various types of cancer, including its mechanism of action, common drugs used, administration methods, and potential side effects.', 'Role of radiation therapy in cancer treatment, including its use for localized tumor control, different delivery techniques (e.g., external beam radiation, brachytherapy), and potential side effects.', 'Surgery as a treatment modality, including its role in tumor removal, lymph node dissection, reconstructive procedures, and potential risks and complications.', ""Exploring the field of immunotherapy, which harnesses the body's immune system to fight cancer."", ""Targeted therapy, which involves using drugs that specifically target cancer cells' unique features or vulnerabilities. Topics may include molecular targeted therapy, kinase inhibitors, and monoclonal antibodies."", 'Discussing the use of hormone blockers, hormone receptor modulators, and potential side effects.', 'Use of stem cell transplantation, such as autologous or allogeneic transplant, as a treatment modality for certain cancers, including the process, potential complications, and long-term effects.', 'Palliative care in cancer treatment, focusing on managing symptoms, improving quality of life, and providing emotional and psychological support for patients and their families.', 'Overview of personalized medicine and its application in the field of blood cancer', 'Role of molecular profiling techniques, such as next-generation sequencing, in identifying genetic mutations and alterations in blood cancer cells.', 'Targeted therapies that specifically target molecular abnormalities identified through molecular profiling.', 'Discussing how these tests help in treatment selection and predicting response to therapies.', 'Role of liquid biopsies, such as circulating tumor DNA (ctDNA) analysis, in monitoring treatment response, detecting minimal residual disease, and identifying resistance mechanisms in blood cancer.', 'Immune-based therapies, such as immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, or bispecific antibodies, in personalized treatment approaches for blood cancer.', 'Importance of prognostic and predictive biomarkers in blood cancer, such as gene mutations, gene expression profiles, or protein markers, to predict disease outcome and guide treatment decisions.', 'comprehensive molecular profiling, heterogeneity of cancer cells', 'Discussing emerging technologies, novel therapeutic targets, and potential advancements in treatment strategies.', 'Discussing the crucial role of supportive care in addressing the physical, emotional, and psychosocial needs of cancer patients throughout their treatment journey.', 'Common treatment-related side effects, such as nausea, pain, fatigue, and hair loss,', 'Highlighting the significance of addressing the emotional and psychological well-being of cancer patients through counseling, therapy, support groups, and other psychosocial interventions.', 'Discussing the importance of proper nutrition for cancer patients, addressing dietary challenges,', 'Use of medication, non-pharmacological interventions, and palliative care techniques to improve pain control and enhance quality of life.', 'Outline long-term follow-up care, monitoring for recurrence, managing late effects of treatment, and addressing the unique needs of cancer survivors.', 'Discussing available techniques, and highlighting the need for early discussions and referrals to fertility specialists.', 'Discussing the role of rehabilitation and physical therapy in cancer survivorship, focusing on restoring physical function, managing treatment-related impairments, and improving overall quality of life.', 'Providing strategies for coping with anxiety, incorporating mindfulness practices, and promoting mental well-being.', 'Discussing resources, support services, and self-care strategies to help them navigate the challenges they face.', 'Effects and complications that can arise as a result of cancer treatments, such as chemotherapy, radiation therapy, and surgery.', 'Risk of cardiovascular issues, such as heart disease, heart failure, and arrhythmias, as potential long-term effects of certain cancer treatments.', 'Discussing the cognitive changes and difficulties in memory, attention, and thinking that some cancer survivors may experience.', 'Risk of developing secondary cancers as a late complication of cancer treatment,', 'e potential impact of cancer treatments on the endocrine system, leading to hormone imbalances, thyroid dysfunction, or adrenal insufficiency, among others.', 'Discussing strategies to manage and cope with these challenges, and highlighting the importance of survivorship care and support services.'], 'Items/topics_to_exchange': ['aspects of a survivor', 'lymphoma cancer', 'Types & sub-types of Lymphoma', 'Exploring the potential causes and risk factors associated with lymphoma', 'Discussing the diagnostic procedures used to identify and confirm lymphoma, such as biopsies, imaging tests, and blood tests.', 'Discussing the factors that affect prognosis, including stage, subtype, age, and overall health.', 'Discussing the importance of individualized treatment plans based on factors like subtype and stage.', 'Discussing the aspects of Chemotherapy', 'Discussing the aspects of radiation therapy', 'Importance of surgery', 'Immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, and their potential benefits and side effects.', 'Different aspects of Targeted Therapy', 'Exploring hormonal therapy as a treatment option for hormone-sensitive cancers, such as breast or prostate cancer.', 'Exploring the use of stem cell transplantation', 'Details abot Palliative Care', 'Emphasizing the importance of individualized treatment approaches.', 'Discussing how these profiles guide treatment decisions', 'Highlighting examples of targeted therapies used in different types of blood cancers, such as tyrosine kinase inhibitors or monoclonal antibodies.', 'Exploring the use of genomic testing to identify specific genetic mutations or rearrangements in the genome of blood cancer cells.', 'Discussing the emerging role of liquid biopsies', 'Exploring the use of immune-based therapies', 'Importance of prognostic and predictive biomarkers in blood cancer', 'Challenges and limitations associated with personalized medicine in blood cancer', 'Highlighting ongoing research efforts and clinical trials in personalized medicine for blood cancer', 'Discussion on the crucial role of supportive care in the Cancer patient life', 'Discussing strategies and interventions to alleviate and manage these symptoms effectively.', 'Emotional and psychological well-being of cancer patients', 'Providing guidance on maintaining a healthy diet during and after treatment to support recovery and overall well-being.', 'Exploring approaches to pain management in cancer patients', 'Discussing the development and implementation of survivorship care plans', 'Exploring the importance of fertility preservation options for cancer patients', 'Focusing on restoring physical function, managing treatment-related impairments, and improving overall quality of life.', 'Focusing on restoring physical function, managing treatment-related impairments, and improving overall quality of life.', 'Recognizing the vital role of caregivers and family members in the support network of cancer patients', 'Effect of cancer on human body', 'Discussing the increased risk of cardiovascular issues,', 'Cognitive Dysfunction', 'Importance of long-term surveillance and screening for early detection.', 'potential impact of cancer treatments', ""Addressing the overall impact of long-term effects and late complications on cancer survivors' quality of life.""], 'KOLMSL_Relation': ['Good', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral'], 'Next_Action_Items': ['aspects of a survivor', 'Types of Lymphoma', 'Causes and Risk Factors', 'Symptoms and Diagnosis', 'Staging and Prognosis', 'Treatment Options of Lymphoma', 'Use of chemotherapy as a treatment', 'Discussing the role of radiation therapy in cancer treatment,', 'Importance of surgery as a treatment modality', 'Field of immunotherapy', 'Targeted Therapy', 'Hormonal Therapy', 'Stem Cell Transplantation', 'Palliative Care', 'Introduction to Personalized Medicine in Blood Cancer', 'Molecular Profiling in Blood Cancer', 'Targeted Therapies in Blood Cancer', 'Genomic Testing in Blood Cancer', 'Liquid Biopsies in Blood Cancer', 'Immunotherapy in Blood Cancer', 'Prognostic and Predictive Biomarkers', 'Challenges and limitations associated with personalized medicine in blood cancer', 'Future Perspectives and Clinical Trials', 'Importance of Supportive Care in Cancer Treatment', 'Managing Treatment Side Effects', 'Psychological Support for Cancer Patients', 'Nutritional Support during and after Cancer Treatment', 'Pain Management in Cancer', 'Survivorship Care Plans', 'Fertility Preservation', 'Rehabilitation and Physical Therapy', 'Managing Fear of Recurrence', 'Support for Caregivers and Family Members', 'Late Effects of Cancer Treatment', 'Cardiac Complications', 'Cognitive Dysfunction', 'Second Primary Cancers', 'Endocrine Dysfunction', 'Quality of Life and Survivorship', 'Gastrointestinal and Digestive Issues'], 'Proposed_Next_Channel_Of_interaction': ['email', 'In-Person', 'email', 'Video', 'In-Person', 'Video', 'In-Person', 'Video', 'email', 'In-Person', 'email', 'email', 'email', 'email', 'Video', 'Video', 'Video', 'In-Person', 'In-Person', 'Video', 'Video', 'email', 'email', 'In-Person', 'In-Person', 'email', 'Video', 'Video', 'Video', 'Video', 'In-Person', 'In-Person', 'In-Person', 'Video', 'Video', 'Video', 'Video', 'In-Person', 'In-Person', 'In-Person']}"
20,"{'kol': 'Micheal Smith', 'Interaction_Date': ['1-Apr-19', '1-May-19', '1-Jun-19', '1-Jul-19', '1-Aug-19', '1-Sep-19', '1-Oct-19', '1-Nov-19', '1-Dec-19', '1-Jan-20', '1-Feb-20', '1-Mar-20', '1-Apr-20', '1-May-20', '1-Jun-20', '1-Jul-20', '1-Aug-20', '1-Sep-20', '1-Oct-20', '1-Nov-20', '1-Dec-20', '1-Jan-21', '1-Feb-21', '1-Mar-21', '1-Apr-21', '1-May-21', '1-Jun-21', '1-Jul-21', '1-Aug-21', '1-Sep-21', '1-Oct-21', '1-Nov-21', '1-Dec-21', '1-Jan-22', '1-Feb-22', '1-Mar-22', '1-Apr-22', '1-May-22', '1-Jun-22', '1-Jul-22'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer'], 'KOL_years_of_Experience': [20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23], 'KOL_Location': ['New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey', 'New Jersey'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['11K', '11.1K', '11.3K', '11.4K', '11.5K', '11.7K', '11.8K', '11.8K', '11.9K', '12K', '11.8K', '12K', '12.2K', '12.3K', '12.5K', '13K', '13.2K', '13.3K', '13.5K', '13.6K', '13.7K', '13.8K', '14K', '14.3K', '14.5K', '14.5K', '14.6K', '14.6K', '14.6K', '14.6K', '14.6K', '14.6K', '14.6K', '14.7K', '14.7K', '14.7K', '14.7K', '14.7K', '15K', '15K'], 'SocialMedia_Linkedin': ['6K', '6.2K', '6.3K', '6.3K', '6.6K', '6.7K', '6.8K', '6.81K', '6.9K', '7K', '6.5K', '7K', '7.3K', '7.4K', '7.8K', '8K', '8.3K', '8.4K', '8.5K', '8.6K', '8.7K', '8.8K', '9K', '9.3K', '9.5K', '9.5K', '9.6K', '9.6K', '9.6K', '9.6K', '9.6K', '9.6K', '9.8K', '9.8K', '9.8K', '9.9K', '10K', '9.8K', '10K', '10K'], 'SocialMedia_YouTube': ['7K', '7.1K', '7.3K', '7.4K', '7.5K', '7.6K', '7.7K', '7.8K', '7.9K', '7.9K', '7.5K', '8K', '8.4K', '8.5K', '8.7K', '9K', '9.4K', '9.5K', '9.6K', '9.67K', '9.77K', '9.9K', '10.2K', '10.5K', '10.7K', '10.7K', '10.8K', '10.8K', '10.8K', '10.8K', '10.8K', '10.9K', '10.8K', '10.8K', '10.8K', '10.8K', '10.8K', '11K', '11K', '11K'], 'Overall_Kol_Rating': [3.7, 3.8, 3.82, 3.83, 3.9, 3.95, 4.0, 4.0, 4.1, 4.2, 4.17, 4.25, 4.26, 4.3, 4.4, 4.43, 4.5, 4.51, 4.52, 4.53, 4.6, 4.65, 4.67, 4.69, 4.57, 4.57, 4.58, 4.58, 4.56, 4.4, 4.3, 4.31, 4.32, 4.33, 4.35, 4.37, 4.5, 4.56, 4.6, 4.65], 'Connection_to_Advisory_Boards': [2, 2, 3, 3, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6], 'Research_Participated': [10, 12, 12, 14, 14, 17, 17, 17, 18, 19, 19, 20, 20, 21, 21, 22, 22, 23, 23, 23, 23, 23, 23, 24, 24, 24, 26, 26, 26, 27, 27, 28, 28, 28, 28, 28, 28, 29, 30, 30], 'Research_Experience': [5, 6, 6, 7, 7, 8, 8, 8, 9, 9, 9, 10, 10, 10, 10, 10, 10, 11, 11, 11, 11, 11, 11, 12, 12, 12, 13, 13, 14, 14, 15, 16, 16, 16, 16, 16, 17, 17, 17, 17], 'Fundinghistory_researchgrants': ['20000', '20000', '30000', '40000', '40000', '60000', '100000', '100000', '100000', '100000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '210000', '210000', '220000', '225000', '226000', '227000', '228000', '229000', '229000', '230000', '235000', '236000', '236000', '237000', '238000', '239000', '240000', '240000', '240000', '240000', '242000', '242000'], 'Fundinghistory_ConsultingFees': [0, 0, 30000, 100000, 200000, 360000, 360000, 360000, 360000, 370000, 370000, 370000, 370000, 370000, 370000, 370000, 380000, 380000, 380000, 380000, 390000, 395000, 395000, 396000, 397000, 398000, 398000, 399000, 399500, 400000, 400000, 410000, 420000, 430000, 430000, 435000, 436000, 437000, 438000, 438000], 'Fundinghistory_EducationalGrants': ['20000', '20000', '30000', '40000', '40000', '60000', '100000', '100000', '100000', '100000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '210000', '210000', '220000', '225000', '226000', '227000', '228000', '229000', '229000', '230000', '235000', '236000', '236000', '237000', '238000', '239000', '240000', '240000', '240000', '240000', '242000', '242000'], 'No_Of_Publications': [5, 6, 6, 7, 7, 8, 8, 9, 10, 11, 11, 12, 12, 13, 13, 14, 15, 15, 16, 16, 17, 17, 18, 18, 19, 19, 20, 20, 21, 21, 22, 22, 23, 23, 23, 24, 24, 24, 25, 25], 'Trainings_Delivered': [10, 11, 11, 12, 12, 13, 13, 13, 14, 14, 15, 15, 17, 17, 18, 18, 18, 19, 19, 20, 20, 21, 21, 22, 22, 23, 23, 23, 23, 24, 24, 24, 24, 25, 25, 25, 25, 25, 26, 26], 'Professional_Certification': [3, 3, 4, 4, 5, 5, 6, 6, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 9, 9, 9], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [0, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 0.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [0, 0, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'National_presentations_Presented': [5, 5, 6, 6, 7, 7, 8, 8, 9, 9, 10, 10, 10, 11, 11, 11, 12, 12, 12, 13, 13, 13, 14, 14, 15, 15, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 17, 17, 17], 'KOL_FollowUp': ['No', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Discussion about new medical asset generation event happening', 'How this event can be a great opportunity for healthcare professionals and others', 'How this event can be an exciting prospect for medical field', 'Discussion about how these events can address pressing healthcare challenges', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'Discuss about how these events have potential for collaboration between academia and industry', 'How collaborative environment can address ethical and regulatory aspects of medical asset generation', 'To discuss about how these events can provide a platform for discussion on regulatory frameworks and IP rights', 'How these events can revolutionize healthcare', 'Discuss about key note speeches', 'Networking oppurtunities and programs', 'About what kind of research presentations will be conducted and what kind of researchers will be there', 'Various workshops and training sessions', 'Startup pitch competitions', 'Collaborative appoarches to asset generation in key note speeches', 'Risk management and mitigation in asset generation in key note speeches', 'Data Driven Decision making in asset generation in key note speeches', 'Innovative financing models in key note speeches', 'Ethical Considerations in asset generation in key note speeches', 'Future trends in medical asset generation in key note speeches', 'Comparitive Analysis of medical asset acquisition models in research presentations', 'Optimization of medical asset utilization through data analytics in research presentations', 'Impact of collaborative partnerships on medical asset generation', 'Sustainable practice in medical asset generation in research presentations', 'Implementation of technology in medical asset management in research presentations', 'Evaluation of training programs for medical asset management', 'Financial Analysis of medical asset generation in research presentations', 'Role of regulatory compliance in medical asset generation in research presentations', 'Future trends and innovations in medical asset generations in research presentations', 'Problem identification in startup pitch competition', 'Innovative medical asset solutions in medical asset generation event', 'Market potential and target audience in startup pitch competitions', 'Unique value proposition in medical asset generation', 'Business model and revenue generation', 'Scalability and growth potential', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Team Expertise and execution plan in start up pitch competitions', 'Regulatory and compliance considerations in startup pitch competitions', 'Impact and sustainability in startup pitch competitons', 'Digital Health Innovations in stratup pitch competitions'], 'Previous_Meeting_SubTopics': ['Event details,agenda', 'Colloboration,opportunity', 'Rapid advancement in technology,increasing demand for innovative solutions', 'Exchange of ideas,knowledge and expertise', 'Usability,safety and accessibility', 'Collaboration,bridging the gap', 'Adherence to rigourous safety standards,ethical guidelines and applicable regulations', 'Regulatory frameworks,intellectual property rights and responsible innovation', 'Collaboration,interdisciplinary approaches and patient centric design,quality of care and well being', 'Speeches topic,speakers invited', 'Collaboration,networking', 'Research presentations,researchers', 'Workshops,training programs and study sessions', 'Startup pitches,asset show ups,judges reviews', 'collaborative models and partnerships between healthcare organizations,technology providers', 'Issues related to patient safety,regulatory compliance,financial implications and operational challenges', 'Role of data analytics,predictive modeling and machine learning in making informed decisions', 'Leasing,public-private partnerships and value based reimbursement models', 'Equitable access to healthcare resources,fair distribution of assets and responsible disposal of equipment', 'Digital health innovations,IoT,integration and personalize medicine', 'Purchasing,leasing or share resource agreements and present research findings', 'Utilization of medical assets,including equipment scheduling,maintainence planning and resource allocation,with aim of imporiving operational efficiency', 'Impact of collaborative partnerships between healthcare organizations,manufacturers', 'Sustainable practices in medical asset generation,including environment friendly procurement,energy-efficient equipment', 'IOT,RFID,asset management .Impact of technology on asset tracking,maintainence and optimization', 'Asset utilization,maintainence practices and overall operational efficiency', 'Total cost of ownership,return on investment and cost-benefit analysis of various asset acquisition and management strategies', 'Standards for equipment safety,quality control and legal requirements', 'Robotics,ai,advanced imaging techniques and virtual reality', 'High cost,limited access,equipment maintainence or supply chain bottlenecks', 'Technologies,software programs or business models', 'Target audience such as hospitals,clincics,research facilities and healthcare organizations', 'Solution stand out,competitive advantage', 'Pricing strategies,potential partnerships and revenue streams', 'Expansion plans,target markets beyond the initial launch', 'Patents,trademarks or proprietary technologies', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal', 'Patient safety,operational efficiency and cost savings', 'Mobile apps,wearables or remote devices to improve heakthcare delivery'], 'Current_Discussion_Topic': ['How this event can be a great opportunity for healthcare professionals and others', 'How this event can be an exciting prospect for medical field', 'Discussion about how these events can address pressing hralthcare challenges', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'Discuss about how these events have potential for collaboration between academia and industry', 'How collaborative environment can address ethical and regulatory aspects of medical asset generation', 'To discuss about how these events can provide a platform for discussion on regulatory frameworks and IP rights', 'How these events can revolutionize healthcare', 'Discuss about key note speeches', 'Networking oppurtunities and programs', 'About what kind of research presentations will be conducted and what kind of researchers will be there', 'Various workshops and training sessions', 'Startup pitch competitions', 'Collaborative appoarches to asset generation in key note speeches', 'Risk management and mitigation in asset generation in key note speeches', 'Data Driven Decision making in asset generation in key note speeches', 'Innovative financing models in key note speeches', 'Ethical Considerations in asset generation in key note speeches', 'Future trends in medical asset generation in key note speeches', 'Comparitive Analysis of medical asset acquisition models in research presentations', 'Optimization of medical asset utilization through data analytics in research presentations', 'Impact of collaborative partnerships on medical asset generation', 'Sustainable practice in medical asset generation in research presentations', 'Implementation of technology in medical asset management in research presentations', 'Evaluation of training programs for medical asset management', 'Financial Analysis of medical asset generation in research presentations', 'Role of regulatory compliance in medical asset generation in research presentations', 'Future trends and innovations in medical asset generations in research presentations', 'Problem identification in startup pitch competition', 'Innovative medical asset solutions in medical asset generation event', 'Market potential and target audience in startup pitch competitions', 'Unique value proposition in medical asset generation', 'Business model and revenue generation', 'Scalability and growth potential', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Team Expertise and execution plan in start up pitch competitions', 'Regulatory and compliance considerations in startup pitch competitions', 'Impact and sustainability in startup pitch competitons', 'Digital Health Innovations in stratup pitch competitions', 'Health Tech Infrastructure'], 'Current_Meeting_Subtopics': ['Colloboration,opportunity', 'Rapid advancement in technology,increasing demand for innovative solutions', 'Exchange of ideas,knowledge and expertise', 'Usability,safety and accessibility', 'Collaboration,bridging the gap', 'Adherence to rigourous safety standards,ethical guidelines and applicable regulations', 'Regulatory frameworks,intellectual property rights and responsible innovation', 'Collaboration,interdisciplinary approaches and patient centric design,quality of care and well being', 'Speeches topic,speakers invited', 'Collaboration,networking', 'Research presentations,researchers', 'Workshops,training programs and study sessions', 'Startup pitches,asset show ups,judges reviews', 'collaborative models and partnerships between healthcare organizations,technology providers', 'Issues related to patient safety,regulatory compliance,financial implications and operational challenges', 'Role of data analytics,predictive modeling and machine learning in making informed decisions', 'Leasing,public-private partnerships and value based reimbursement models', 'Equitable access to healthcare resources,fair distribution of assets and responsible disposal of equipment', 'Digital health innovations,IoT,integration and personalize medicine', 'Purchasing,leasing or share resource agreements and present research findings', 'Utilization of medical assets,including equipment scheduling,maintainence planning and resource allocation,with aim of imporiving operational efficiency', 'Impact of collaborative partnerships between healthcare organizations,manufacturers', 'Sustainable practices in medical asset generation,including environment friendly procurement,energy-efficient equipment', 'IOT,RFID,asset management .Impact of technology on asset tracking,maintainence and optimization', 'Asset utilization,maintainence practices and overall operational efficiency', 'Total cost of ownership,return on investment and cost-benefit analysis of various asset acquisition and management strategies', 'Standards for equipment safety,quality control and legal requirements', 'Robotics,ai,advanced imaging techniques and virtual reality', 'High cost,limited access,equipment maintainence or supply chain bottlenecks', 'Technologies,software programs or business models', 'Target audience such as hospitals,clincics,research facilities and healthcare organizations', 'Solution stand out,competitive advantage', 'Pricing strategies,potential partnerships and revenue streams', 'Expansion plans,target markets beyond the initial launch', 'Patents,trademarks or proprietary technologies', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal', 'Patient safety,operational efficiency and cost savings', 'Mobile apps,wearables or remote devices to improve heakthcare delivery', 'Robust health tech infrastructure,secure data storage or telecommnunication networks'], 'Current_Channel_of_interaction': ['In Person', 'In Person', 'In Person', 'Video', 'Video', 'Email', 'In Person', 'In Person', 'Email', 'Phone', 'In Person', 'Email', 'In Person', 'Phone', 'Email', 'Phone', 'Email', 'In Person', 'Email', 'In Person', 'Phone', 'In Person', 'Email', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'Email', 'Phone', 'Email', 'InPerson', 'Email', 'Phone', 'In Person', 'Phone', 'Email'], 'Company_Event': ['Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions'], 'Interaction_intent': ['Discuss how it is a great opporutnity for healthcare professionals and innovators to colloborate and generate new medical assets', 'With the rapid advancement in technology and increasing demand for innnovative solutions,events play a crucial role in fostering collaboration and driving progress', 'Events bring experts from various fields.The exchange of ideas,knowledge and expertise can spark innovation and accelerate creation of new medical assets', 'To discuss about new medical assets or technologies should meet the needs of healthcare patients and providers.Usability,safety and accessibility shoul be taken care of', 'Discuss about how these events have potential for collaboration between academia and industry where researchers,scientist and engineers can collaborate and bridge the gap between theoretical advancements and practical implementations', 'To discuss about these events should address the regulatory and ethical aspects of medical asset generation before they reach the market', 'Event like this can provide a platform for discussions on regulatory frameworks,intellectual property rights and responsible innovation ensuring development of new assets is not only innovative but also accountable', 'Discuss about how these events can bring collaboration,interdisciplinary approaches and focus on patient centric can lead to medical asset generation that can revolutionize healthcare', 'To get overview of speakers or speeches that would be there in the event', 'Throw light on how these events can become a medium for collaboration with like minded people', ""To get overview of what kind of research presentations will be conducted and researcher's background"", 'To discuss about various workshops and training session that will be conducted and how it will help the people attending that event', 'To discuss about various workshops and training session that will be conducted and how it will help the people attending that event', 'Explore collaborative models- and partnerships between healthcare organizations,technology providers,manufacturers and regulatory bodies to optimize asset generation processes,improve efficiency and foster innovation', 'To discuss about strategies for identifying and mitigating risks associated with medical asset generation,including issues related to patient safety,regulatory compliance,financial implications and operational challenges', 'To discuss the role of data analytics,predictive modeling and machine learning in making informed decisions regarding medical asset acquisition,utilization,maintainence and replacement', 'Explore alternative financing models and strategies for medical asset generation such as leasing,public-private partnership and value based reimbursment models', 'To address the issues social responsibility,sustainability and ethical implications of resource allocation', 'To discuss the potential impact of these trends on healthcare delivery,asset management and patient care', 'To discuss about comparing different models for medical asset acquisition,such as purchasing,leasing or share resource agreements on their cost effectiveness,efficiency', 'To discuss about research study that utilizes data analytics techniques to optimize utilization of medical assets', 'To discuss about benefits,challenges and outcome of partnerships', 'To discuss the enviromental impact and cost-effectiveness of adopting sustainable practices in healthcare settings', 'To discuss the impact of technology on asset tracking,maintenence and optimization', 'To discuss about effectiveness of training programs in improving asset utilization,maintainence practices and overall operational efficiency', 'To discuss about insights into optimizing financial outcomes in medical asset generation', 'To discuss about research findings on the impact of compliance on asset acquisition,utilization and patient safety outcomes', 'To discuss about potential impact of innovation on healthcare deliveryv,asset management and patient care', 'To discuss about emphasizing the need for innovative solutions to address these problems', 'To discuss about startups giving pitches that offer innovative solutions to improve medical asset generation', 'To discuss about the market research and insights of the demand,competition and growth prospects for the proposed solutions', 'To discuss how a particular solution offers and addresses specifica pain points in asset generation', 'To discuss about the business models of the startups and their plans for revenue generation', 'To discuss the expansion plans,target markets beyond the initial launc,and the ability to adapt the solution to different healthcare or geographic locations', 'To discuss about any patents,trademarks or proprietary technologies that provide a competitive advantage and barriers to entry to potential competitors', ""To discuss about team's execution plans,milestones and strategies for market penetration,customer acquisition and product development"", 'To discuss how the startup ensure adherance to regulatory standards,certifications and any potential legal or ethical implications', 'To emphasize on the sustainability aspect of the solutions,such as reducing waste,energy efficiency or environmental considerations', 'To discuss about startups that leverage digital health technologies such as mobile apps,wearable or remote devices to improve haleathcare delivery', 'To discuss about startups that focus on robust health tech infrastructure including data storage,interoperability solutions to enable seamless healthcare data exchange and communication'], 'Items/topics_to_exchange': ['Colloboration,opportunity', 'Technology,Collaboration,driving progress', 'Exchange of ideas,knowledge and expertise,address challenges', 'Usability,safety and accessibility,demand of healthcare patients and providers', 'Collaboration,bridging the gap', 'Rigorous safety,ethical guidelines and applicable regulations', 'Regulatory frameworks,intellectual property rights and responsible innovation,innovation', 'Collaboration,interdisciplinary approaches and patient centric design,quality of care and well being', 'Speeches topic,speakers invited', 'Collaboration,networking and connects', 'Research presentations,researchers', 'Workshops,training programs and study sessions', 'Startup pitches,asset show ups,reviews', 'collaborative models and partnerships between healthcare organizations,technology providers', 'collaborative models and partnerships between healthcare organizations,technology providers', 'Role of data analytics,predictive modeling and machine learning in making informed decisions', 'Leasing,public-private partnerships and value based reimbursement models.Discuss benefits and challenges of each approach and share examples of successful implementations', 'Equitable access to healthcare resources,fair distribution of assets and responsible disposal of equipment', 'Digital health innovations,IoT,integration and personalize medicine', 'Purchasing,leasing or share resource agreements and present research findings', 'Utilization of medical assets,including equipment scheduling,maintainence planning and resource allocation,with aim of imporiving operational efficiency', 'Impact of collaborative partnerships between healthcare organizations,manufacturers', 'Sustainable practices in medical asset generation,including environment friendly procurement,energy-efficient equipment', 'IOT,RFID,asset management .Impact of technology on asset tracking,maintainence and optimization', 'Asset utilization,maintainence practices and overall operational efficiency', 'Asset utilization,maintainence practices and overall operational efficiency', 'Standards for equipment safety,quality control and legal requirements', 'Robotics,ai,advanced imaging techniques and virtual reality', 'High cost,limited access,equipment maintainence or supply chain bottlenecks', 'Technologies,software programs or business models', 'Technologies,software programs or business models', 'Solution stand out,competitive advantage', 'Pricing strategies,potential partnerships and revenue streams', 'Expansion plans,target markets beyond the initial launch', 'Patents,trademarks or proprietary technologies', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal imlications', 'Patient safety,operational efficiency and cost savings', 'Mobile apps,wearables or remote devices to improve heakthcare delivery,patient engagement', 'Robust health tech infrastructure,secure data storage or telecommnunication networks'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral'], 'Next_Action_Items': ['How this event can be an exciting prospect for medical field', 'Discussion about how these events can address pressing healthcare challenges', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'Discuss about how these events have potential for collaboration between academia and industry', 'How collaborative environment can address ethical and regulatory aspects of medical asset generation', 'To discuss about how these events can provide a platform for discussion on regulatory frameworks and IP rights', 'How these events can revolutionize healthcare', 'Development of impactful medical assets', 'Discussion about how these events can address pressing healthcare challenges', 'How connections can help people', 'Startup pitch competition', 'Marketing startegy', 'Topic about key note speeches', 'Data Driven Decision making in asset generation', 'Marketing startegy', 'How these events can revolutionize healthcare', 'How connections can help people', 'How these events can revolutionize healthcare', 'Startup pitch competition', 'Topic about key note speeches', 'Data Driven Decision making in asset generation', 'How connections can help people', 'To discuss about how these events can provide a platform for discussion on regulatory frameworks and IP rights', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'Discussion about how these events can address pressing healthcare challenges', 'Marketing startegy', 'Discussion about how these events can address pressing healthcare challenges', 'How these events can revolutionize healthcare', 'Topic about key note speeches', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'Future trends in asset generation', 'How connections can help people', 'How these events can revolutionize healthcare', 'Financial Analysis of medical asset generation in research presentations', 'Regulatory frameworks,intellectual property rights and responsible innovation', 'Networking oppurtunities and programs', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Technical Feasibility and Intellectual Property in start up pitch competitions', 'Team Expertise and execution plan in start up pitch competitions'], 'Proposed_Next_Channel_Of_interaction': ['In Person', 'In Person', 'Video', 'Video', 'Email', 'In Person', 'In Person', 'Email', 'In Person', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'Email', 'In Person', 'Phone', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'Phone', 'Email', 'In Person', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'In Person', 'Phone', 'Email', 'Phone']}"
21,"{'kol': 'Michelle Fox', 'Interaction_Date': ['22-Apr-19', '1-May-19', '15-May-19', '2-Jun-19', '4-Jun-19', '12-Jun-19', '14-Jul-19', '1-Aug-19', '31-Oct-19', '17-Nov-19', '6-Dec-19', '15-Jan-20', '7-Feb-20', '30-Mar-20', '17-Apr-20', '25-Apr-20', '7-May-20', '12-Jun-20', '27-Jul-20', '2-Aug-20', '13-Sep-20', '19-Oct-20', '6-Nov-20', '22-Dec-20', '30-Dec-20', '3-Jan-21', '28-Jan-21', '5-Feb-21', '28-Feb-21', '7-Mar-21', '29-Mar-21', '18-Apr-21', '2-May-21', '23-May-21', '1-Jun-21', '20-Jul-21', '12-Aug-21', '15-Aug-21', '3-Sep-21', '24-Oct-21'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer'], 'KOL_years_of_Experience': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7], 'KOL_Location': ['New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City', 'New York City'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['8K', '20K', '25K', '30K', '30K', '29K', '29K', '32K', '35K', '35K', '35K', '35K', '38K', '38K', '38K', '38K', '38K', '38K', '37K', '37K', '37K', '37K', '37K', '40K', '40K', '40K', '40K', '40K', '40K', '39K', '39K', '40K', '41K', '41K', '41K', '41K', '44K', '45K', '46K', '46K'], 'SocialMedia_Linkedin': ['10K', '15K', '17k', '20K', '20K', '20K', '20K', '21K', '22K', '24K', '25K', '25K', '25K', '28K', '28K', '28K', '28K', '28K', '28K', '28K', '29K', '29K', '29K', '30K', '30K', '30K', '30K', '30K', '30K', '31K', '32K', '32K', '32K', '35K', '35K', '35K', '35K', '35K', '35K', '35K'], 'SocialMedia_YouTube': ['15K', '14K', '16K', '21K', '22K', '22K', '22K', '25K', '25K', '25K', '27K', '27K', '27K', '27K', '29K', '29K', '29K', '29K', '29K', '29K', '29K', '29K', '29K', '31K', '31K', '31K', '31K', '33K', '33K', '33K', '33K', '33K', '33K', '32K', '32K', '32K', '32K', '30K', '30K', '30K'], 'Overall_Kol_Rating': [3.7, 4.0, 3.8, 3.9, 3.9, 4.0, 3.8, 3.8, 4.1, 4.1, 3.8, 3.9, 3.9, 4.0, 3.8, 3.8, 4.1, 3.8, 3.9, 3.9, 4.0, 3.8, 3.8, 4.1, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.1, 4.2, 4.3, 4.3, 4.3, 4.3, 4.5, 4.5, 4.5], 'Connection_to_Advisory_Boards': [2, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6], 'Research_Participated': [6, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10], 'Research_Experience': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 5, 5, 5, 5, 6, 6, 6], 'Fundinghistory_researchgrants': ['50000', '55000', '55500', '55000', '55000', '60000', '62000', '62000', '65000', '65000', '68000', '70000', '72000', '72000', '72000', '72000', '72000', '72000', '74000', '74000', '74000', '74000', '74000', '76000', '76000', '76000', '76000', '76000', '76000', '76000', '76000', '81000', '84000', '85000', '88000', '89000', '90000', '92000', '95000', '96000'], 'Fundinghistory_ConsultingFees': [200, 200, 220, 200, 200, 200, 225, 225, 225, 250, 250, 250, 250, 250, 250, 250, 250, 250, 275, 275, 275, 275, 275, 275, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 300, 400, 400, 400], 'Fundinghistory_EducationalGrants': ['50000', '55000', '55500', '55000', '55000', '60000', '62000', '62000', '65000', '65000', '68000', '70000', '72000', '72000', '72000', '72000', '72000', '72000', '74000', '74000', '74000', '74000', '74000', '76000', '76000', '76000', '76000', '76000', '76000', '76000', '76000', '81000', '84000', '85000', '88000', '89000', '90000', '92000', '95000', '96000'], 'No_Of_Publications': [2, 3, 3, 3, 3, 3, 4, 4, 5, 5, 5, 5, 5, 5, 6, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 9, 9, 9, 9, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19], 'Trainings_Delivered': [10, 10, 10, 12, 12, 12, 13, 13, 13, 14, 14, 14, 14, 15, 15, 15, 15, 15, 15, 16, 16, 16, 16, 17, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18], 'Professional_Certification': [3, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 8, 9, 10, 10, 10, 10, 10], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'International_Presentations_Presented': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7], 'National_presentations_Presented': [50, 50, 50, 50, 50, 50, 50, 50, 50, 50, 50, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 70, 70, 70, 70, 70, 70, 70, 70, 70, 70, 70, 70, 70, 70, 70], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes'], 'Previous_meeting_agenda': ['No', 'Reality for blood cell cancers', 'How we can save our body via Blood cancer', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Non-Pharmacologic Approaches to overcome with the cancer side effects', 'Introduction of Multidisciplinary care (MDC)', 'Benefits of Multidisciplinary care (MDC) teams', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Is Stage 4 lymphoma curable?', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Prevention or reduction of treatment toxicities', 'Strategy for Implementation of Supportive Care Within Cancer Care'], 'Previous_Meeting_SubTopics': ['No', 'How blood cancer starts', 'How we can fight with blood cancer', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Non-Pharmacologic Approaches', 'Multidisciplinary care (MDC)', 'Inroduction of MDC teams', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Trying to understand the risk stages of lymphoma cancer', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'How to prevent treatent toxicities', 'Focuses on Strategy for Implementation of Supportive Care'], 'Current_Discussion_Topic': ['Personalized medicine (PM) or precision medicine in oncology', 'How we can save our body via Blood cancer', ""Discussion about Do and don't if you are suffering via Blood cancer"", 'Is lymphoma a serious cancer?', 'Medical treatement of lymphona cancer', 'Causes of Lymphoma Cancer', 'What is Supportive Care Services', 'What is Lymphedema Management', 'Introduction of Advances in Diagnostic Techniques\u200b\u200b of blood cancer', 'Positron Emission Tomography (PET)', 'Personalized medicine (PM) or precision medicine in oncology', 'Development of cancer therapies', 'Surgical Approaches to Reduce Lymphedema', 'Long term side effects of treatment for acute lymphoblastic leukaemia', 'How we can overcome with the cancer side effects', 'Non-Pharmacologic Approaches to overcome with the cancer side effects', 'Introduction of Multidisciplinary care (MDC)', 'Benefits of Multidisciplinary care (MDC) teams', 'Requirements for an effective multidisciplinary team', 'the current situation of multidisciplinary team in the middle east', 'Which MDT models and configurations lead to optimal patient outcomes?', ""What is Hodgkin's lymphoma"", ""What is Non-Hodgkin's lymphoma"", 'Signs and symptoms of lymphoma', 'Factors that can increase the risk of lymphoma', 'Is lymphoma a serious cancer?', 'Is Stage 4 lymphoma curable?', 'What is the effect of lymphoma on the lymphocytes', 'How is lymphoma diagnosed?', 'How can I reduce my risk of developing lymphoma?', 'What can I expect if I have lymphoma?', 'What are the survival rates for lymphoma', 'Precision or personalize medicine in cancer care', 'Types of cancer where precision medicine is used', 'Limitations to precision medicine in cancer', 'Costs of precision medicine in cancer care', 'Principles of Supportive Care', 'Prevention or reduction of treatment toxicities', 'Strategy for Implementation of Supportive Care Within Cancer Care', 'Emerging therapies and Clinical Trials\u200b\u200b'], 'Current_Meeting_Subtopics': ['Personalized medicine (PM) or precision medicine in oncology', 'How we can fight with blood cancer', 'What are the precationary measure of blood cancer', 'Details about the Lyphoma cancer', 'Treatment of Lyphoma cancer', 'Details about the Lyphoma cancer', 'What are the things to keep in mind to help cancer survivors', 'Details about the Lyphedema management and Therpy', 'Technology advacement in the detection of blood cancer', 'How PET techinque is effective to detect cancer', 'How personalized medicine can help in cancer treatment', 'Details about the Cancer therpies', 'How Surgical Approaches are useful to Reduce Lymphedema', 'side effects of treatment for acute lymphoblastic leukaemia', ""What are the do and don'ts to overcome with the side effects of cancer"", 'Non-Pharmacologic Approaches', 'Multidisciplinary care (MDC)', 'Inroduction of MDC teams', 'Why we need MD teams', 'Scenerio of MDT in middle east', 'Which model of Multidisciplinary give optimal patient outcome', ""Details about Hodgkin's lymphoma"", ""Detils on Non-Hodgikin's lymphoma"", 'How you can detect Lymphoma by symptoms', 'Risk factors of Lymphoma', 'How deadly cancer is Lymphoma', 'Trying to understand the risk stages of lymphoma cancer', 'Impact of lymphoma on blood cells', 'Diagonasis of Lymphoma Cancer', 'How to reduce the risk of cancer', 'what you can expect after completing treatment', 'Survival rates for lymphoma', 'Details on Personalize medicines', 'Trying to understand in which cancer we can use precision medicine', 'What are the Limitations to precision medicine in cancer', 'Costs of precision medicine', 'Key points of supportive care', 'How to prevent treatent toxicities', 'Focuses on Strategy for Implementation of Supportive Care', 'Emerging therapies and Clinical Trials\u200b\u200b in blood cancer'], 'Current_Channel_of_interaction': ['In-Person', 'In-Person', 'In-Person', 'Video', 'Video', 'Video', 'In-Person', 'Video', 'Video', 'In-Person', 'In-Person', 'In-Person', 'Video', 'Video', 'Video', 'In-Person', 'In-Person', 'In-Person', 'In-Person', 'In-Person', 'In-Person', 'Video', 'Video', 'Video', 'Video', 'In-Person', 'In-Person', 'email', 'email', 'email', 'phone', 'phone', 'phone', 'In-Person', 'In-Person', 'Video', 'email', 'phone', 'In-Person', 'Video'], 'Company_Event': ['Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer'], 'Interaction_intent': ['To get information of the drug', 'Precautions from Blood Cancer', ""Do and Don'ts in blood Cancer"", 'Awareness on lymphoma cancer', 'Precautions from Lymphoma Cancer', 'Details On Lymphoma \n Cancer', 'Supportive Care services', 'How we can help lymphedema patients', 'Details of Diagnostic techiques', 'PET techinque', 'Personalized medicine (PM)', 'Development of cancer therapies', 'How Surgical Approaches are useful to Reduce Lymphedema', 'side effects of treatment for acute lymphoblastic leukaemia', 'side effects after the cancer treatment', 'Non-Pharmacologic Approaches', 'Introduction of Multidisciplinary care (MDC)', 'Benefits of Multidisciplinary care (MDC) teams', 'Requirements for an effective multidisciplinary team', 'What is the status of MDT in middle east', 'Focus on the optimal patient outcome', ""Details about Hodgkin's lymphoma"", ""What is Non-Hodgkin's lymphoma"", 'How you can detect Lymphoma by symptoms', 'Risk factors of Lymphoma', 'Seriousness of Lymphoma Cancer', 'Trying to understand the risk stages of lymphoma cancer', 'How Lymphoma impacted on blood cells', 'Detection of Lymphoma cancer', 'How to reduce the risk of cancer', 'what you can expect after completing treatment', 'Survival rates for lymphoma', 'Details on Personalize medicines', 'Trying to understand in which cancer we can use precision medicine', 'Details on Limitations to precision medicine in cancer', 'How precision medicine cost varies', 'Key points of supportive care', 'Reduction of treatment toxicities', 'Strategy for Implementation of Supportive Care Within Cancer Care', 'Different types of Emerging therapies and Clinical Trials\u200b\u200b in blood cancer'], 'Items/topics_to_exchange': ['Introduction and overview of medicines', 'Information about Blood Cancer', 'Precautions in blood cancer', 'Details about the Lyphoma cancer', 'Details about the Lyphoma cancer', 'What are the causes of lyphoma cancer', 'Details on Supportive Care services', 'Lyphedema management', 'Technology advacement in the detection of blood cancer', 'How PET techinque is effective', 'How personalized medicine can help in cancer treatment', 'Details about the Cancer therpies', 'How Surgical Approaches are useful to Reduce Lymphedema', 'lymphoblastic leukaemia', 'Side effects of cancer', 'Non-Pharmacologic Approaches', 'Introduction of Multidisciplinary care (MDC)', 'Benefits of Multidisciplinary care (MDC) teams', 'Requirements for an effective multidisciplinary team', 'Scenerio of MDT in middle east', 'Which model of Multidisciplinary give optimal patient outcome', ""Hodgkin's lymphoma"", ""Non-Hodgikin's lymphoma"", 'Signs and symptoms of lymphoma', 'Factors that can increase the risk of lymphoma', 'How deadly cancer is Lymphoma', 'Is Stage 4 lymphoma curable?', 'Effect of lymphoma on the lymphocytes', 'How is lymphoma diagnosed?', 'How can I reduce my risk of developing lymphoma?', 'What can I expect if I have lymphoma?', 'What are the survival rates for lymphoma', 'Precision or personalize medicine in cancer care', 'Types of cancer where precision medicine is used', 'Limitations to precision medicine in cancer', 'Costs of precision medicine', 'What are the various points which can define the supportive care', 'Prevention or reduction of treatment toxicities', 'Strategy for Implementation of Supportive Care', 'Emerging therapies and Clinical Trials\u200b\u200b'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Neutral', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good'], 'Next_Action_Items': ['Discuss about the effect of medicines', ""Discussion about Do and don't if you are suffering via Blood cancer"", 'Is lymphoma a serious cancer?', 'Medical treatement of lymphona cancer', 'Causes of Lymphoma Cancer', 'What is Supportive Care Services', 'What is Lymphedema Management', 'Introduction of Advances in Diagnostic Techniques\u200b\u200b of blood cancer', 'Positron Emission Tomography (PET)', 'Personalized medicine (PM) or precision medicine in oncology', 'Development of cancer therapies', 'Surgical Approaches to Reduce Lymphedema', 'Long term side effects of treatment for acute lymphoblastic leukaemia', 'How we can overcome with the cancer side effects', 'Non-Pharmacologic Approaches to overcome with the cancer side effects', 'Multidisciplinary care (MDC)', 'benefits of Multidisciplinary care (MDC) teams', 'Requirements for an effective multidisciplinary team', 'the current situation of multidisciplinary team in the middle east', 'Which MDT models and configurations lead to optimal patient outcomes?', ""What is Hodgkin's lymphoma"", ""What is Non-Hodgkin's lymphoma"", 'Signs and symptoms of lymphoma', 'Factors that can increase the risk of lymphoma', 'Is lymphoma a serious cancer?', 'Is Stage 4 lymphoma curable?', 'What is the effect of lymphoma on the lymphocytes', 'How is lymphoma diagnosed?', 'How can I reduce my risk of developing lymphoma?', 'What can I expect if I have lymphoma?', 'What are the survival rates for lymphoma', 'Precision or personalize medicine in cancer care', 'Types of cancer where precision medicine is used', 'Limitations to precision medicine in cancer', 'Costs of precision medicine in cancer care', 'Principles of Supportive Care', 'Prevention or reduction of treatment toxicities', 'Strategy for Implementation of Supportive Care Within Cancer Care', 'Emerging therapies and Clinical Trials\u200b\u200b', 'Collaborative Approaches and Multidisciplinary Care\u200b\u200b'], 'Proposed_Next_Channel_Of_interaction': ['In-Person', 'In-Person', 'Video', 'Video', 'Video', 'In-Person', 'Video', 'Video', 'In-Person', 'In-Person', 'In-Person', 'Video', 'Video', 'Video', 'In-Person', 'In-Person', 'In-Person', 'In-Person', 'In-Person', 'In-Person', 'Video', 'Video', 'Video', 'Video', 'In-Person', 'In-Person', 'email', 'email', 'email', 'phone', 'phone', 'phone', 'In-Person', 'In-Person', 'Video', 'email', 'phone', 'In-Person', 'Video', 'email']}"
22,"{'kol': 'Patrick Simmons', 'Interaction_Date': ['1-Apr-19', '1-May-19', '1-Jun-19', '1-Jul-19', '1-Aug-19', '1-Sep-19', '1-Oct-19', '1-Nov-19', '1-Dec-19', '1-Jan-20', '1-Feb-20', '1-Mar-20', '1-Apr-20', '1-May-20', '1-Jun-20', '1-Jul-20', '1-Aug-20', '1-Sep-20', '1-Oct-20', '1-Nov-20', '1-Dec-20', '1-Jan-21', '1-Feb-21', '1-Mar-21', '1-Apr-21', '1-May-21', '1-Jun-21', '1-Jul-21', '1-Aug-21', '1-Sep-21', '1-Oct-21', '1-Nov-21', '1-Dec-21', '1-Jan-22', '1-Feb-22', '1-Mar-22', '1-Apr-22', '1-May-22', '1-Jun-22', '1-Jul-22'], 'Current_Tier': ['Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional'], 'KOL_Qualification': ['MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD', 'MD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer', 'Skin Cancer'], 'KOL_years_of_Experience': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8], 'KOL_Location': ['New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York', 'New York'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['20K', '20.3K', '20.6K', '20.9K', '21K', '21.3K', '21.8K', '22K', '22.4K', '22.6K', '22.7K', '22.9K', '23K', '23.3K', '23.8K', '24K', '24.2K', '24.4K', '24.8K', '25K', '25.2K', '25.3K', '25.7K', '25.7K', '25.8K', '26K', '26K', '26K', '26K', '26.2K', '26.3K', '26.3K', '26.3K', '27K', '27.3K', '27.7K', '27.9K', '28K', '28.2K', '30K'], 'SocialMedia_Linkedin': ['20K', '20.5K', '20.7K', '21K', '21.3K', '21.5K', '21.9K', '22.4K', '22.9K', '23K', '23.3K', '23.5K', '23.9K', '24K', '24.4K', '24.8K', '25K', '25.2K', '25.3K', '25.6K', '25.8K', '26K', '26.5K', '26.5K', '26.7K', '26.8K', '26.8K', '26.8K', '26.8K', '26.9K', '27K', '27K', '27K', '27.2K', '27.5K', '27.6K', '27.8K', '28.2K', '28.4K', '29.8K'], 'SocialMedia_YouTube': ['21K', '21.3K', '21.5K', '21.8K', '22K', '22.4K', '22.9K', '23.4K', '23.9K', '24.2K', '24.6K', '24.8K', '25K', '25.3K', '25.5K', '25.9K', '26.1K', '26.5K', '26.6K', '26.8K', '27K', '27.3K', '27.7K', '27.7K', '27.8K', '27.9K', '27.9K', '27.9K', '27.9K', '28K', '28.2K', '28.2K', '28.2K', '28.3K', '28.4K', '28.6K', '28.8K', '29K', '29.3K', '29.9K'], 'Overall_Kol_Rating': [3.1, 3.2, 3.34, 3.39, 3.5, 3.56, 3.65, 3.64, 3.7, 3.6, 3.65, 3.58, 3.6, 3.62, 3.63, 3.65, 3.66, 3.69, 3.72, 3.75, 3.75, 3.67, 3.68, 3.76, 3.79, 3.87, 3.9, 3.93, 3.99, 4.0, 4.1, 4.13, 4.14, 4.16, 4.17, 4.2, 4.23, 4.23, 4.25, 4.26], 'Connection_to_Advisory_Boards': [2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5], 'Research_Participated': [3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8], 'Research_Experience': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6], 'Fundinghistory_researchgrants': ['20000', '40000', '40000', '40000', '140000', '140000', '140000', '140000', '180000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '220000', '230000', '220000', '230000', '230000', '230000', '230000', '250000', '250000', '250000'], 'Fundinghistory_ConsultingFees': [0, 0, 0, 30000, 30000, 30000, 80000, 80000, 80000, 80000, 140000, 140000, 140000, 140000, 140000, 160000, 160000, 160000, 160000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000, 170000], 'Fundinghistory_EducationalGrants': ['20000', '40000', '40000', '40000', '140000', '140000', '140000', '140000', '180000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '200000', '220000', '230000', '220000', '230000', '230000', '230000', '230000', '250000', '250000', '250000'], 'No_Of_Publications': [1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5], 'Trainings_Delivered': [2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6], 'Professional_Certification': [2, 2, 2, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'National_presentations_Presented': [3, 3, 4, 4, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['No', 'Planning for medical asset generation', 'Discussion about content and structure of these training sessions', 'How to make training more practical and applicable', 'Focus on design thinking', 'Address role of technology in medical asset generation', 'Challenges and potential barriers in implementing patient driven solutions', 'Incorporating hands on exercises and group activities', 'Allocating participants to brainstorm and develop their own project ideas', 'Offering post training support such as online resources or post follow-up session', 'Networking opportunities at upcoming medical asset generation event', 'About what kind of research presentations will be conducted and what kind of researchers will be there', 'Various workshops and training sessions', 'Startup pitch competitions', 'Collaborative appoarches to asset generation in key note speeches', 'Risk management and mitigation in asset generation in key note speeches', 'Data Driven Decision making in asset generation in key note speeches', 'Innovative financing models in key note speeches', 'Ethical Considerations in asset generation in key note speeches', 'Future trends in medical asset generation in key note speeches', 'Comparitive Analysis of medical asset acquisition models in research presentations', 'Optimization of medical asset utilization through data analytics in research presentations', 'Impact of collaborative partnerships on medical asset generation', 'Sustainable practice in medical asset generation in research presentations', 'Implementation of technology in medical asset management in research presentations', 'Evaluation of training programs for medical asset management', 'Financial Analysis of medical asset generation in research presentations', 'Role of regulatory compliance in medical asset generation in research presentations', 'Future trends and innovations in medical asset generations in research presentations', 'Problem identification in startup pitch competition', 'Innovative medical asset solutions in medical asset generation event', 'Market potential and target audience in startup pitch competitions', 'Unique value proposition in medical asset generation', 'Business model and revenue generation', 'Scalability and growth potential', 'How we can maximize networking opportunities', 'Involving patient advocates as session leaders and workshop facilitators', 'Incorporating social media into networking strategy', 'Creating dedicated spaces such as lounge areas or interactive booths', 'Team Expertise and execution plan in start up pitch competitions'], 'Previous_Meeting_SubTopics': ['No', 'Importance of providing healthcare professionals with knowledge and skills necessary', 'Overview of patient centric care,equipping healthcare professionals with necessary equipment', 'Emphasizing the importance of patient centric care,conducting interviews,surveys and focus groups', 'Importance of design thinking and its features', 'Explore emerging technologies like AI,ML and IoT .Participants should gain insights how these technologies can be leveraged to develop patient-driven solutions', 'Organizational resistance,regulatory compliance,resource constraints and identifying strategies to overcome these challenges', 'Encourage collaboration,develop practical skills,training more engaging and interactive', 'Putting learning into practice,fostering culture of innovation', 'Post training support such as online resource or follow up session,platform for sharing experience', 'Details of upcoming event,collaboration,connections', 'Research presentations,researchers', 'Workshops,training programs and study sessions', 'Startup pitches,asset show ups,judges reviews', 'collaborative models and partnerships between healthcare organizations,technology providers', 'Issues related to patient safety,regulatory compliance,financial implications and operational challenges', 'Role of data analytics,predictive modeling and machine learning in making informed decisions', 'Leasing,public-private partnerships and value based reimbursement models', 'Equitable access to healthcare resources,fair distribution of assets and responsible disposal of equipment', 'Digital health innovations,IoT,integration and personalize medicine', 'Purchasing,leasing or share resource agreements and present research findings', 'Utilization of medical assets,including equipment scheduling,maintainence planning and resource allocation,with aim of imporiving operational efficiency', 'Impact of collaborative partnerships between healthcare organizations,manufacturers', 'Sustainable practices in medical asset generation,including environment friendly procurement,energy-efficient equipment', 'IOT,RFID,asset management .Impact of technology on asset tracking,maintainence and optimization', 'Asset utilization,maintainence practices and overall operational efficiency', 'Total cost of ownership,return on investment and cost-benefit analysis of various asset acquisition and management strategies', 'Standards for equipment safety,quality control and legal requirements', 'Robotics,ai,advanced imaging techniques and virtual reality', 'High cost,limited access,equipment maintainence or supply chain bottlenecks', 'Technologies,software programs or business models', 'Target audience such as hospitals,clincics,research facilities and healthcare organizations', 'Solution stand out,competitive advantage', 'Pricing strategies,potential partnerships and revenue streams', 'Expansion plans,target markets beyond the initial launch', 'Dedicated networking session,Tables or discussion groups around topics related to medical asset generation', 'Firsthand experience,perspectives,inclusive environment', 'Social media platforms,event specific hashtags,reach with broader audience', 'Dedicating spaces to encourage networking and relationship building', 'Execution plans,market penetration,product development'], 'Current_Discussion_Topic': ['Planning for medical asset generation', 'Discussion about content and structure of these training sessions', 'How to make training more practical and applicable', 'Focus on design thinking', 'Address role of technology in medical asset generation', 'Challenges and potential barriers in implementing patient driven solutions', 'Incorporating hands on exercises and group activities', 'Allocating participants to brainstorm and develop their own project ideas', 'Offering post training support such as online resources or post follow-up session', 'Networking opportunities at upcoming medical asset generation event', 'About what kind of research presentations will be conducted and what kind of researchers will be there', 'Various workshops and training sessions', 'Startup pitch competitions', 'Collaborative appoarches to asset generation in key note speeches', 'Risk management and mitigation in asset generation in key note speeches', 'Data Driven Decision making in asset generation in key note speeches', 'Innovative financing models in key note speeches', 'Ethical Considerations in asset generation in key note speeches', 'Future trends in medical asset generation in key note speeches', 'Comparitive Analysis of medical asset acquisition models in research presentations', 'Optimization of medical asset utilization through data analytics in research presentations', 'Impact of collaborative partnerships on medical asset generation', 'Sustainable practice in medical asset generation in research presentations', 'Implementation of technology in medical asset management in research presentations', 'Evaluation of training programs for medical asset management', 'Financial Analysis of medical asset generation in research presentations', 'Role of regulatory compliance in medical asset generation in research presentations', 'Future trends and innovations in medical asset generations in research presentations', 'Problem identification in startup pitch competition', 'Innovative medical asset solutions in medical asset generation event', 'Market potential and target audience in startup pitch competitions', 'Unique value proposition in medical asset generation', 'Business model and revenue generation', 'Scalability and growth potential', 'How we can maximize networking opportunities', 'Involving patient advocates as session leaders and workshop facilitators', 'Incorporating social media into networking strategy', 'Creating dedicated spaces such as lounge areas or interactive booths', 'Team Expertise and execution plan in start up pitch competitions', 'Regulatory and compliance considerations in startup pitch competitions'], 'Current_Meeting_Subtopics': ['Importance of providing healthcare professionals with knowledge and skills necessary', 'Overview of patient centric care,equipping healthcare professionals with necessary equipment', 'Emphasizing the importance of patient centric care,conducting interviews,surveys and focus groups', 'Importance of design thinking and its features', 'Explore emerging technologies like AI,ML and IoT .Participants should gain insights how these technologies can be leveraged to develop patient-driven solutions', 'Organizational resistance,regulatory compliance,resource constraints and identifying strategies to overcome these challenges', 'Encourage collaboration,develop practical skills,training more engaging and interactive', 'Putting learning into practice,fostering culture of innovation', 'Post training support such as online resource or follow up session,platform for sharing experience', 'Details of upcoming event,collaboration,connections', 'Research presentations,researchers', 'Workshops,training programs and study sessions', 'Startup pitches,asset show ups,judges reviews', 'collaborative models and partnerships between healthcare organizations,technology providers', 'Issues related to patient safety,regulatory compliance,financial implications and operational challenges', 'Role of data analytics,predictive modeling and machine learning in making informed decisions', 'Leasing,public-private partnerships and value based reimbursement models', 'Equitable access to healthcare resources,fair distribution of assets and responsible disposal of equipment', 'Digital health innovations,IoT,integration and personalize medicine', 'Purchasing,leasing or share resource agreements and present research findings', 'Utilization of medical assets,including equipment scheduling,maintainence planning and resource allocation,with aim of imporiving operational efficiency', 'Impact of collaborative partnerships between healthcare organizations,manufacturers', 'Sustainable practices in medical asset generation,including environment friendly procurement,energy-efficient equipment', 'IOT,RFID,asset management .Impact of technology on asset tracking,maintainence and optimization', 'Asset utilization,maintainence practices and overall operational efficiency', 'Total cost of ownership,return on investment and cost-benefit analysis of various asset acquisition and management strategies', 'Standards for equipment safety,quality control and legal requirements', 'Robotics,ai,advanced imaging techniques and virtual reality', 'High cost,limited access,equipment maintainence or supply chain bottlenecks', 'Technologies,software programs or business models', 'Target audience such as hospitals,clincics,research facilities and healthcare organizations', 'Solution stand out,competitive advantage', 'Pricing strategies,potential partnerships and revenue streams', 'Expansion plans,target markets beyond the initial launch', 'Dedicated networking session,Tables or discussion groups around topics related to medical asset generation', 'Firsthand experience,perspectives,inclusive environment', 'Social media platforms,event specific hashtags,reach with broader audience', 'Dedicating spaces to encourage networking and relationship building', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal'], 'Current_Channel_of_interaction': ['In Person', 'In Person', 'In Person', 'In Person', 'In Person', 'Phone', 'Phone', 'Email', 'Phone', 'Email', 'In Person', 'Email', 'In Person', 'Phone', 'Email', 'Phone', 'Email', 'In Person', 'Email', 'In Person', 'Phone', 'In Person', 'Email', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'Email', 'Phone', 'Email', 'Phone', 'In Person', 'Email', 'Phone', 'Email', 'Phone'], 'Company_Event': ['Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions', 'Medical Asset Generation-Patient driven solutions'], 'Interaction_intent': ['To discuss about plan of training and workshop sessions and importance of these sessions for healthcare professionals to develop innovative and patient driven solution', 'Discuss about these training sessions should aim to equip healthcare professionals with the necessary tools to generate medical assets that truly meet the needs of patients', 'Emphasizing the importance of patient centric care.Deep diving into specific technologies and techniques for engaging patients like conducting surveys,interviews and focus groups', 'Design thinking will enable healthcare professionals to approach asset generation from a creative and innovative perspective.Introducing tools like user personas,journey mapping and rapid prototyping', 'To discuss about emerging technologies and how these technologies can be leveraged to develop patient driven solutions and need for healthcare professionals to stay updated on latest technologies', 'To discuss about acknowledging potential obstacles and proving participants with startegies to overcome them effectively', 'Incorporating hands on exercises to reinforce the concepts and encourage collaboration', 'To discuss about encouraging participants to apply there learnings in real world scenarios', 'To discuss how ongoing support and follow up is essential to ensure participants can sucessfully implement what they have learned', 'To discuss the details of upcoming medical event and network,collaboration opportunities in it', ""To get overview of what kind of research presentations will be conducted and researcher's background"", 'To discuss about various workshops and training session that will be conducted and how it will help the people attending that event', 'To discuss about startup would be giving pitches and presenting their medical assets and judges will be giving reviews and how these events will promote innovation in medical field', 'Explore collaborative models- and partnerships between healthcare organizations,technology providers,manufacturers and regulatory bodies to optimize asset generation processes,improve efficiency and foster innovation', 'To discuss about strategies for identifying and mitigating risks associated with medical asset generation,including issues related to patient safety,regulatory compliance,financial implications and operational challenges', 'To discuss the role of data analytics,predictive modeling and machine learning in making informed decisions regarding medical asset acquisition,utilization,maintainence and replacement', 'Explore alternative financing models and strategies for medical asset generation such as leasing,public-private partnership and value based reimbursment models', 'To address the issues social responsibility,sustainability and ethical implications of resource allocation', 'To discuss the potential impact of these trends on healthcare delivery,asset management and patient care', 'To discuss about comparing different models for medical asset acquisition,such as purchasing,leasing or share resource agreements on their cost effectiveness,efficiency', 'To discuss about research study that utilizes data analytics techniques to optimize utilization of medical assets', 'To discuss about benefits,challenges and outcome of partnerships', 'To discuss the enviromental impact and cost-effectiveness of adopting sustainable practices in healthcare settings', 'To discuss the impact of technology on asset tracking,maintenence and optimization', 'To discuss about effectiveness of training programs in improving asset utilization,maintainence practices and overall operational efficiency', 'To discuss about insights into optimizing financial outcomes in medical asset generation', 'To discuss about research findings on the impact of compliance on asset acquisition,utilization and patient safety outcomes', 'To discuss about potential impact of innovation on healthcare deliveryv,asset management and patient care', 'To discuss about emphasizing the need for innovative solutions to address these problems', 'To discuss about startups giving pitches that offer innovative solutions to improve medical asset generation', 'To discuss about the market research and insights of the demand,competition and growth prospects for the proposed solutions', 'To discuss how a particular solution offers and addresses specifica pain points in asset generation', 'To discuss about the business models of the startups and their plans for revenue generation', 'To discuss the expansion plans,target markets beyond the initial launc,and the ability to adapt the solution to different healthcare or geographic locations', 'To discuss about maximizing the networking opportunities in upcoming medical asset generation event', 'Involving patient advocates as session leaders and their importance of involvment', 'To discuss about encoraging virtual networking through social media platforms', 'To discuss about creating designated spaces for informal and networking opportunities to facilitate connection between attendees', ""To discuss about team's execution plans,milestones and strategies for market penetration,customer acquisition and product development"", 'To discuss how the startup ensure adherance to regulatory standards,certifications and any potential legal or ethical implications'], 'Items/topics_to_exchange': ['Importance of providing healthcare professionals with knowledge and skills necessary', 'Overview of patient centric care,equipping healthcare professionals with necessary equipment', 'Emphasizing the importance of patient centric care,conducting interviews,surveys and focus groups.Providing real life case studies and examples', 'Importance of design thinking and its features,Design thinking powerful approach to foster innovation', 'Explore emerging technologies like AI,ML and IoT .Participants should gain insights how these technologies can be leveraged to develop patient-driven solutions,ethical and privacy concerns', 'Organizational resistance,regulatory compliance,resource constraints and identifying strategies to overcome these challenges', 'Encourage collaboration,develop practical skills,training more engaging and interactive', 'Putting learning into practice,fostering culture of innovation,Encouraging participants to appy their learnings will benefit overall advancement of patient-driven care', 'Offering post training support such as online resources or post follow-up session,platform for sharing their experience and learning from each other', 'Details of upcoming event,collaboration,connections', 'Research presentations,researchers', 'Workshops,training programs and study sessions', 'Startup pitches,asset show ups,reviews', 'collaborative models and partnerships between healthcare organizations,technology providers', 'collaborative models and partnerships between healthcare organizations,technology providers', 'Role of data analytics,predictive modeling and machine learning in making informed decisions', 'Leasing,public-private partnerships and value based reimbursement models.Discuss benefits and challenges of each approach and share examples of successful implementations', 'Equitable access to healthcare resources,fair distribution of assets and responsible disposal of equipment', 'Digital health innovations,IoT,integration and personalize medicine', 'Purchasing,leasing or share resource agreements and present research findings', 'Utilization of medical assets,including equipment scheduling,maintainence planning and resource allocation,with aim of imporiving operational efficiency', 'Impact of collaborative partnerships between healthcare organizations,manufacturers', 'Sustainable practices in medical asset generation,including environment friendly procurement,energy-efficient equipment', 'IOT,RFID,asset management .Impact of technology on asset tracking,maintainence and optimization', 'Asset utilization,maintainence practices and overall operational efficiency', 'Asset utilization,maintainence practices and overall operational efficiency', 'Standards for equipment safety,quality control and legal requirements', 'Robotics,ai,advanced imaging techniques and virtual reality', 'High cost,limited access,equipment maintainence or supply chain bottlenecks', 'Technologies,software programs or business models', 'Technologies,software programs or business models', 'Solution stand out,competitive advantage', 'Pricing strategies,potential partnerships and revenue streams', 'Expansion plans,target markets beyond the initial launch', 'Dedicated networking session,Tables or discussion groups around topics related to medical asset generation.Patient enagement strategies,technology integration and implementation challenges', 'Firsthand experience,perspectives,inclusive environment', 'Social media platforms,event specific hashtags,reach with broader audience,Participants sharing insights beyond the physical space', 'Social media platforms,event specific hashtags,reach with broader audience', 'Execution plans,market penetration,product development', 'Adherance to regulatory standards,certifications,potential legal imlications'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral'], 'Next_Action_Items': ['Discussion about content and structure of these training sessions', 'How to make training more practical and applicable', 'Focus on design thinking', 'Address role of technology in medical asset generation', 'Challenges and potential barriers in implementing patient driven solutions', 'Incorporating hands on exercises and group activities', 'Allocating participants to brainstorm and develop their own project ideas', 'Offering post training support such as online resources or post follow-up session', 'Potential of these sessions to create patient-driven solutions', 'How network opportunities can be maximized', 'Startup pitch competition', 'Marketing startegy', 'Topic about key note speeches', 'Data Driven Decision making in asset generation', 'Marketing startegy', 'How these events can revolutionize healthcare', 'How connections can help people', 'How these events can revolutionize healthcare', 'Startup pitch competition', 'Topic about key note speeches', 'Data Driven Decision making in asset generation', 'How connections can help people', 'To discuss about how these events can provide a platform for discussion on regulatory frameworks and IP rights', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'Discussion about how these events can address pressing healthcare challenges', 'Marketing startegy', 'Discussion about how these events can address pressing healthcare challenges', 'How these events can revolutionize healthcare', 'Topic about key note speeches', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'New medical assets ensuring they meet the demands of heathcare providers and patients', 'Future trends in asset generation', 'How connections can help people', 'How these events can revolutionize healthcare', 'How to further enhance networking opportunities', 'Discussing summary of all the events to be conducted for maximizing network oppurtunities', 'Explore the possibility of inviting patient advocates or representatives from patient advocacy groups', 'Incorporating social media into networking strategy', 'Regulatory frameworks,intellectual property rights and responsible innovation', 'Networking oppurtunities and programs'], 'Proposed_Next_Channel_Of_interaction': ['In Person', 'In Person', 'In Person', 'In Person', 'Phone', 'Phone', 'Email', 'Phone', 'Phone', 'Video Call', 'In Person', 'Phone', 'Email', 'Phone', 'Email', 'In Person', 'Phone', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'Phone', 'Email', 'In Person', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Phone', 'Email', 'Phone', 'In Person', 'Video Call', 'In Person', 'Video', 'Phone', 'Email', 'In Person']}"
23,"{'kol': 'Percy Julian', 'Interaction_Date': ['27-Apr-19', '23-May-19', '18-Jun-19', '14-Jul-19', '9-Aug-19', '4-Sep-19', '30-Sep-19', '26-Oct-19', '21-Nov-19', '17-Dec-19', '12-Jan-20', '7-Feb-20', '4-Mar-20', '30-Mar-20', '25-Apr-20', '21-May-20', '16-Jun-20', '12-Jul-20', '7-Aug-20', '2-Sep-20', '28-Sep-20', '24-Oct-20', '19-Nov-20', '15-Dec-20', '10-Jan-21', '5-Feb-21', '3-Mar-21', '29-Mar-21', '24-Apr-21', '20-May-21', '15-Jun-21', '11-Jul-21', '6-Aug-21', '1-Sep-21', '27-Sep-21', '23-Oct-21', '18-Nov-21', '14-Dec-21', '9-Jan-22', '14-Feb-22'], 'Current_Tier': ['Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional', 'Regional'], 'KOL_Qualification': ['MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH', 'MD, MCH'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer'], 'KOL_years_of_Experience': [8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10], 'KOL_Location': ['Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC', 'Washington DC'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['10K', '10K', '10K', '10K', '10K', '10K', '10K', '10K', '10K', '10K', '10K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '12K', '21K', '21K', '21K', '21K', '21K', '22K', '22K', '22K', '22K', '22K', '22K', '24K', '26K'], 'SocialMedia_Linkedin': ['6K', '6K', '6K', '6K', '6K', '6K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8.5K'], 'SocialMedia_YouTube': ['6K', '6K', '6K', '5K', '5K', '5K', '5K', '7K', '7K', '7K', '7K', '7K', '7K', '7K', '7K', '7K', '7K', '7K', '7K', '7K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8.7K'], 'Overall_Kol_Rating': [3.7, 3.7, 3.7, 3.7, 3.9, 3.9, 4.2, 4.2, 4.2, 4.2, 3.9, 4.1, 4.1, 4.1, 4.2, 4.2, 4.2, 4.1, 4.1, 3.9, 3.9, 4.2, 3.9, 4.1, 4.1, 4.1, 3.8, 3.8, 3.9, 3.8, 3.8, 4.9, 3.8, 4.1, 3.8, 3.8, 4.2, 4.2, 4.2, 4.4], 'Connection_to_Advisory_Boards': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6], 'Research_Participated': [5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 9], 'Research_Experience': [6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'Fundinghistory_researchgrants': ['10000', '10000', '10000', '10000', '15000', '15000', '15000', '15000', '18000', '18000', '18000', '18000', '18000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '55000'], 'Fundinghistory_ConsultingFees': [100, 100, 100, 100, 100, 100, 100, 100, 100, 100, 100, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 200, 500, 500, 500, 500, 500, 500, 500, 500, 500, 500, 500, 500, 500], 'Fundinghistory_EducationalGrants': ['10000', '10000', '10000', '10000', '15000', '15000', '15000', '15000', '18000', '18000', '18000', '18000', '18000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '20000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '50000', '55000'], 'No_Of_Publications': [4, 4, 4, 4, 4, 4, 4, 4, 6, 6, 6, 6, 6, 8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10], 'Trainings_Delivered': [4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 7, 7, 7, 9, 9, 9, 9, 9, 9, 9, 12, 12, 12, 12, 12, 12], 'Professional_Certification': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5], 'KOL_affiliations_academicinstitutionss': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0, 3.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 3], 'International_Presentations_Presented': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'National_presentations_Presented': [48, 48, 48, 48, 48, 48, 48, 48, 48, 48, 54, 54, 54, 54, 54, 54, 54, 54, 54, 54, 54, 54, 54, 54, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60, 60], 'KOL_FollowUp': ['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'No'], 'Previous_meeting_agenda': ['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Precautionary measures in treating patients', 'Factors leading to blood cancer', 'Onco-Genetic Factors leading to blood cancer', 'Different Factors leading to blood cancer', 'Environmental Factors leading to blood cancer', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', ""Effect of Chemotherapy on Patient's Vital Organs"", 'Precautionary measures for old age patients', 'Health Vitals for Old Aged Patients', 'No'], 'Previous_Meeting_SubTopics': ['No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Precautionary measures in chemotherapy', 'Genetic factors leading to Blood Cancers', 'Role of Oncogenes in Blood Cancer', 'Who is at risk of Blood Cancer', 'Role of Environment in Blood Cancer', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Reducing chances of organ failures', 'Increased risk of Septic Shock due to Chemotherapy', 'Complications due to Blood pressure', 'No'], 'Current_Discussion_Topic': ['Advatage of drug blending', 'Increasing drug efficacy by film coating', 'Efficacy comparison', 'Treatment reception by patients', 'Treatment reception by patients', 'Treatment reception by patients', 'Treatment reception by health care providers', 'Treatment reception by health care providers', 'Treatment reception by health care providers', 'How Blood cancer affects Mental health', 'How Blood cancer affects Mental health', 'Symptoms of Blood Cancer', 'Role of environment in blood cancer', 'Precautionary measures in treating patients', 'Factors leading to blood cancer', 'Onco-Genetic Factors leading to blood cancer', 'Different Factors leading to blood cancer', 'Environmental Factors leading to blood cancer', 'High Risk Environment and Cancer', 'Role of Smoking and Tobacco', 'Family History and Cancer', 'History of Cancer in Patients', 'Chemical Exposure And Blood cancer', ""Genetic Factor and Down's Syndrome as an Indicator for Risk Assessment"", 'Role of HIV in Cancer', 'Role of HTLV-1 in Cancer', 'Role of Immunity in Cancer', 'Past Infections as an indicator for cancer diagnosis', 'Type of Blood Cancer', 'Blood Cancer treatment', 'Bone Marrow Transplantation in Blood cancer', 'Chemotherapy in Blood cancer', 'Radiation therapy as a treatment in blood cancer', 'Biological Therapy or Immunotherapy as treatment', 'Combining different therapies method', ""Effect of Chemotherapy on Patient's Vital Organs"", 'Precautionary measures for old age patients', 'Health Vitals for Old Aged Patients', 'Cancer treatment with Old Age complications', ""Effect of Chemotherapy on Patient's Vital Organs""], 'Current_Meeting_Subtopics': ['How Drug blending offers superior efficasy at affordable rate', 'How drug film coating increases drug absorption by human body', 'Efficacy as compared to previous generation of medicines', 'Treatment reception in terms of efficacy by patient', 'Treatment reception in terms of drug being more affordable', 'Treatment reception in terms of drug having less side effects', 'Treatment reception in terms of easy availability of drug', 'Treatment reception in terms of post treatment pain management', 'Treatment reception in terms replacement with generic medicine', 'Mental health management by patient', 'Role of family and friends in mental health management', 'Early signs to detect blood cancer', 'How living in high radiation environment can lead to blood cancer', 'Precautionary measures in chemotherapy', 'Genetic factors leading to Blood Cancers', 'Role of Oncogenes in Blood Cancer', 'Who is at risk of Blood Cancer', 'Role of Environment in Blood Cancer', 'Precautions for High Risk Environments', 'Smoking or tobacco use leads to increased risk factor', 'Family history of leukemia', 'Previous cancer treatment or exposure to radiation therapy', 'Exposure to certain chemicals like benzene and other petrochemicals', 'Genetic factors such as those with Downs syndrome have a higher risk of developing leukemia.', 'HIV (Human Immunodeficiency Virus) increases cancer risk', 'HTLV-1 (Human T-lymphotropic virus) increases cancer risk', 'Risk due to Weak immune system', 'Certain infections that may lead to Blood Cancer', 'Difference between Leukemia, Lymphoma and Myeloma', 'Different types and efficacy of blood cancer treatment', 'Effectiveness of Bone Marrow transplant in Blood Cancer', 'Personalized chemotherapy as an efficient method of treatment', 'Effectiveness of Radiation therapy in Blood Cancer', 'Biological Therapy to kill cancer cells, How it works.', 'How combing different techniques helps making treatment more effective', 'Reducing chances of organ failures', 'Increased risk of Septic Shock due to Chemotherapy', 'Complications due to Blood pressure', 'Managing cancer drug intake with other medicines', 'Reducing chances of organ failures'], 'Current_Channel_of_interaction': ['In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'Video', 'Video', 'Video', 'email', 'email', 'In-person', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'In-person', 'In-person', 'In-person', 'video', 'In-person', 'Phone', 'In-person', 'In-person', 'In-person', 'In-person', 'Video Call'], 'Company_Event': ['Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer'], 'Interaction_intent': ['To get insight into drug blending', 'To get insight into drug manufacturing with film coating technique', 'Comparing efficacy of emerging therapies', 'Drug reception by patients', 'Drug reception by patients', 'Drug reception by patients', 'Drug reception by health care providers', 'Drug reception by health care providers', 'Drug reception by health care providers', 'Awareness about Blood cancer and Mental health', 'Awareness about Mental health', 'Symptoms of Blood Cancer', 'Understanding Role of environment in blood cancer', 'Precautionary measures in cancer', 'Factors leading to onset of blood cancer', 'Onco-Genetic Factors', 'Factors leading to blood cancer', 'Environmental Factors and blood cancer', 'Environment and Cancer', 'Role of Tobacco', 'Family History of cancer', 'History of Cancer', 'Chemical Exposure to certain chemicals', ""Genetic Factor and Down's Syndrome"", 'HIV and cancer', 'HTLV-1 and Cancer', 'Significance of Immunity in Cancer', 'How Past Infections indicates for cancer', 'Know different type of Blood Cancer', 'Ways to treat Blood Cancer', 'How Bone Marrow Transplantation works', 'Chemotherapy effectiveness in blood cancer', 'Awareness session on Radiation therapy', 'Immunotherapy as treatment', 'Assessing different therapies method', 'Introduction to Chemotherapy and Vital Organ', 'Precautionary measures cancer patients', 'Important Health Vitals to monitor in cancer', 'Precautions for treating with Old Age patients', 'Introduction to Chemotherapy and Vital Organ'], 'Items/topics_to_exchange': ['Superior efficasy and afforable medicines due to drug blending', 'Advantage of drug absorption due to film coating', 'Efficacy comparison and reasons behind it', 'Drug reception in terms of efficacy by patient', 'Drug reception in terms of drug being more affordable', 'Drug reception in terms of drug having less side effects', 'Drug reception in terms of easy availability of drug', 'Drug reception in terms of post treatment pain management', 'Replacement with generic medicine', 'Mental health management by self-management', 'mental health management', 'Initial signs to detect blood cancer', 'High radiation environment and blood cancer', 'Precautionary measures in treatment', 'Genetic factors and Blood Cancers', 'Role Oncogenes plays', 'Risk of having Blood Cancer', 'Role Environment plays in Blood Cancer', 'Precautions for working in High Risk Environments', 'Smoking or tobacco and risk factor associated', 'Family history indicates chances of leukemia', 'Previous cancer treatment and exposure to radiation therapy', 'Cancer and chemicals like benzene and other petrochemicals', 'Genetic factors and cancer risk assessment', 'HIV (Human Immunodeficiency Virus) and cancer risk', 'HTLV-1 (Human T-lymphotropic virus) and cancer risk', 'Weak immune system leading to cancer', 'Infections leading to Blood Cancer', 'What makes Leukemia, Lymphoma and Myeloma so different', 'Comparing blood cancer treatment', 'what makes Bone Marrow so effective in treatment', 'Personalized chemotherapy', 'Effectiveness of Radiation therapy as an alternative to chemotherapy', 'Biological Therapy to kill cancer cells', 'How different techniques helps makes treatment more effective', 'Managing organ failures', 'Reasons for Septic Shock due to Chemotherapy', 'Importance of Blood pressure in cancer management', 'Managing cancer drug intake for old age patients', 'Managing organ failures'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral'], 'Next_Action_Items': ['Drug efficasy improvement', 'Efficacy comparison', 'Drug Treatment by patients', 'Drug Treatment by patients', 'Drug Treatment by patients', 'Drug Treatment by health care providers', 'Drug Treatment by health care providers', 'Drug Treatment by health care providers', 'Mental health management', 'How Blood cancer affects Mental health', 'Symptoms of Blood Cancer', 'Role of environment in blood cancer', 'Precautionary measures in treating patients', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Factors leading to blood cancer', 'Type of Blood Cancer', 'Blood Cancer treatment', 'Bone Marrow Transplantation in Blood cancer', 'Chemotherapy in Blood cancer', 'Radiation therapy as a treatment in blood cancer', 'Biological Therapy or Immunotherapy as treatment', 'Combining different therapies method', ""Effect of Chemotherapy on Patient's Vital Organs"", 'Precautionary measures for old age patients', 'Health Vitals for Old Aged Patients', 'Cancer treatment with Old Age complications', 'Targeted Therapy in Leukemia', 'Targeted Therapy in Leukemia'], 'Proposed_Next_Channel_Of_interaction': ['In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'Video', 'Video', 'Video', 'email', 'email', 'In-person', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'Video', 'In-person', 'In-person', 'In-person', 'video', 'In-person', 'Phone', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person']}"
24,"{'kol': 'Shaun Brown', 'Interaction_Date': ['4-May-19', '29-May-19', '22-Jun-19', '21-Jul-19', '10-Sep-19', '3-Oct-19', '30-Oct-19', '23-Nov-19', '18-Dec-19', '17-Jan-20', '13-Feb-20', '8-Mar-20', '31-Mar-20', '25-Apr-20', '20-May-20', '18-Jun-20', '15-Jul-20', '13-Aug-20', '10-Sep-20', '8-Oct-20', '7-Nov-20', '7-Dec-20', '5-Jan-21', '2-Feb-21', '27-Feb-21', '27-Mar-21', '25-Apr-21', '17-May-21', '13-Jun-21', '12-Jul-21', '30-Jul-21', '28-Aug-21', '20-Sep-21', '19-Oct-21', '14-Nov-21', '14-Dec-21', '12-Jan-22', '13-Feb-22', '13-Mar-22', '10-Apr-22'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': ['MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM', 'MD,DM'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer'], 'KOL_years_of_Experience': [23, 23, 23, 23, 23, 23, 23, 23, 23, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 24, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 25, 26, 26, 26, 26], 'KOL_Location': ['California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California', 'California'], 'KOL_Territory': ['West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast', 'West Coast'], 'SocialMedia_Twitter': ['27.1K', '27.6K', '28.1K', '30.5K', '30.7K', '31.1K', '31.2K', '31.8K', '32.5K', '35K', '35.4K', '36.2k', '36.8K', '38K', '38.7K', '40.1K', '42.2K', '42.5K', '43K', '43.3K', '43.5K', '44K', '46K', '46.4K', '47K', '47.3K', '46.5K', '47K', '47.2K', '47.5K', '47.9K', '48.1K', '48.4k', '49K', '49.7K', '50.9K', '54.3K', '55.3K', '57K', '57.4k'], 'SocialMedia_Linkedin': ['17.3K', '17.4K', '17.8K', '18.5K', '18.6K', '18.9K', '19K', '19.3K', '19.5K', '21K', '21.3K', '21.7K', '22.5K', '23.2K', '24.3K', '25.6K', '26.6K', '26.8K', '27.1K', '27.2K', '27.4K', '27.9K', '28.4K', '28.5K', '28.5K', '28.6K', '27.2K', '27.5K', '27.8K', '28.1K', '28.6K', '28.7K', '29.2K', '29.7K', '30.1K', '30.3K', '31K', '32.2K', '33.5K', '34.6K'], 'SocialMedia_YouTube': ['5.6K', '5.6K', '5.7K', '6.1K', '6.1K', '6.3K', '6.3K', '6.4K', '7.2K', '7.5K', '7.5K', '8K', '8.3K', '9.5K', '9.7K', '10.5K', '10.6K', '10.6K', '10.6K', '10.7K', '10.9K', '11.1K', '11.6K', '11.7K', '11.7K', '11.9K', '11.5K', '12K', '12.4K', '12.6K', '13K', '13.2K', '13.8K', '14.2K', '14.6K', '14.9K', '15.6K', '16.1K', '16.5k', '17.1k'], 'Overall_Kol_Rating': [3.9, 3.9, 4.0, 4.2, 4.2, 4.2, 4.2, 4.1, 4.1, 4.1, 4.1, 4.1, 4.1, 4.2, 4.2, 4.2, 4.2, 4.2, 4.2, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.1, 4.2, 4.2, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3, 4.3], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5], 'Research_Participated': [11, 11, 11, 11, 11, 11, 11, 11, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 12, 13, 13, 13, 13, 13, 13, 13, 13, 13, 13, 14, 14, 14, 14, 14, 14, 14, 15, 15, 15], 'Research_Experience': [20, 20, 20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 2, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23], 'Fundinghistory_researchgrants': ['40,000', '40,000', '60,000', '60,000', '60000', '60000', '60000', '60000', '110000', '110000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '250000', '250000', '250000', '300000', '300000', '300000', '300000', '300000', '300000', '300000', '325000', '325000', '325000', '325000', '325000', '325000', '325000', '360000', '360000', '360000'], 'Fundinghistory_ConsultingFees': [600, 600, 600, 600, 600, 600, 600, 600, 600, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 900, 900, 900, 900, 900, 900, 900, 900, 900, 900], 'Fundinghistory_EducationalGrants': ['40,000', '40,000', '60,000', '60,000', '60000', '60000', '60000', '60000', '110000', '110000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '1,50,000', '250000', '250000', '250000', '300000', '300000', '300000', '300000', '300000', '300000', '300000', '325000', '325000', '325000', '325000', '325000', '325000', '325000', '360000', '360000', '360000'], 'No_Of_Publications': [13, 13, 13, 13, 13, 13, 13, 14, 14, 14, 14, 14, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 15, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16, 16], 'Trainings_Delivered': [13, 13, 14, 14, 14, 16, 16, 17, 17, 17, 18, 18, 18, 20, 20, 20, 20, 20, 20, 20, 21, 21, 21, 22, 22, 22, 22, 22, 22, 23, 23, 23, 24, 24, 24, 24, 25, 26, 26, 27], 'Professional_Certification': [8, 8, 8, 8, 8, 8, 8, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 9, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 10, 11], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Hospital_and_medical_Centres': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Government_and_Regulatory_bodies': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [24, 24, 24, 25, 25, 25, 25, 26, 26, 26, 26, 26, 26, 27, 27, 28, 28, 28, 28, 28, 29, 29, 29, 30, 30, 30, 31, 31, 31, 31, 31, 32, 32, 32, 32, 32, 33, 33, 33, 34], 'National_presentations_Presented': [121, 122, 123, 123, 124, 126, 127, 127, 127, 128, 129, 130, 131, 131, 131, 132, 132, 134, 135, 136, 137, 139, 140, 140, 141, 143, 143, 144, 146, 147, 149, 149, 150, 151, 152, 153, 154, 156, 157, 158], 'KOL_FollowUp': ['No', 'Yes', 'No', 'No', 'No', 'Yes', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes'], 'Previous_meeting_agenda': ['Dicussion about research of new drug', 'Feasibility of Study', 'Discussion about effectivness of study.', 'Discussion on Regulatory guidlines for the research', 'Competitive drug available in market', 'To get KoL agrrement for the role of Principal Investigator support', 'To get KoL onboaded for the role', 'Regulatory guidlines regarding clinical trial sites', 'Preparation for trial with all the guidlines', 'Clinical trial sites', 'Safety procedure for clinical trial', 'For reviewing all the procedure', 'Compare our research with competitive drug', 'Initial cost of drug', 'Claims for drug', 'For reporting trial progress', 'Insurance covering drug', 'Taking feedback on guilines followed', 'Trial Progress Report', 'To get direction for trial', 'Details about vounteer condition post trial', 'Safety of volunteer.', 'Compare our research with competitive drug', 'Initial cost of drug', 'Insurance coverage of drug', 'Regulatory guidlines post trial', 'Trial Progress Report', 'Reaseach direction', 'Effectivness of study', 'To review all the guidlines', 'Safety procedure.', 'Trial Progress Report', 'Compare our research with competitive drug', 'Claims/Insurance/Copay Programs', 'Patient Demographic', 'Safety review', 'Regulatory guidlines for post trial', 'Claims/Insurance/Copay Programs', 'Safety procedure.', 'Post Trial Follow Up of the volunteer'], 'Previous_Meeting_SubTopics': ['Feasibility of Study', 'Feasibility of Study', 'Regulatory guidlines', 'Competitive Analysis', 'Principal Investigator support\u200b', 'Principal Investigator support\u200b', 'Regulatory guidlines', 'Regulatory guidlines', 'Patient Demographics for clinical trial sites', 'Safety', 'Review Preparation', 'Competitive Analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Trial Progress', 'Claims/Insurance/Copay Programs', 'Regulatory guidlines', 'Trial Progress', 'Trial Progress', 'Post Trial Follow Up', 'Safety', 'Competitive Analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Regulatory guidlines', 'Trial Report', 'Feasibility of Study', 'Feasibility of Study', 'Regulatory guidlines', 'Safety', 'Trial Progress', 'Competitive Analysis', 'Claims/Insurance/Copay Programs', 'Patien Demographic', 'Safety', 'Regulatory guidlines', 'Claims/Insurance/Copay Programs', 'Safety', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation'], 'Current_Discussion_Topic': ['Feasibility of Study', 'Discussion about effectivness of study.', 'Discussion on Regulatory guidlines for the research', 'Competitive drug available in market', 'To get KoL agrrement for the role of Principal Investigator support', 'To get KoL onboaded for the role', 'Regulatory guidlines regarding clinical trial sites', 'Preparation for trial with all the guidlines', 'Clinical trial sites', 'Safety procedure for clinical trial', 'For reviewing all the procedure', 'Compare our research with competitive drug', 'Initial cost of drug', 'Claims for drug', 'For reporting trial progress', 'Insurance covering drug', 'Taking feedback on guilines followed', 'Trial Progress Report', 'To get direction for trial', 'Details about vounteer condition post trial', 'Safety of volunteer.', 'Compare our research with competitive drug', 'Initial cost of drug', 'Insurance coverage of drug', 'Regulatory guidlines post trial', 'Trial Progress Report', 'Reaseach direction', 'Effectivness of study', 'To review all the guidlines', 'Safety procedure.', 'Trial Progress Report', 'Compare our research with competitive drug', 'Claims/Insurance/Copay Programs', 'Patient Demographic', 'Safety review', 'Regulatory guidlines for post trial', 'Claims/Insurance/Copay Programs', 'Safety procedure.', 'Post Trial Follow Up of the volunteer', 'Post Trial Follow Up implementation of guidlines'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'In-Person', 'In-Person', 'Video Conference', 'Video Call', 'In-Person', 'Video Conference', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Conference', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'E-mail', 'Video Conference', 'Video Conference', 'Video Call', 'Video Call', 'E-mail', 'Video Call', 'In-Person', 'In-Person', 'In-Person'], 'Company_Event': ['Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug'], 'Interaction_intent': ['To check feasibility of study', 'Feasibility of Study', 'Regulatory guidlines', 'Competitive Analysis', 'Principal Investigator support\u200b', 'Principal Investigator support\u200b', 'Regulatory guidlines', 'Regulatory guidlines', 'Patient Demographics for clinical trial sites', 'Safety', 'Review Preparation', 'Competitive Analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Trial Progress', 'Claims/Insurance/Copay Programs', 'Regulatory guidlines', 'Trial Progress', 'Trial Progress', 'Post Trial Follow Up', 'Safety', 'Competitive Analysis', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Regulatory guidlines', 'Trial Progress', 'Feasibility of Study', 'Feasibility of Study', 'Regulatory guidlines', 'Safety', 'Trial Progress', 'Competitive Analysis', 'Claims/Insurance/Copay Programs', 'Patien Demographic', 'Safety', 'Regulatory guidlines', 'Claims/Insurance/Copay Programs', 'Safety', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation'], 'Items/topics_to_exchange': ['discussion about new research to be started', 'Discussion about how effective will research will be', 'Discussion on the all the regulatory guildlines for the research', 'Discussion on all the competition available on market', 'To get Kol aggrement for the role Principal Investigator', 'Disussion on all the procedure for the onboardin of KoL', 'To dicuss all the guidlines regading the clinical trial sites', 'Preparation for trial with all the guidlines', 'Selection sited for clinical area according to patient demographics', 'For all the safety procedure to be followed at clinical trial site', 'Review all the procedure for the trial start.', 'To see how our drug doing intitially', 'To discuss initial approx cost for drug', 'To discuss scenario who can claim for drug', 'To report about the progress of the trial', 'For discussing all the insurance that will cover drug', 'To check if all the guildlines is being followed in clinical trial', 'Reporting the futher process of the trial', 'To get direction of the trial progress', 'Details about vounteer condition post trial', 'Safety of the volunteers.', 'Compare initial research result with available drug', 'Cost of drug', 'Insurance coverage of drug', 'Regulatory guidlines post trial', 'Trial Report', ""For research direction and it's feasibiliyt"", 'Effectivness of study', 'To review all the guidlines', 'Safety procedure.', 'Trial Progress Report', 'Compare our research with competitive drug', 'Claims/Insurance/Copay Programs', 'Patient Demographic', 'Safety review', 'Regulatory guidlines for post trial', 'Claims/Insurance/Copay Programs', 'Safety procedure.', 'Post Trial Follow Up of the volunteer', 'Post Trial Follow Up implementation of guidlines'], 'KOLMSL_Relation': ['Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Feasibility of Study', 'Competitive Analysis', 'Principal Investigator support\u200b', 'Regulatory guidlines', 'Principal Investigator support\u200b', 'Feasibility of Study', 'Regulatory guidlines', 'Regulatory guidlines', 'Clinical sites', 'Trial Start', 'Trial start', 'Trial Report', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Regulatory guidlines', 'Regulatory guidlines', 'Clinical sites', 'Trial Progess', 'Trial Progess', 'Trial Progess', 'Regulatory guidlines', 'Safety', 'Claims/Insurance/Copay Programs', 'Claims/Insurance/Copay Programs', 'Regulatory guidlines', 'Trial Progess', 'Feasibility of Study', 'Trial Progess', 'Trial Progess', 'Regulatory guidlines', 'Feasibility of Study', 'Safety', 'Competitive Analysis', 'Competitive Analysis', 'Feasibility of Study', 'Competitive Analysis', 'Regulatory guidlines', 'Regulatory guidlines', 'Post Trial Follow Up and Implementation', 'Post Trial Follow Up and Implementation'], 'Proposed_Next_Channel_Of_interaction': ['In-Person', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'In-Person', 'In-Person', 'Video Conference', 'Video Call', 'In-Person', 'Video Conference', 'Video Call', 'In-Person', 'In-Person', 'In-Person', 'Video Call', 'Video Conference', 'In-Person', 'Video Call', 'In-Person', 'In-Person', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'In-Person', 'Video', 'Video Call', 'E-mail', 'Video Conference', 'Video Conference', 'Video Call', 'Video Call', 'E-mail', 'Video Call', 'In-Person', 'In-Person', 'In-Person', 'In-Person']}"
25,"{'kol': 'Viennie Effertz', 'Interaction_Date': ['2-Mar-19', '9-May-19', '1-Jun-19', '7-Jul-19', '9-Sep-19', '10-Nov-19', '6-Jan-20', '19-Mar-20', '22-May-20', '6-Jul-20', '19-Sep-20', '22-Nov-20', '14-Jan-21', '19-Apr-21', '22-Jun-21', '6-Aug-21', '9-Oct-21', '12-Dec-21', '13-Mar-22', '18-May-22', '25-Jul-22', '21-Oct-22', '11-Nov-22', '10-Dec-22', '21-Jan-23', '23-Feb-23', '25-Mar-23'], 'Current_Tier': ['National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National', 'National'], 'KOL_Qualification': ['MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD', 'MD,PhD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer', 'Myleoma Cancer'], 'KOL_years_of_Experience': [26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 26, 27, 27, 27, 27, 27, 27, 28, 28, 28, 28, 28, 28, 29, 29, 29], 'KOL_Location': ['New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire', 'New Hamshire'], 'KOL_Territory': ['East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast', 'East Coast'], 'SocialMedia_Twitter': ['20K', '20K', '20.2K', '20.4K', '20.6K', '20.6K', '20.6K', '20.6K', '20.8K', '20.8K', '20.9K', '20.9K', '20.9K', '20.9K', '21K', '21K', '21K', '21K', '21.2K', '21.6K', '21.6K', '22K', '22K', '22K', '22K', '22K', '22K'], 'SocialMedia_Linkedin': ['17K', '17K', '17K', '17.2K', '17.5K', '17.5K', '17.5K', '17.5K', '17.8K', '17.8K', '17.8K', '17.8K', '17.8K', '17.8K', '19K', '19K', '19K', '19K', '20K', '20.4K', '20.4K', '21K', '21K', '21K', '21K', '21K', '21K'], 'SocialMedia_YouTube': ['15K', '15K', '15.2K', '15.5K', '15.7K', '15.7K', '15.7K', '15.7K', '15.8K', '15.8K', '15.9K', '15.9K', '15.9K', '15.9K', '17K', '17K', '17K', '17K', '17.3K', '17.7K', '17.7K', '18.4K', '18.4K', '18.4K', '18.4K', '18.4K', '18.4K'], 'Overall_Kol_Rating': [3.7, 3.7, 3.7, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4], 'Research_Participated': [15, 15, 15, 16, 16, 16, 16, 16, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 19], 'Research_Experience': [17, 17, 17, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 19, 19, 19, 19, 19, 20, 20, 20, 20, 20, 20], 'Fundinghistory_researchgrants': ['100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '120000', '120000', '120000', '120000', '120000'], 'Fundinghistory_ConsultingFees': [400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400, 400], 'Fundinghistory_EducationalGrants': ['100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '100000', '120000', '120000', '120000', '120000', '120000'], 'No_Of_Publications': [15, 15, 16, 17, 17, 17, 17, 17, 17, 17, 18, 18, 18, 18, 18, 18, 21, 21, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'Trainings_Delivered': [20, 20, 20, 21, 21, 21, 21, 21, 21, 21, 21, 21, 21, 22, 22, 22, 22, 22, 22, 22, 22, 23, 23, 23, 23, 23, 23], 'Professional_Certification': [7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'KOL_affiliations_academicinstitutionss': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0, 0.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0], 'International_Presentations_Presented': [48, 48, 48, 48, 48, 48, 48, 48, 48, 48, 48, 48, 50, 50, 50, 50, 50, 50, 52, 52, 52, 52, 52, 52, 54, 54, 54], 'National_presentations_Presented': [144, 144, 144, 144, 144, 144, 144, 144, 144, 144, 144, 144, 150, 150, 150, 150, 150, 150, 156, 156, 156, 156, 156, 156, 162, 162, 162], 'KOL_FollowUp': ['Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['Discussion regarding long-term risks and benefits of using the drug', 'Identifying various competators and gather information about them', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the clinical trial', 'Safety measures of the drug on general patients', 'Efficacy & Accuracy of Drug', 'Patient Safety during Clinical Trial', 'To discuss regarding \n Procedures\n Risks and benefits and the rights of patients , treatment options in case of adverse events', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Product overview and its differentiating way', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Finding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug'], 'Previous_Meeting_SubTopics': ['Analysis of various competators in industry', 'Analysis of various competators in industry', 'Discussion on Principal Investigator Support', 'Safety', 'Efficacy & Accuracy of Drug', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'Discussion regarding claims/insurance and copay programs', 'Technical feasibility', 'Financial feasibility', 'Market feasibility', 'Operational feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Current_Discussion_Topic': ['Identifying various competators and gather information about them', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the clinical trial', 'Safety measures of the drug on general patients', 'Efficacy and effectivenes of drug', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Claims made,Insurance Coverage,Training,Customer Support Programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Finding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Current_Meeting_Subtopics': ['List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process', 'List of major changes to asset generation process'], 'Current_Channel_of_interaction': ['In-Person', 'Email', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'Video Conference', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person'], 'Company_Event': ['Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug', 'Clinical Trial-Zortobombib Drug'], 'Interaction_intent': ['identifying competitors in industry', 'To determine competative advantage by analysing strengths and weaknesses of Competators', 'Indentifying Principal Investigator for the Clinical trial who has substantial experience as PI in past and how much support he can provide in Clinical Trial', 'To discuss the safety measures of drug on general patients and discuss complications if any', 'Discussion on efficacy and its ability to eliminate the disease', 'Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent of Patient', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'To discuss about the claims,insurance and copay programs', 'Technical feasibility', 'Financial feasibility', 'Market feasibility', 'Operational feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'Items/topics_to_exchange': ['Analysis of various competators in industry', 'Analyse competators strengths & weaknesses and determine your competative advange', 'Indentifying Principal Investigator for the Clinical trial who has substantial experience as PI in past', 'Safety measures and its complications', 'efficacy and accuracy of drug', 'Are there risks to taking part in the trial?\n Who is watching out for any problems?\n Who is making sure that people who take part are safe?\n Is the trial trying to answer an important research question?', 'To discuss regarding \n Procedures\n Risks and benefits and the rights of patients , treatment options in case of adverse events', 'Review & Approval for Clinical trial', 'Identifying organization who will monitor ongoing trials', 'Discussion on IRB Registration Reqirements', 'Discussion on Financial Disclosure by Clinical Investigators', 'Discussion regarding submitting application for investigational new drug', 'how many phases will be needed for testing particular drug', 'Discussion regarding demographic sites, age group , ethinicity , sex of the various patients whose will take part in clinical trial', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Liability Insurance,Claims regarding a product,Training programs,customer support programs,Loyalty or reward programs', 'Discussion regarding right equipment, enough equipment, and the right technical knowledge to complete clinical trial', 'To discuss on ROI and also outlinle financial risks', 'market analysis, market competition breakdown, and sales projections.', 'Discussion regarding resources, skills, and competencies to conduct clinical trials', 'Discussion on creating contingency plan to list down all vulnerabilities and how to tackle them', 'Findiding eligible patients in particular sites with specific disease', 'Discussion regarding methods that can be used for post clinical trial follow up', 'Discussion regarding submission of the clinical trial results for approval to be used in general public', ""Discussion to check the drug's performance in real life scenarios"", 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good', 'Good'], 'Next_Action_Items': ['Analyse competators strengths & weaknesses and determine your competative advange', 'Discussion on Principal Investigator Support', 'Safety : Discussion on Safety Measures', 'Safety : discussion regarding efficay and accuracy of drug', 'Safety : Patient Safety during Clinical Trial', 'Discusion Regarding informed Consent', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Discussion rules and regulations to be followed for Safety of Clinical Trial', 'Regulatory Guidelines', 'Regulatory Guidelines', 'Discussion regarding submitting application for investigational new drug', 'Discuss various phases of testing in patients', 'Discussion regarding various demographic sites where clinical trial will take place', 'To discuss about the claims,insurance and copay programs', 'Discuss compliance and ethical practices', 'Technical feasibility', 'Financial feasibility', 'Market Feasibility', 'Operational Feasibility', 'Review points of vulnerability during conducting of clinical trials', 'discussion on the clinical trial feasibility challenges', 'Discussion on Post Clinical Trial follow up', 'Discussion on registering the drug to FDA', 'Discussion regarding Phase 4 trial', 'Discussion regarding long-term risks and benefits of using the drug', 'Discussion regarding rare side effects.', 'Discussion regarding rare side effects.'], 'Proposed_Next_Channel_Of_interaction': ['Phone Call', 'In-Person', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'Phone Call', 'Video Call', 'Video Call', 'In-Person', 'Video Call', 'Phone Call', 'Video Call', 'Phone Call', 'In-Person', 'In-Person', 'Video Call', 'Video Call', 'Video Call', 'Phone Call', 'Video Call', 'In-Person', 'Video Call', 'Video Call', 'In-Person', 'In-Person']}"
26,"{'kol': 'William Brown', 'Interaction_Date': ['18-Apr-19', '10-May-19', '1-Jun-19', '23-Jun-19', '15-Jul-19', '6-Aug-19', '28-Aug-19', '19-Sep-19', '11-Oct-19', '2-Nov-19', '24-Nov-19', '16-Dec-19', '7-Jan-20', '29-Jan-20', '20-Feb-20', '13-Mar-20', '4-Apr-20', '26-Apr-20', '18-May-20', '9-Jun-20', '1-Jul-20', '23-Jul-20', '14-Aug-20', '5-Sep-20', '27-Sep-20', '19-Oct-20', '10-Nov-20', '2-Dec-20', '24-Dec-20', '15-Jan-21', '6-Feb-21', '28-Feb-21', '22-Mar-21', '13-Apr-21', '5-May-21', '27-May-21', '18-Jun-21', '10-Jul-21', '1-Aug-21', '23-Aug-21'], 'Current_Tier': ['International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International', 'International'], 'KOL_Qualification': [',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD', ',MD, PHD'], 'Therapeutic_Area': ['Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology', 'Oncology'], 'Speciality_within_TA': ['Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer', 'Blood Cancer'], 'KOL_years_of_Experience': [5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8], 'KOL_Location': ['Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln', 'Lincoln'], 'KOL_Territory': ['Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska', 'Nebraska'], 'SocialMedia_Twitter': ['55K', '55K', '55K', '55K', '55K', '55K', '55K', '55K', '55K', '55K', '55K', '55K', '56K', '56K', '56K', '56K', '56K', '56K', '56K', '56K', '56K', '56K', '57K', '57K', '57K', '57K', '57K', '57K', '57K', '57K', '61K', '61K', '61K', '61K', '61K', '62K', '63K', '63K', '64K', '64K'], 'SocialMedia_Linkedin': ['16K', '16K', '16K', '16K', '16K', '16K', '16K', '16K', '16K', '16K', '16K', '16K', '16K', '16K', '17K', '17K', '17K', '17K', '17K', '17K', '17K', '17K', '17K', '17K', '17K', '17K', '17K', '17K', '17K', '17K', '18K', '18K', '18K', '18K', '18K', '18K', '18K', '18K', '18K', '18K'], 'SocialMedia_YouTube': ['5K', '5K', '5K', '5K', '5K', '5K', '5K', '5K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '6K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K', '8K'], 'Overall_Kol_Rating': [3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.8, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 3.9, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.0, 4.1, 4.1, 4.1, 4.1, 4.1, 4.2, 4.3, 4.3, 4.3, 4.3], 'Connection_to_Advisory_Boards': [3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6], 'Research_Participated': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7], 'Research_Experience': [3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 7, 7, 8, 8], 'Fundinghistory_researchgrants': ['60000', '60000', '60000', '60000', '60000', '60000', '60000', '60000', '60000', '60000', '60000', '60000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000'], 'Fundinghistory_ConsultingFees': [500, 500, 500, 500, 500, 500, 500, 500, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 600, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 800, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000, 1000], 'Fundinghistory_EducationalGrants': ['60000', '60000', '60000', '60000', '60000', '60000', '60000', '60000', '60000', '60000', '60000', '60000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '65000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000', '70000'], 'No_Of_Publications': [5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 6, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 7, 8, 8, 8, 8], 'Trainings_Delivered': [4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 8, 11, 11, 11, 11, 11, 11, 11], 'Professional_Certification': [3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 4, 4, 4, 4, 4, 4, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 6, 6, 6, 7], 'KOL_affiliations_academicinstitutionss': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2], 'KOL_Affiliations_Hospital_and_medical_Centres': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2], 'KOL_Affiliations_ProfessionalAssocaitionsandsocities': [1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 1.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 3.0, 3.0, 3.0, 3.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 2.0, 3.0, 3.0, 3.0, 3.0, 3.0], 'KOL_Affiliations_Pharma_and_biotech_companies': [2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 2, 4, 4, 4, 4, 4, 4, 4, 3, 3, 3, 3, 4], 'KOL_Affiliations_Government_and_Regulatory_bodies': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2, 2, 2, 2, 2, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 2, 2, 2, 2], 'KOL_Affiliations_patientadvocacy_and_nonprofit_organisations': [1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 3, 3, 3, 3, 3], 'International_Presentations_Presented': [25, 25, 25, 30, 30, 30, 30, 30, 30, 30, 30, 30, 30, 30, 30, 35, 35, 35, 35, 35, 35, 35, 35, 35, 35, 35, 35, 35, 40, 40, 40, 40, 40, 40, 40, 40, 40, 40, 40, 40], 'National_presentations_Presented': [40, 40, 40, 48, 48, 48, 48, 48, 48, 48, 48, 48, 48, 48, 48, 56, 56, 56, 56, 56, 56, 56, 56, 56, 56, 56, 56, 56, 64, 64, 64, 64, 64, 64, 64, 64, 64, 64, 64, 64], 'KOL_FollowUp': ['No', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'Yes', 'Yes', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_meeting_agenda': ['No', 'Targeted Therapy in Leukemia', 'Biological Therapy or Immunotherapy as treatment', 'Treatment Options for Myeloma', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Stem cell transplantation in pediatric blood cancers', 'Chimeric antigen receptor (CAR) NK Cell therapy for blood cancers.', 'Epigenetic therapies for blood cancers', 'No', 'No', 'No', 'No', 'Liquid biopsies in monitoring disease progression', 'Prognostic markers in blood cancer', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Previous_Meeting_SubTopics': ['No', 'Advances in targeted therapies for leukemia', 'Immunotherapy options for Lymphoma treatment', 'Emerging treatments for multiple myeloma', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'Hematopoietic stem cell transplantation in pediatric blood cancers', 'Updates on chimeric antigen receptor (CAR) NK Cell therapy for blood cancers.', 'Advances in epigenetic therapies for blood cancers', 'No', 'No', 'No', 'No', 'Role of liquid biopsies in monitoring disease progression in blood cancers.', 'New prognostic markers in blood cancer risk assessment', 'No', 'No', 'No', 'No', 'No', 'No', 'No', 'No'], 'Current_Discussion_Topic': ['Targeted Therapy in Leukemia', 'Biological Therapy or Immunotherapy as treatment', 'Treatment Options for Myeloma', 'Genetic Profiling for Diagnosis', 'Stem Cell in Blood Cancer Treatment', 'Managing Relapse Myeloid Leukemia', 'Precision Medicine and Personalized Therapies', 'Early detection and Prevention of Blood Cancer', 'CAR-T Cell Therapy', 'Genomic sequencing in guiding treatment decision', 'Immunotherapies for Myelodysplastic Syndromes', 'Targeted therapies for Leukemia', 'Minimal residual disease monitoring', 'Advancement in the understanding of the tumour microenvironment in blood cancers', 'Treatment for Rare Blood Cancers', 'Resistance to current therapies in blood cancers', 'Long term effects of blood cancer treatments', 'Immunomodulatory drugs for multiple myeloma', 'Molecular basis of blood cancers', 'Venous thromboembolism in blood cancer patients', 'Next-generation sequencing in blood cancers diagnosis', 'Supportive care for blood cancer patients', 'Stem cell transplantation in pediatric blood cancers', 'Chimeric antigen receptor (CAR) NK Cell therapy for blood cancers.', 'Immunogenomics in blood cancer research', 'Epigenetic therapies for blood cancers', 'Side effects management in blood cancer patients.', 'Incorporating precision oncology into clinical practice', 'Improving outcomes in high-risk blood cancer patients', 'Liquid biopsies in monitoring diesease progression', 'Prognostic markers in blood cancer', 'CNS management in blood cancers.', 'Immunotherapy combinations for hematological malignancies', 'Role of targeted agents in myeloproliferative neoplasms treatment', 'Challenges in pediatric blood cancer research', ""Immune checkpoint inhibitors in Hodgkin's lymphoma treatment"", 'Gene therapy approaches for blood cancers', 'Optimizing quality of life for blood cancer parents.', 'Optimizing clinical trial design in blood cancer research.', 'Graft management post bone marrow transplantation'], 'Current_Meeting_Subtopics': ['Advances in targeted therapies for leukemia', 'Immunotherapy options for Lymphoma treatment', 'Emerging treatments for multiple myeloma', 'Genetic profiling in the diagnosis and treatment of blood cancer', 'Role of stem cell transplantation in blood cancer management', 'Novel approaches to managing relapsed/refractory acute myeloid leukemia', 'Precision medicine and personalized therapies for blood cancers', 'Strategies for early detection and prevention of blood cancers', 'Updates on CAR-T cell therapy for lymphoma and leukemia', 'Impact of genomic sequencing in guiding treatment decisions for blood cancers.', 'Novel immunotherapies for myelodysplastic syndromes.', 'Targeted therapies for chronic lymphocytic leukemia', 'Role of minimal residual disease monitoring in blood cancer treatment', 'Advancement in the understanding of the tumour microenvironment in blood cancers', 'Treatment options for rare blood cancers', 'Overcoming resistance to current therapies in blood cancers', 'Long term effects of blood cancer treatments and survivorship care', 'Immunomodulatory drugs in the treatment of multiple myeloma', 'New insights into the molecular basis of blood cancers', 'Management of venous thromboembolism in blood cancer patients', 'Role of next-generation sequencing in diagnosing blood cancers', 'Supportive care interventions for blood cancer patients', 'Hematopoietic stem cell transplantation in pediatric blood cancers', 'Updates on chimeric antigen receptor (CAR) NK Cell therapy for blood cancers.', 'Impact of immunogenomics in blood cancer research and treatment', 'Advances in epigenetic therapies for blood cancers', 'Management of treatment related side effects in blood cancer patients.', 'Incorporating precision oncology into clinical practice for blood cancers', 'Stategies for improving outcomes in high-risk blood cancer patients', 'Role of liquid biopsies in monitoring diesease progression in blood cancers.', 'New prognostic markers in blood cancer risk assessment', 'Management of central nervous system involvement in blood cancers.', 'Updates on immunotherapy combinations for hematological malignancies', 'Role of targeted agents in the treatment of myeloproliferative neoplasms', 'Challenges and opportunities in pediatric blood cancer research', ""Immune checkpoint inhibitors in the treatment of Hodgkin's lymphoma"", 'Update on gene therapy approaches for blood cancers', 'Role of supportive care in optimizing quality of life for blood cancer parents.', 'Strategies for optimizing clinical trial design in blood cancer research.', 'Management of graft versus host post transplantation'], 'Current_Channel_of_interaction': ['Video', 'Video', 'Video', 'Video', 'In-person', 'In-person', 'In-person', 'Email', 'Email', 'Email', 'Email', 'Video', 'Video', 'Video', 'Video', 'Video', 'Phone', 'Phone', 'Email', 'Phone', 'In-person', 'Video', 'Video', 'In-person', 'In-person', 'In-person', 'Video', 'Phone', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'Video', 'In-person', 'Video', 'Email', 'Phone', 'Video', 'Video'], 'Company_Event': ['Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer', 'Medical Conference for Blood Cancer'], 'Interaction_intent': ['Awareness for Targeted Therapy', 'What is Biological Therapy', 'Information about Myeloma and treatment option', 'Need of genetic profiling', 'What is Stem Cell', ""Do's and Don't to manage Myeloid Leukemia"", 'Raising awareness about precision medicine and personalized therapies', 'To understand importance of early cancer detection', 'CAR-T cell therapy as an advancement treatment', 'Genomic sequencing in treatment decision', ""Do's and Don'ts in Myelodysplastic Syndrome treatment"", 'Importance of targeted therapies in Leukemia', 'To get familiar with Minimal residual disease monitoring', 'Understanding tumour microenvironment', 'Rare Blood cancer and recent advancement in treatment', 'Overcoming Cancer treatment resistance', ""Long Term Effect and it's management in Cancer treatment"", 'Familiarity with Immunomodulatory drugs', 'Molecular basis of blood cancers', ""Do's and Don'ts in venous thromboembolism management"", 'Discussing Next-generation blood cancers diagnosis', 'Late Complication management in Cancer Patients', ""Do's and Don'ts in Hematopoietic stem cell transplantation in pediatric blood cancer"", 'Introduction to Emergin cell therapies and Chimeric antigen receptor (CAR) NK Cell therapy', 'Impact assessment of Immunogenomics', 'To get famaliar with Epigenetic therapies', 'Side effects management and supportive care in blood cancer patients.', 'Incorporating precision oncology and targeted therapy', 'Discussion on new stategies for improving outcomes in high-risk blood cancer patients', 'Liquid biopsies in progression monitoring', 'Prognostic markers as an advanced diagnosis and treatment tool in blood cancer', 'Role of CNS management', 'Advancemnet in hematological malignancies', 'Targeted agents in myeloproliferative neoplasms treatment', 'Challenges and solution in Pediatric Cancer research', ""Is immune checkpoint inhibition efficient way of dealing with Hodgkin's Lymphoma"", 'Gene therapy in early treatment of cancer patients', ""Supportive care and it's importance in optimizing quality of life"", 'New strategies discussion in blood cancer research', 'Supportive care in bone marrow transplantation'], 'Items/topics_to_exchange': ['Advances in targeted therapies for blood cancer', 'Biological therapy options for Lymphoma treatment', 'Emerging treatments for multiple myeloma', 'Genetic profiling for diagnosis', 'Stem cell an effective option in treating blood cancer', 'Approach to deal with relapsed acute myeloid Leukemia', 'Introduction to Precision Medicine and Personalized Therapies', 'Roadmap for early blood cancer detection and treatment', 'Introduction to advancement in CAR-T cell therapy', 'Genomic sequencing in Guiding treatment for blood cancer', 'Understanding Immunotherapies for Myelodysplastic Syndromes', 'Effectiveness of targeted therapies for chronic lymphocytic leukemia', 'Role minimal residual disease monitoring plays in cancer treatment', 'Tumour microenviroment and Cancer progression', 'Personalized treatment in Rare Blood Cancer', 'Reasons and Solution for Therapy resistance', 'Post treatment care in Blood cancer treatment', 'Advantage of using Immunomodulatory drugs in the treatment of multiple myeloma', 'New insights into the molecular basis of blood cancers', 'Precautionary measures in case of venous thromboembolism', 'Role of next-generation sequencing as diagnostic method', 'Supportive care to manage late complications', 'Precautionary measures in Hematopoietic stem cell transplantation in pediatric blood cancer', 'Updates on chimeric antigen receptor (CAR) NK Cell therapy', 'Imapact of immunogenomics', 'Novel methodolgy in epigenetic therapies for blood cancer', 'Management of treatment related side effects in blood cancer patients.', 'Incorporating precision oncology into clinical practice for blood cancers', ""Stategies for improving high risk patient's outcomes"", 'Liquid biopsies monitoring', 'New prognostic markers in cancer risk assessment', 'Central nervous system involvement in blood cancers.', 'Immunotherapy combinations for hematological malignancies', 'Role of targeted agents in myeloproliferative neoplasms', ""Do's and Don'ts in Pediatric Cancer research"", ""Is immune checkpoint inhibition in Hodgkin's Lymphoma treatment"", 'New advancement in gene therapy', 'Supportive care to manage long term effect and late complications in survivors', 'New ways of conducting clinical trials', 'Graft management in transplantation'], 'KOLMSL_Relation': ['Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Good', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Neutral', 'Good', 'Neutral'], 'Next_Action_Items': ['Immunotherapy as treatment', 'Treatment Options for Myeloma', 'Genetic Profiling for Diagnosis', 'Stem Cell in Blood Cancer Treatment', 'Managing Relapse Myeloid Leukemia', 'Precision Medicine and Personalized Therapies', 'Early detection and Prevention of Blood Cancer', 'CAR-T Cell Therapy', 'Genomic sequencing in guiding treatment decision', 'Immunotherapies for Myelodysplastic Syndromes', 'Targeted therapies for Leukemia', 'Minimal residual disease monitoring', 'Advancement in the understanding of the tumor microenvironment in blood cancers', 'Treatment for Rare Blood Cancers', 'Resistance to current therapies in blood cancers', 'Long term effects of blood cancer treatments', 'Immunomodulatory drugs for multiple myeloma', 'Molecular basis of blood cancers', 'Venous thromboembolism in blood cancer patients', 'Next-generation sequencing in blood cancers diagnosis', 'Supportive care for blood cancer patients', 'Stem cell transplantation in pediatric blood cancers', 'Chimeric antigen receptor (CAR) NK Cell therapy for blood cancers.', 'Immunogenomics in blood cancer research', 'Epigenetic therapies for blood cancers', 'Side effects management in blood cancer patients.', 'Incorporating precision oncology into clinical practice', 'Improving outcomes in high-risk blood cancer patients', 'Liquid biopsies in monitoring diesease progression', 'Prognostic markers in blood cancer', 'CNS management in blood cancers.', 'Immunotherapy combinations for hematological malignancies', 'Role of targeted agents in myeloproliferative neoplasms treatment', 'Challenges in pediatric blood cancer research', ""Immune checkpoint inhibitors in Hodgkin's lymphoma treatment"", 'Gene therapy approaches for blood cancers', 'Optimizing quality of life for blood cancer parients.', 'Optimizing clinical trial design in blood cancer research.', 'Graft management post bone marrow transplantation', 'Targeted therapies for leukemia'], 'Proposed_Next_Channel_Of_interaction': ['Video', 'Video', 'Video', 'Video', 'In-person', 'In-person', 'In-person', 'Email', 'Email', 'Email', 'Email', 'Video', 'Video', 'Video', 'Video', 'Video', 'Phone', 'Phone', 'Email', 'Phone', 'In-person', 'Video', 'Video', 'In-person', 'In-person', 'In-person', 'Video', 'Phone', 'In-person', 'In-person', 'In-person', 'In-person', 'In-person', 'Video', 'In-person', 'Video', 'Email', 'Phone', 'Video', 'Video']}"
